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Summary 
Mycobacterium tuberculosis (M.tb) glutamine synthetase (GS) is a potentially valuable 
therapeutic target for tackling the problem of tuberculosis disease.  Its regulation via the 
adenylylation of a tyrosine residue on each subunit makes it distinct from the human form of 
the enzyme.  Previous reports of heterologous expression of M.tb GS in Escherichia coli  (E. 
coli) have shown that the endogenous  adenylyl transferase (ATase) activity of E. coli does 
not adenylylate M.tb GS sufficiently, with only 25% of the M.tb GS subunits produced 
displaying adenylylation (Mehta et al., 2004). The use of this expression system was 
therefore not considered optimal for the expression of adenylylated M.tb GS for further 
study.   
Here we have described an E. coli production system lacking endogenous GS and ATase 
activity, which utilises the co-expression of the M.tb ATase with M.tb GS. By co-expressing 
M.tb ATase and M.tb GS we improved the percentage of subunits modified (or adenylylated) 
with ± 60-70% to ± 85-94%. In this way, we have produced recombinant M.tb GS that has a 
better adenylylation state than any previously reported.  
Three methods were used to assess the degree of adenylylation of adenylylated and 
deadenylylated M.tb GS, and E. coli GS.  The first assay used, termed the -glutamyl 
transferase enzyme assay, is a variation of the reverse of the reaction that GS catalyses: 
              Glutamate + NH4
+ + ATP →    glutamine + ADP + Pi + H
+  
In this reverse reaction; hydroxylamine and glutamine react to form -glutamylhydroxamate 
and free ammonia in the presence of ADP, arsenate and manganese or magnesium.  This 
forms the basis of an assay for GS activity. Based on the data from the -glutamyl 
transferase assay, the adenylylation state of adenylylated M.tb GS expressed in this novel 
system is at least 68% compared to the 25% obtained from Mehta and co-workers.  
The second assay used is the determination of the inorganic phosphate concentration after 
the hydrolysis of both adenylylated and deadenylylated Mtb GS. In the case of the 
deadenylylated enzyme, there is no formation of phosphate after the hydrolysis. For the 
adenylylated Mtb GS, each adenyl moiety contains 1 phosphate, and 1 µM of GS (containing 
12 subunits) should contain 12 µM of phosphate, if each subunit is adenylylated.  The result 
obtained for the adenylylated M.tb GS enzyme was the formation of 0.93 µM phosphate 
produced per µM GS active site, i.e. 94% adenylylated compared to the 25% obtained from 
Mehta and co-workers. 
The third method used to assess the adenylylation is mass spectrometry.  MS spectra 
showed distinct peaks for adenylylated and deadenylylated enzymes, with calculated 
masses agreeing with the theoretical values.  Based on this data, it can be concluded that 
the adenylylation state of adenylylated M.tb GS expressed in this novel system is at least 
85% from the MS spectra obtained.   
In addition, the rate of conversion of ATP, glutamate and ammonia to glutamine and ADP 
was assessed using HPLC.  This is termed the ‘forward’ or ‘biosynthetic” reaction and is 
assayed by HPLC to determine the conversion of ATP to ADP. 
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The primary invention of this project relates to a biochemical pathway that yielded a new 
drug target that can be exploited to develop new therapies against M.tb. GS catalyses the 
conversion of glutamate to glutamine via a glutamyl phosphate intermediate, utilising ATP. 
ATP is utilized as either Mg-ATP or Mn-ATP, depending on the adenylylation state of the 
enzyme. The enzyme is regulated via adenylylation in bacteria containing the GS-I form of 
the enzyme, a mechanism not found in the GS-II in humans. 
213 compounds were tested against the adenylylated and deadenylylated forms of both M.tb 
GS and E. coli GS at a concentration of 10 μM. The rational design and selection of these 
inhibitors were based on the typical ATP binding site. It has been shown that GS in the 
adenylylated form uses a novel histidine kinase-like reaction mechanism in the 
phosphorylation of the carboxyl of glutamate. The primary outcome of the project was the 
demonstration of the selective inhibition of adenylylated GS and the identification of specific 
compounds capable of inhibiting adenylylated GS. These compounds could be considered 
for further hit-to-lead and lead optimisation campaigns for the development of novel 
candidates for the treatment of TB. Based on the dose-response assays, two compounds 
have emerged as the most promising anti-M.tb GS inhibitors with IC50 (μM) values of 9.6 μM 
and 17.4 μM respectively. They have regularly produced the most potent inhibitory activity 
against M.tb adenylylated GS enzyme in fixed concentration screens with 87% and 81% 
inhibition, respectively. These compounds, 10057 and 10059, are structurally very similar. 
These two compounds that have been found to be inhibitory to M.tb GS may now be used as 
templates to synthesize additional target specific compounds as part of a lead optimisation 
programme and further optimised to yield a suitable drug candidate for clinical evaluation. 
In the study we also looked at the utilization of ATP by looking at the enzyme kinetics of both 
M.tb GS and E. coli GS as well as the kinetic isotope effect of these enzymes. It is proposed 
that for enzymes such as M.tb GS and E. coli GS, the enzyme kinetics follow the classical 
Michaelis-Menton kinetics where an equilibrium is set up between the enzyme concentration 
[E] and the substrate concentration [S] and binding of the second ATP is dependent on the 
conversion of the second active site into an ATP binding form by the release of ATP from the 
first active site, as defined by the coordinated half-sites mechanism.  
As the regulation of the enzyme activity and ligand binding in these enzymes function in a 
coordinated half-the-sites manner, and binding in the second site only occurs on release of 
the ADP from the first site, it is therefore proposed that deuteration of the ATP improves the 
binding characteristics but does not impact on the catalysis of phosphoryl transfer. As the 
equilibrium shifts towards the binding of ATP with increasing ATP concentration, the 
deuterated ATP effectively binds twice as efficiently as the non-deuterated ATP, thereby 
negating the impact of the deuteration on the apparent enzyme activity at high ATP 
concentrations, yielding a KIE of 1. 
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Opsomming 
 
Mikobakterium tuberkulosis (M.tb) glutamien sintetase (GS) is 'n potensieel waardevolle 
terapeutiese teiken vir die aanpak van die probleem van tuberkulose siekte. Die regulering 
deur die adenylylation van 'n tyrosine groep op elke subeenheid laat dit verskil van die 
menslike vorm van die ensiem. Vorige verslae van heteroloë uitdrukking van M.tb GS in 
Escherichia coli (E. coli) het getoon dat die endogene adeniel transferase (ATase) aktiwiteit 
van E. coli nie M.tb GS optimaal adenylylate nie, met slegs 25% adenylylation van die M.tb 
GS subeenhede (Mehta et al., 2004). Die gebruik van hierdie uitdrukking stelsel is dus nie 
oorweeg as die optimale stelsel vir die uitdrukking van adenylylated M.tb GS vir verdere 
studie.  
 
Hier beskryf ons 'n E. coli produksie stelsel wat ontbreek in endogene GS en ATase 
aktiwiteit asook die mede-uitdrukking van M.tb ATase met M.tb GS. Deur mede-uitdrukking 
van M.tb ATase en M.tb GS het ons die persentasie van die subeenhede wat gemodifiseerd 
is (of adenylylated is) verbeter van ± 60-70% na ± 85-94%. Op hierdie manier, het ons 
rekombinante M.tb GS wat 'n beter adenylylation is as ooit van te vore berig.  
 
Drie metodes is gebruik om die graad van adenileering te evalueer by adenileerde en d-
adenileerde M.tb GS en E. coli GS. Die eerste toets wat gebruik was, staan bekend as die -
glutamiel transferase ensiem toets, is 'n variasie van die omgekeurede reaksie wat GS 
kataliseer:  
               Glutamaat + NH4 + + ATP → glutamine + ADP + Pi + H 
+  
In hierdie omgekeerde reaksie; hidroksielamien en glutamine reageer om -
glutamylhydroxamate en vry ammoniak in die teenwoordigheid van ADP, arsenaat en 
mangaan of magnesium te vorm. Hierdie reaksie vorm die basis van 'n toets vir GS 
aktiwiteit. Op grond van die data uit die -glutamiel transferase toets, die adenileering 
toestand van adenileerde M.tb GS wat in hierdie unieke stelsel uitgedruk word is ten minste 
68% adenileerd in vergelyking met die 25% wat deur Mehta en mede-werkers gekry is.  
 
Die tweede toets wat gebruik was, is die bepaling van die anorganiese fosfaat konsentrasie 
na die hidrolise van beide adenileerde en d-adenileerde M.tb GS. In die geval van die d-
adenileerde ensiem, is daar geen vorming van fosfaat na hidrolise nie. In die geval van die 
adenileerde M.tb GS sal elke adeniel moietie 1 fosfaat bevat dus sal 1 μM van GS (wat 12 
subeenhede bevat) 12 μM fosfaat moet bevat, as elke subeenheid geadenileerd is. Die 
resultaat wat verkry word vir die adenileerde M.tb GS ensiem was die vorming van 0,94 μM 
fosfaat geproduseer per μM GS aktiewe setel, naamlik 94% adenileering in vergelyking met 
die 25% adenileerde GS wat deur Mehta en mede-werkers gepubliseer is.  
 
Die derde metode wat gebruik was is massaspektrometrie. Die MS-spektra toon duidelike 
die pieke vir die adenileerde en d-adenileerde ensieme aan, die berekende massas het 
ooreengestem met die teoretiese massa. Die afleiding kan gemaak word dat die 
adenileering toestand van M.tb GS wat in hierdie unieke stelsel uitgedruk is 85% is. 
 
Daarbenewens is die tempo van omskakeling van ATP, glutamaat en ammoniak na 
glutamien en ADP deur HPLC bepaal. Dit word die "vorentoe" of "biosintetiese" reaksie 
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genoem en word deur HPLC geanaliseer die omskakeling van ATP na ADP te bepaal.  
 
Die primêre uitvinding van hierdie projek hou verband met 'n biochemiese pad wat 'n nuwe 
dwelm teiken kan oplewer wat aangewend kan word om nuwe behandelings teen M.tb te 
ontwikkel. GS kataliseer die omskakeling van glutamaat na glutamine deurmiddel van 'n 
glutamiel fosfaat intermediêre deur gebruik te maak van ATP. ATP word gebruik as of Mg-
ATP of Mn-ATP, afhangende van die adenileerde toestand van die ensiem. Die ensiem word 
gereguleer deur adenileering in bakterieë en is die GS-I vorm van die ensiem, 'n meganisme 
wat nie by die GS-II ensiem wat by die mens voorkom bestaan nie.  
 
213 verbindings is teen die adenileerde en d-adenileerde vorme van beide M.tb GS en E. 
coli GS getoets teen 'n konsentrasie van 10 μM. Die rasionele ontwerp en seleksie van 
hierdie inhibeerders is gebaseer op die tipiese ATP bindings setel. Dit het getoon dat GS in 
die adenileerde vorm 'n unieke histidien kinase-agtige reaksie meganisme gebruik in die 
fosforilering van die karboksielgroep van glutamaat. Die primêre uitkoms van die projek was 
die demonstrasie van die selektiewe inhibisie van adenileerde GS en die identifisering van 
spesifieke verbindings wat in staat is om adenileerde GS te inhibeer. Hierdie verbindings kan 
oorweeg word vir verdere tref-tot-teiken en teiken optimalisering veldtogte vir die 
ontwikkeling van nuwe kandidate vir die behandeling van TB. Op grond van die dosis-
reaksie toetse, het twee verbindings na vore gekom as die mees belowende anti-M.tb GS 
inhibitore met IC50 (μM) waardes van 9.6 μM en 17.4 μM onderskeidelik. Hulle het gereeld 
die mees kragtige inhiberende aktiwiteit getoon teen M.tb adenileerde GS ensiem in vaste 
konsentrasie toetse met 87% en 81% inhibisie, onderskeidelik. Hierdie verbindings, 10057 
en 10059, is struktureel baie soortgelyk. Hierdie twee verbindings wat gevind is om 
inhiberend te wees vir M.tb GS kan nou gebruik word as template om bykomende teiken 
spesifieke verbindings te sintetiseer as deel van 'n teiken optimalisering program en verdere 
identifikasie van nuwe geskikte kandidate vir kliniese evaluering.  
 
In die studie het ons ook gekyk na die gebruik van ATP deur te kyk na die ensiemkinetika 
van M.tb GS en E. coli GS asook die kinetiese isotoop effek van hierdie ensieme. Daar word 
voorgestel dat ensieme soos M.tb GS en E. coli GS, die ensiemkinetika volg van die 
klassieke Michaelis-Menton kinetika waar 'n balans gehandhaf word tussen die ensiem 
konsentrasie [E] en die substraatkonsentrasie [S] en waar die binding van die tweede ATP 
afhanklik is van die sukses van die tweede aktiewe setel om in 'n ATP bindend vorm 
verander te word deur die vrystelling van ‘n ATP uit die eerste aktiewe setel, soos 
gedefinieer deur die gekoördineerde half-setel meganisme.  
 
As die regulering van die ensiemaktiwiteit en ligand binding in hierdie ensieme funksioneer 
in 'n gekoördineerde half-die-setel wyse en binding in die tweede plek kom slegs op die 
vrylating van die ADP uit die eerste plek, word dit dus voorgestel dat deuterasie van die ATP 
die binding eienskappe verbeter, maar nie 'n impak het op die katalise van die fosforielgroep 
oordrag nie. As die ewewig skuif na die binding van ATP met toenemende ATP 
konsentrasie, die deuterated ATP effektief bind twee keer so doeltreffend as die nie-
deuterated ATP, wat dan die impak van die deuterasie op die skynbare ensiemaktiwiteit teen 
hoë konsentrasies aan ATP, die opbrengs van 'n KIE van 1. 
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SRB    Sulforhodamine B 
TB    Tuberculosis 
TCA    Trichloroacetic acid 
Tm    Annealing temperature 
TraSH    Transposon site hybridization 
V    Volts  
WHO    World Health Organisation 
XDR    Extensively drug-resistant 
ZN    Ziehl-Neelsen stain 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 1  INTRODUCTION 
1 
 
Chapter 1 
 
Literature Review 
 
1.1 Mycobacteria 
Mycobacteria are non-motile, unicellular, aerobic, Gram-positive rod shaped bacilli. 
The complete genome sequence of the best-characterized strain of Mycobacterium 
tuberculosis (M.tb), H37Rv, has been determined and analysed in order to improve 
the understanding of the biology of this slow-growing pathogen and to help the 
conception of new prophylactic and therapeutic interventions. The genome 
comprises of 4,411,529 base pairs and contains around 4,000 genes. It has a very 
high guanine and cytosine content which is reflected in the biased amino-acid 
content of the proteins. M.tb differs radically from other bacteria in that a very large 
portion of its coding capacity is devoted to the production of enzymes involved in 
lipogenesis and lipolysis, and to two new families of glycine-rich proteins with a 
repetitive structure that may represent a source of antigenic variation. M.tb can be 
characterised by the following parameters: (1) the presence of mycolic acids in their 
cell walls, (2) 61-71% rich guanine and cytosine content of the genome and (3) being 
acid-fast (Shinnick and Good, 1994). 
M.tb, the aetiological agent of the disease tuberculosis (TB), has returned to become 
one of the leading causes of preventable deaths in 200 countries and territories, 
including South Africa. 
1.2 Tuberculosis Epidemic 
The first reported study of TB dates back to the “Canon of Medicine” written by Ibn 
Sina (Avicenna) almost 1000 years ago. He was the first physician to identify 
pulmonary TB as a contagious disease and suggest that it could spread through 
contact with soil and water. Avicenna also developed the method of quarantine in 
order to limit the spread of TB. Regardless of this early characterisation of TB as a 
disease and the pioneering work leading to the identification in the nineteenth 
century of M.tb as the causative agent by Robert Koch, TB remains today one of the 
world’s major health problems and the leading cause of death from a single 
infectious agent (Saleem and Azher, 2013). 
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According to the World Health Organisation (WHO), it is estimated that 1.77 million 
deaths resulted from TB in 2007, including 456,000 people with HIV (WHO, 2010).  
There were 9.4 million new TB cases in 2008 (WHO, 2010). The estimated 
tuberculosis incidence rates by country are indicated in Figure 1.1. Although current 
treatment can be effective, existing frontline drugs must be taken for at least six 
months to prevent relapse.  Poor treatment compliance contributes directly to the 
emergence of multidrug- and extensively drug-resistant (MDR and XDR) strains of 
M.tb. 
 
 
Figure 1.1: Estimated tuberculosis incidence rates, by country, in 2009 (WHO, 2010) 
 
1.3 Transmission of M.tb 
TB is spread through the air by droplet nuclei, these particles are 1 to 5 mm in 
diameter. These droplet nuclei which are spread from person to person (which are 
produced by persons with pulmonary or laryngeal TB cough, sneeze or speak) do 
contain the M.tb complex (Edwards and Kirkpatrick, 1986). They also may be 
produced by aerosol treatments, sputum induction, aerosolization during 
bronchoscopy, and through manipulation of lesions or processing of tissue or 
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secretions in the hospital or laboratory. Due to the small size of the droplet nuclei air 
currents normally present in any indoor space can keep them airborne for long 
periods of time (Riley, 1993). These small droplet nuclei are able to reach the alveoli 
within the lungs, and replication of the bacilli can then start (Murray, 1986). There are 
four factors which will determine the likelihood of the transmission of M.tb: (1) the 
number of organisms being expelled into the air, (2) the concentration of organisms 
in the air determined by the volume of the space and its ventilation, (3) the length of 
time an exposed person breathes the contaminated air, and (4) presumably the 
immune status of the exposed individual. HIV-infected persons and others with 
impaired cell mediated immunity are thought to be more likely to become infected 
with M.tb after exposure than persons with normal immunity; also, HIV-infected 
persons and others with impaired cell-mediated immunity are much more likely to 
develop disease if they are infected. However, they are no more likely to transmit 
M.tb (Horsburgh, 1996). There are a number of measures which can be put into 
place to reduce the spread of TB namely: (1) Ventilation with fresh air is especially 
important, particularly in health care settings, (2) the number of viable airborne 
tubercle bacilli can be reduced by ultraviolet irradiation of air in the upper part of the 
room and (3) the most important means to reduce the number of bacilli released into 
the air is by treating the patient with effective anti-tuberculosis chemotherapy (Riley, 
1993; Centers for Disease Control and Prevention , 1994; Jindani et al., 1980).  
 
 
1.4 Multidrug-resistant and extensively drug-resistant TB in South Africa 
The serious threat of TB, especially multidrug- and extensively drug-resistant (MDR 
and XDR) TB, is a great concern in Southern Africa particularly to individuals with 
HIV/AIDS. XDR-TB comes about when resistance to isoniazid (INH) and rifampicin 
(RIF) is compounded by an additional resistance to the second line drugs, including 
any fluoroquinolones and at least one of the three injectables (kanamycin, amikacin 
or capreomycin) (Andrews et al., 2007). 
 
The concern about XDR-TB was emphasized following a clinical study in 2006 at the 
Church of Scotland Hospital in KwaZulu-Natal, South Africa. Of the 536 TB patients 
hospitalized at the time, 221 were found to have MDR-TB, of which 53 were 
diagnosed with XDR-TB. Of these, 52 died within 25 days. At the time, it was thought 
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that the co-infection of 44 of these patients with HIV was reason behind their 
development of XDR-TB (Wise, 2006). However, evidence presented by Dr. Tony 
Moll at the 2nd TB conference, 1-4 June 2010 in Durban South Africa, indicated that 
the XDR-TB primarily originated in the hospital through inadequate infection control. 
XDR-TB development in patients that never had TB or HIV infection before, but were 
hospitalized for other ailments in wards that held one or two undiagnosed XDR-TB 
patients. In another study done in a HIV co-infected population at a South African 
gold mine, it was found that existing TB control measures were insufficient to control 
the spread of drug resistant TB. Furthermore inappropriate therapy as well as a 
delay in diagnosis contributed to drug resistance and transmission of the disease. 
Poor treatment compliance contributes directly to the emergence of multidrug- and 
extensively drug-resistant (MDR and XDR) strains of M.tb (Calver et al., 2010). 
 
1.5 TB treatment 
The discovery of streptomycin in 1946 followed by the successful testing of INH in 
1952, which was shown to be the most important antibiotic in the standard treatment 
regime against TB, started the era of antibiotics for TB. Other drugs were developed 
in the following years: pyrazinamide in 1954, ethambutol in 1962 and rifampicin in 
1963 (Tuberculosis, In Encyclopaedia Britannica, 2010). 
 
The treatment of TB differs from that of other infectious diseases due to the long 
treatment time needed to cure the patient (Cole and Riccardi, 2011). A characteristic 
difficulty of TB is the persistence of the pathogenic mycobacteria, regardless of 
prolonged antibiotic treatment. The micro-environment containing dormant bacteria 
could change over a period of time causing the bacteria to recommence growth, at 
which stage they are vulnerable to standard drugs (Parrish et al., 1998). Because 
some of the subpopulations of M.tb may not be eliminated effectively with standard 
antibiotics, prolonged periods of the treatments are required (Barry et al., 2009). 
These heterogeneous subpopulations of the bacteria are able to survive within 
granulomatous lesions surrounded by foamy macrophages in a persistent or latent 
state, without clinical symptoms (Korf et al., 2005). Most bactericidal drugs are only 
effective against actively growing bacilli and the extended treatment times are 
needed to then inhibit the regrowth of the bacteria (Cardona, 2006). The length of 
treatment depends on the presence of non-replicating bacteria and pathogens in a 
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stationary phase present in old lesions of fibrotic tissue (Sosnik et al., 2009). The 
implementation of a 6 month or longer treatment regime with antibiotics for cases of 
susceptible TB resulted in a remarkable reduction in the number of deaths of TB 
cases per 100 000 population in the 1960s, such that TB was thought to be a curable 
disease that was easy to manage. 
 
Antibiotics against TB can be classified into two lines of combination treatment, of 
which application of the more expensive and less efficient second line is dictated by 
the development of drug resistance to the first. The decision to commence with a 
treatment regime for TB is not taken lightly, due to the severe side effects that can 
occur. For example, first line drugs can cause, drug induced hepatitis, nausea, 
deafness and progressive loss of vision (Department of Health, 2004). The first line 
of drugs includes INH, rifampicin, ethambutol, pyrazinamide and streptomycin used 
for the treatment of drug sensitive TB (See table 1.1). There is currently 6 second 
line drugs used for the treatment of MDR-TB. However these drugs have more toxic 
side effects (e.g. cycloserine). Second line drugs are difficult to come by in 
developing countries (e.g. flouroquinolones) or are less effective than first line drugs 
(e.g. p-aminosalicylic acid). XDR-TB brought the concept of ‘third line’ drugs that are 
not listed by the WHO as second line drugs or of which the efficacies are not yet 
proven (Nardell, 2009).  
Table 1.1: First and second-line drugs used in the treatment of TB, with their 
structures, targets and cellular processes (Handbook of Anti-Tuberculosis Agents, 
www. thomson-pharma.com, www. drugbank.ca and http://pubchem.ncbi.nlm.gov). 
First line TB drugs Target Cellular process 
Isoniazid 
 
Cell wall Mycolic acid 
synthesis 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 1  INTRODUCTION 
6 
 
Rifampicin 
 
RNA synthesis Binds to RNA 
polymerase to 
prevent mRNA 
synthesis and 
consequent 
protein 
production. 
Ethambutol 
 
Cell wall Prevents 
arabinogalactan 
synthesis 
Pyrazinamide 
 
Cell wall Fatty acid 
biosynthesis 
Streptomycin 
 
Translation Binding of the 
drug to ribosomes 
inhibits protein 
synthesis 
Second line TB drugs Target Cellular process 
Cycloserine 
 
Cell wall Inhibits cell wall 
synthesis 
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Ethionamide 
 
Cell wall Pro-drug which 
when activated 
inhibits mycolic 
acid biosynthesis 
Prothionamide 
 
Cell wall Pro-drug which 
when activated 
inhibits mycolic 
acid biosynthesis 
Ofloxacin 
 
DNA structure 
replication 
Prevent DNA 
supercoiling and 
replication 
Ciprofloxacin 
 
DNA structure 
replication 
Prevent DNA 
supercoiling and 
replication 
p-aminosalicylic 
acid 
 
Folate 
metabolism 
Disrupt 
intracellular folate 
levels 
 
The current standard first line treatment regimen according to the South African 
tuberculosis control programme of 2004 consist out of an initial (or intensive) phase 
of 2 months consisting of 4 drugs INH, rifampicin, pyrazinamide and ethambutol. 
Streptomycin is added to the regime when the person is re-treated for TB. A 
continuation phase of 4 months with INH and rifampicin follows after the intensive 
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phase to effect sterilization, i.e. the complete elimination of the infecting mycobateria 
(Cole and Riccardi 2011). Due to the duration of the treatment and the increased 
probability of non-compliance that this holds for the patient, drug resistance to any 
one drug can develop. 
 
Most of the standard chemotherapy is not effective for individuals that have MDR-TB 
and there is practically no cure for XDR-TB. Drug resistant mycobacterial pathogens 
are increasingly detected in persons who have been previously treated for TB where 
a possible cause could be the failure to complete lengthy drug regimens and the 
pathogens becoming resistant to especially the two first line drugs, INH and 
rifampicin through mutations in genes such as the InhA and RpoB genes (Sosnik et 
al., 2009). The approach to control this disease now is either to discover new 
chemotherapies effective against M.tb and with different targets as well as to 
enhance the potential of existing drugs to treat MDR-TB (Rastogi et al., 1998)  
 
Treating TB patients who are co-infected with HIV poses some major challenges. 
This includes drug-drug interactions between antiretroviral drugs (protease inhibitors 
and non-nucleoside reverse transcriptase inhibitors) and rifamycins, which could 
result in subtherapeutic concentrations of anti-retroviral drugs. When overlapping 
toxicities of the anti-retroviral and anti-tuberculosis drugs increase, discontinuation of 
the treatment may be required. Another complication is immunupathological 
reactions and clinical deterioration due to immune reconstitution inflammatory 
syndrome where a worsening or recurrence of TB occurs when anti-retroviral 
treatment is commenced. It is suggested that anti-retroviral therapy should be 
delayed until the intensive phase of anti-tuberculosis treatment is completed, but 
delayed anti-retroviral therapy on the other hand also increases the risk of morbidity 
and mortality in patients in the advanced stages of HIV infection (McIlleron et al., 
2007).  
 
If a new TB treatment is going to replace the already existing therapy then it should 
at least shorten the duration of the treatment or reduce the number of dosages to be 
taken. Furthermore the new drug should improve the treatment of MDR-TB or 
provide effective treatment against latent TB infection (Barry, 1997). The 
identification and investigation of new drug targets is also an approach to follow. 
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Drug discovery programmes are normally focussed on pathogen proteins whose 
function is known to be essential to the bacterial cell, combined with a lack of 
mammalian homologues. The solution lies in a combined effort to improvements of 
current drug regimes by shortening the treatment period, supply treatment for 
multidrug resistant TB and to discover an effective treatment for persistent or latent 
tuberculosis infection. 
 
1.5.1 Drugs in late stage development for the treatment of TB 
Seven candidate TB drugs (Table 1.2) representing five different chemical classes 
are currently known to be undergoing clinical evaluation (Thomson Pharma, August 
2013, Cole and Riccardi, 2011). These will be described by chemical class, in order 
according to stage of clinical development. 
 
Fluoroquinolones: 
Gatifloxacin and Moxifloxacin: The furthest advanced of these seven are two drugs 
belonging to the family of C8-methoxy fluoroquinolones: gatifloxacin and 
moxifloxacin. Both gatifloxacin and moxifloxacin are approved drugs for other 
indications (gatifloxacin from Bristol-Myers Squibb in the United States and 
moxifloxacin from Bayer Healthcare Pharmaceuticals). Both are now in phase III 
clinical evaluation for treatment of newly diagnosed, drug sensitive, adult, pulmonary 
TB. 
 
Diarylquinolines: TMC-207 
TMC-207: This novel compound, also referred to in the literature as R207910, is a 
diarylquinoline, owned by Johnson & Johnson and being developed by its subsidiary, 
Tibotec. It was originally discovered by whole-cell phenotypic screening and acts by 
inhibiting the M.tb adenosine triphosphate (ATP) synthase. 
 
Nitroimidazoles: PA-824 and OPC-67683 
The nitroimidazoles represent a novel class of drugs for TB treatment. Two members 
of this chemical class are presently in phase II of clinical development: PA-824, a 
nitroimidazo-oxazine, being evaluated currently for drug sensitive TB, and OPC-
67683, a nitroimidazo- oxazole, currently being studied in MDR-TB patients. 
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Ethylenediamine: SQ109 
SQ109 is a novel 1,2-ethylenediamine. It was originally identified as part of 
collaboration between the biotech company Sequella, Inc., and the National Institute 
of Allergy and Infectious Diseases of the U.S. National Institutes of Health to 
synthesize via combinatorial chemistry and screen ethambutol analogs for killing 
M.tb in vitro under aerobic conditions using a high-throughput bioluminescence-
based assay. 
 
Pyrrole: LL-3858 
LL-3858 is a pyrrole derivative being developed by Lupin, Ltd. Little published 
information is available about this compound. Its mechanism of action is unknown. 
Its MIC in vitro against M.tb has been reported to be 0.12 to 0.25 μg/mL, and it 
demonstrated synergistic activity with rifampicin in vitro. As of the last public report, 
this compound is in phase I of clinical development in India. 
 
Table 1.2: Selected drugs in late stage development for the treatment of 
Tuberculosis, with their structures, clinical phase, class and mechanism of action 
(www. thomson-pharma.com, www. drugbank.ca and http://pubchem.ncbi.nlm.gov). 
Selected drug in 
development 
Structure Clinical 
Phase 
Class: Mechanism of 
action 
Gatifloxacin 
 
Phase III Fluoroquinolone: 
Inhibition of DNA 
gyrase and 
topoisomerase II 
Moxifloxacin 
 
Phase III Fluoroquinolone: 
Inhibition of DNA 
gyrase and 
topoisomerase II 
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TMC-207 
 
Phase II Diarylquinoline: 
Inhibition of ATP 
synthase 
PA-824 
 
Phase II Nitroimidazol: 
Oxidative stress 
OPC-67683 
 
 
Phase II Nitroimidazol: 
Oxidative stress 
SQ-109  
 
Phase I Ethylenediamine: 
Inhibition of cell-wall 
synthesis 
LL-3858 
 
Phase I Pyrrole derivative: 
Unknown 
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1.6 Drug targets 
1.6.1 M.tb drug targets 
The quest for better, faster and cheaper drugs will require innovative approaches to 
novel drug target identification. The increase in data available and the improved 
understanding of the physiology and metabolism of M.tb are making the task of 
target identification easier. There are certain criteria a protein must meet in order to 
progress to the next stage of being identified as a new drug target. Important factors 
include low or no homology between the target and host (to minimize the host-drug 
interaction), an unambiguously proven role the target plays in the diseased state and 
the importance of the target to the pathogen’s growth and survival (like metabolic 
choke points) (Hasan et al., 2006). In TB, identification of targets that play a role in 
the maintenance of the dormant phase of the bacteria is receiving the most attention. 
Genes and gene products that are involved in dormancy or persistence should make 
good drug targets, considering the extended periods of time for which the latent 
infection can persist. An example is isocitrate lyase, a key enzyme of the glyoxylate 
shunt. Important tuberculosis drugs like INH and ethambutol target cell wall 
synthesis, so enzymes involved in this pathway will always be favoured targets for 
drug development. Organisms related to M.tb exhibit different degrees of 
pathogenicity or virulence, and by comparing pathogenic with non-pathogenic 
organisms, a few virulence factors have been identified and marked as drug targets. 
Rifampicin targets RNA polymerase, and other essential transcription factors like the 
sigma factors (SigH, SigF and SigA) can also be potential drug targets. Transporter 
proteins and other proteins needed for maintaining the important nutrient 
environment can also serve as possible targets for drug development. 
Serine/threonine protein kinases, tyrosine phosphatase and histidine kinase two 
component systems are vital to the signal transduction system in a number of 
organisms during the stress responses, developmental processes and the 
pathogenicity (Chopra et al., 2003). 
 
New targets for drugs are therefore required.  These new drugs should also simplify 
and shorten the treatment period, as well as reduce drug-drug interactions in 
patients co-infected with HIV.  Drug discovery programmes are normally focussed on 
pathogen proteins whose function is known to be essential to the bacterial cell, 
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combined with a lack of mammalian homologues.  One such potential drug target for 
TB is glutamine synthetase (GS). 
 
1.6.2 Glutamine synthetase (GS) 
GS (EC 6.3.1.2) is a complex dodecameric oligomer (Figure 1.2) which is the 
ubiquitous central enzyme in nitrogen metabolism (Metha et al., 2004). GS catalyzes 
the reversible conversion of L-glutamic acid, ATP and ammonia to L-glutamine, ADP 
and inorganic phosphate via a γ-glutamyl phosphate intermediate (Shapiro and 
Stadman, 1970).  It is a central enzyme in nitrogen metabolism, and can be 
regulated by at least four different mechanisms: (a) adenylylation and 
deadenylylation of a conserved tyrosine residue, (b) conversion between a relaxed 
(inactive) and taut (active) state depending on the divalent metal cation present, (c) 
cumulative feedback inhibition by multiple end products of glutamine metabolism, 
and (d) repression and derepression of GS biosynthesis in response to nitrogen 
availability (Shapiro and Stadman, 1970).   
 
     
Figure 1.2: The dodecameric structure of GS (Kenyon et al., 2011). 
 
Three distinct forms of GS occur, with GS-I found only in bacteria (eubacteria) and 
archaea (archaebacteria) (Kumada et al., 1993).  GS-II occurs only in eukaryotes, 
and soil-dwelling bacteria, while GS-III genes have been found only in a few bacterial 
species.  Two significant prokaryotic GS-I sub-divisions exist: GS-I and GS-I 
(Brown et al., 1994). The GS-I enzyme is regulated via the 
adenylylation/deadenylylation cascade, which does not occur in the GS-I or GS-II 
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sub-divisions.  M.tb and Escherichia coli (E.coli) GS are regulated in this manner, 
while the human homologue belongs to GS-II and is not subject to adenylylation, a 
difference that can be exploited by developing drugs that are only active against the 
adenylylated form of the enzyme.   
 
The extent of adenylylation of E.coli GS is regulated in response to the intracellular 
concentrations of α-ketoglutarate and glutamine, via the reversible adenylylation of a 
tyrosine residue (Tyr-406) in each subunit of GS (Tyler, 1978; Gaillardin and 
Magasanik, 1978; Floor et al., 1975; Janssen and Magasanik, 1977 and Senior, 
1975). The presence of adenylylated GS predominates in a nitrogen-rich, carbon-
limited media, while the deadenylylated form tends to predominate under conditions 
of nitrogen limitation (Tyler, 1978; Gaillardin and Magasanik, 1978; Floor et al., 1975; 
Janssen and Magasanik, 1977 and Senior, 1975). This regulation of the 
adenylylation state of GS is accomplished by three proteins: (1) 
uridylyltransferase/uridylyl-removing enzyme, (2) the signal transduction protein PII, 
and (3) adenylyl transferase or ATase.  High intracellular concentrations of glutamine 
activate the uridylyl-removing enzyme, which causes the deuridylylation of PII.  This 
interacts with ATase, which then catalyses the adenylylation of GS.  A high 
intracellular α-ketoglutarate concentration activates uridylyltransferase, which 
transfers UMP to each subunit of PII, forming PII-UMP.  The PII-UMP interacts with 
the ATase, which in turn catalyses the removal of AMP from the GS.  Research on 
the effect of glucose, ammonia and glutamic acid concentrations has shown that the 
adenylylation state of GS is a function of metabolic flux rather than absolute 
concentration only (Wolhueter et al., 1973).  The activity of GS is therefore regulated 
by both the nature and the availability of the ammonia source (Merrick and Edwards, 
1995; Senior, 1975).  The level of GS activity is inversely related to the degree of 
adenylylation (Kenyon et al., 2011; Okano et al., 2010, reviewed in Shapiro and 
Stadtman, 1970; Ginsberg and Stadtman, 1973 and Wolhueter et al., 1973) and that 
adenylylated residues may be present on any number of subunits from zero to 
twelve, depending on carbon and nitrogen availability (Harper et al., 2010 Holzer et 
al., 1968; Shapiro et al., 1967; Shapiro and Stadtman 1968; Kingdon et al., 1967; 
Mecke et al., 1966 and Reitzer and Magasanik, 1987). GS is therefore responsible 
for the assimilation of ammonia when the available ammonia in the environment is 
restricted, as well as for the formation of glutamine for the synthesis of protein and 
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other nitrogen compounds.  In ammonia-rich medium, the level of GS is low and GS 
functions primarily for the synthesis of glutamine. 
 
The identification of genes which are required for mycobacterial growth by means of 
transposon site hybridization (TraSH) studies done by Sassetti indicated that the 
glutamate degradation pathway is essential for growth in which GS plays an 
essential role (Sassetti et al., 2003). In another study done by Chandra and co-
workers they shown that GS is necessary for cell wall resistance and pathogenicity 
(Chandra et al., 2010). GS can therefore be offered as a potential new drug target. 
 
1.7 Study design and objectives of this thesis 
Hypothesis 
Glutamine synthetase has emerged as a potentially viable drug target for 
tuberculosis, and is also hypothesised that the adenylylation cascade may provide 
additional pharmacological targets for tuberculosis therapy. 
 
Aims 
 To demonstrate the production of soluble adenylylated M.tb GS in E.coli by 
co-expression with M.tb adenylyl transferase. 
 
 To demonstrate the production of soluble deadenylylated M.tb GS in E.coli. 
 
 To examine the inhibitory effect of a library of ATP scaffold-based inhibitors. 
 
 To demonstrate differential inhibition of adenylylated and deadenylylated M.tb 
GS. 
 
 To demonstrate the effect of deuterated ATP on M.tb and E.coli GS 
regulation. 
 
Methodology 
 Previously published reports shown that, when M.tb GS is expressed in E.coli, 
the E.coli adenylyl transferase does not optimally adenylylate the M.tb GS.  
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Here, we will demonstrate the production of soluble adenylylated M.tb GS in 
E.coli by co-expression with M.tb adenylyl transferase. 
 
 Isolation of soluble adenylylated and deadenylylated M.tb GS using anion 
exchange, followed by affinity purification. 
 
 The functionality of both adenylylated and deadenylylated M.tb GS will be 
determined using the -glutamyl transferase assay, an HPLC-based assay to 
determine ADP formation, and determination of inorganic phosphate 
formation. 
 
 The assessment of the degree of adenylylation of M.tb GS will be determined 
by enzyme hydrolysis and Mass spectrometry.   
 
 The inhibitory effect of 214 ATP scaffold-based inhibitors against both 
adenylylated and deadenylylated M.tb GS activity will be measured by the 
HPLC-based assay for ADP formation, and the determination of inorganic 
phosphate. Dose-response assays will be carried out for IC50 determination. 
 
 Compounds showing promising inhibition will be incubated with the H. sapiens 
HeLa cell line and their effect on cell numbers will be determined.  
 
 Compounds identified in inhibitor screens will be tested for antibacterial 
activity using BACTEC assay with H37Rv reference strain at the University of 
Stellenbosch. 
 
 Intracellular survival of M.tb (H37Rv/Beijing220) in mouse bone-marrow 
derived macrophages will be monitored in response to identified compounds 
at the University of Stellenbosch. 
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Chapter 2 
 
PCR-mediated synthesis of Mycobacterium tuberculosis glutamine 
synthetase and functional expression in Escherichia coli 
 
2.1 Introduction 
2.1.1 Importance of glutamine synthetase 
Glutamine synthetase (GS, EC 6.3.1.2) catalyzes the reversible conversion of 
L-glutamic acid, ATP and ammonia to L-glutamine, ADP and inorganic phosphate via 
a -glutamyl phosphate intermediate (Kenyon et al., 2011; Shapiro and Stadman, 
1970).  It is a central enzyme in nitrogen metabolism, and can be regulated by at 
least four different mechanisms: (a) adenylylation and deadenylylation of a 
conserved tyrosine residue (Figure 2.1), (b) conversion between a relaxed (inactive) 
and taut (active) state depending on the divalent metal cation present, (c) cumulative 
feedback inhibition by multiple end products of glutamine metabolism, and (d) 
repression and derepression of GS biosynthesis in response to nitrogen availability 
(Shapiro and Stadman, 1970). 
 
GS enzymes are classified into four forms according to the number of subunits 
present and whether or not the enzyme is post-translationally regulated. Two 
significant prokaryotic GS-I sub-divisions exist: GS-I and GS-I (Hayward et al., 
2009; Brown et al., 1994). The GS-I enzyme is regulated via the 
adenylylation/deadenylylation cascade, which does not occur in the GS-I or GS-II 
sub-divisions.  Mycobacterium tuberculosis (M.tb) and Escherichia coli (E.coli) GS 
are regulated in this manner, while the human homologue belongs to GS-II and is 
not subject to adenylylation, a difference that can be exploited by developing drugs 
that are only active against the adenylylated form of the enzyme.   
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Figure 2.1: Space-filling model of the x-ray structure of M.tb GS (Protein Data Bank number 1HTQ) 
and the chemical structure of the adenylyl group that regulates GS activity. The enzyme is a 
dodecamer of identical subunits forming face-to-face hexagonal rings. Top left, edge-on view with the 
6-fold axis of symmetry running vertically in the plane of the page. A single subunit is coloured yellow, 
with the adenylylation loop in orange and the Tyr-406 in each subunit coloured red. The adenylylation 
loop includes residues 398–410. Bottom left, a top view of the enzyme with the 6-fold axis 
perpendicular to the page. Top right, the chemical structure of the adenylyl group (330 atomic mass 
unit) which attached to Tyr-406 (Metha et al., 2004). 
The extent of adenylylation of E.coli GS is regulated in response to the intracellular 
concentrations of α-ketoglutarate and glutamine, via the reversible adenylylation of a 
tyrosine residue (Tyr-406) in each subunit of GS (Tyler, 1978; Gaillardin and 
Magasanik, 1978; Floor et al., 1975; Janssen and Magasanik, 1977 and Senior, 
1975). The presence of adenylylated GS predominates in a nitrogen-rich, carbon-
limited media, while the deadenylylated form tends to predominate under conditions 
of nitrogen limitation (Tyler, 1978; Gaillardin and Magasanik, 1978; Floor et al., 1975; 
Janssen and Magasanik, 1977 and Senior, 1975). This regulation of the 
adenylylation state of GS is accomplished by three proteins: (1) uridylyltransferase/ 
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uridylyl-removing enzyme, (2) the signal transduction protein PII, and (3) adenylyl 
transferase or ATase.  High intracellular concentrations of glutamine activate the 
uridylyl-removing enzyme, which causes the deuridylylation of PII.  This interacts with 
ATase, which then catalyses the adenylylation of GS.  A high intracellular α-
ketoglutarate concentration activates uridylyltransferase, which transfers UMP to 
each subunit of PII, forming PII-UMP.  The PII-UMP interacts with the ATase, which in 
turn catalyses the removal of AMP from the GS.  Research on the effect of glucose, 
ammonia and glutamic acid concentrations has shown that the adenylylation state of 
GS is a function of metabolic flux rather than absolute concentration only (Wolhueter 
et al., 1973).  The activity of GS is therefore regulated by both the nature and the 
availability of the ammonia source (Merrick and Edwards, 1995; Senior, 1975).  The 
level of GS activity is inversely related to the degree of adenylylation (Kenyon et al., 
2011; Okano et al., 2010, reviewed in Shapiro and Stadtman, 1970; Ginsberg and 
Stadtman, 1973 and Wolhueter et al., 1973) and that adenylylated residues may be 
present on any number of subunits from zero to twelve, depending on carbon and 
nitrogen availability (Harper et al., 2010 Holzer et al., 1968; Shapiro et al., 1967; 
Shapiro and Stadtman 1968; Kingdon et al., 1967; Mecke et al., 1966 and Reitzer 
and Magasanik, 1987). GS is therefore responsible for the assimilation of ammonia 
when the available ammonia in the environment is restricted, as well as for the 
formation of glutamine for the synthesis of protein and other nitrogen compounds.  In 
ammonia-rich medium, the level of GS is low and GS functions primarily for the 
synthesis of glutamine.  
A number of factors make GS a potential drug target in the fight against TB, 
including being considered essential for the survival of M.tb (Reynaud et al., 1998; 
Harth and Horwitz, 1999 and 2003 and Tullius et al., 2003). The GS inhibitor 
L-methionine-S,R-sulphoxamine (MSO) inhibits growth of M.tb both in vitro and in vivo 
(Reynaud et al., 1998 and Harth and Horwitz, 1999). The extracellular location of GS 
is a characteristic that is only found in the pathogenic mycobacteria’s such as M.tb 
and M.bovis, and not with the non-pathogenic strains of M.smegmatis and M.phlei 
(Shapiro and Ginsburg, 1968 and Reynaud et al., 1998). It appears to play an 
important role in cell wall biosynthesis, in the form of a cell wall component found 
only in pathogenic mycobacteria: poly-L-glutamate / glutamine (Wietzerbin et al., 
1975 and Hirschfield et al., 1990). M.tb GS has previously been successfully 
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expressed in heterologous systems, including E.coli and the non-pathogenic 
mycobacterial strain M. smegmatis (Mehta et al., 2004 and Singh et al., 2004).  
Mehta and co-workers expressed M.tb GS in E.coli host strains that were deficient in 
either chromosomal GS (glnA), or both chromosomal GS and ATase (glnE).  They 
found that the E.coli ATase was inefficient in adenylylating the heterologous M.tb 
GS, with only ~25% of subunits being modified.  A lack of E.coli ATase yielded 
completely deadenylylated M.tb GS. From the literature it was evident that this is not 
the optimal road to follow for the production of adenylylated M.tb GS, therefore a 
different approach will be followed here for the production of adenylylated M.tb GS 
production. We will demonstrate the production of soluble adenylylated M. 
tuberculosis glutamine synthetase in E.coli by the co-expression of M.tb glutamine 
synthetase and M.tb  adenylyl transferase.   
Here, we describe the production of both the deadenylylated and adenylylated forms 
of M.tb GS in E.coli.  Deadenylylated M.tb GS is produced by constitutive expression 
in an E.coli strain deficient in both E.coli GS and ATase activities, while adenylylated 
M.tb GS is produced in the same host when co-expressed with an inducible M. 
tuberculosis ATase.  For comparison purposes, E.coli GS was also produced in the 
adenylylated and deadenylylated forms.  Adenylylated E.coli GS was produced in a 
host lacking chromosomal GS and uridylyltransferase, while the deadenylylated 
E.coli GS host strain lacked chromosomal GS and ATase.  Adenylylation was 
measured using the -glutamyl transferase assay, mass spectrometry and 
determination of phosphate content by enzyme hydrolysis.   
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2.1.2 Study Objectives 
 Objective 1: To demonstrate the production of soluble adenylylated M.tb GS 
in E.coli by co-expression with M.tb adenylyl transferase, as well as the 
production of soluble deadenylylated M.tb GS in E.coli. 
 
 Objective 2: To demonstrate the production of soluble adenylylated and 
deadenylylated E.coli GS in E.coli. 
 
 Objective 3: To determine the functionality of both adenylylated and 
deadenylylated M.tb and E.coli GS by making use of (1) the -glutamyl 
transferase assay, (2) an HPLC-based assay for ADP formation 
determination, and (3) determination of inorganic phosphate formation. 
 
 Objective 4: To assess the degree of adenylylation of M.tb and E.coli GS, 
using enzyme hydrolysis and mass spectrometry.   
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2.2 Methods 
2.2.1 Production of glnD and glnE knockout strains of E.coli YMC11 (CGSC)   
The Quick & Easy E.coli Gene Deletion Kit (Gene Bridges GmbH) was used to knock 
out the glnD (uridylyltransferase/uridylyl-removing enzyme) or glnE (adenylyl 
transferase) genes on the E.coli chromosome of YMC11, a strain already lacking 
glnA (Backman et al., 1981).  Primers were designed to the glnD and glnE genes 
(Genbank database, http://www.ncbi.nlm.nih.gov/genbank/), each containing a 
region specific to the relevant gene adjoining a sequence specific to the kit-supplied 
FRT cassette (underlined in Table 2.1). A diagrammatic sketch showing gene 
orientation and primer position for both glnD and glnE are shown in Figure 2.2 and 
Figure 2.3 respectively.    
 
Table 2.1: Sense and antisense oligonucleotides used for the production of glnD and 
glnE knockout strains of E.coli YMC11 
* The region specific to the relevant gene adjoining a sequence specific to the kit-supplied FRT 
cassette. 
 
 
 
 
 
 
 
 
 
 
Primer name Primer sequence (5’ to 3’) 
glnD sense primer Gaggatcccagaaccagcgccatcagcgttaccatggcaccagctacaac
cttgaaccaattaaccctcactaaagggcg* 
glnD antisense primer Gtggatccgcgatatcgtgaaacagcgcggcgatgaaaatcagctcagttga
cggcagtaatacgactcactatagggctc* 
glnE sense primer Gaggatcctgcgcctgtttgaactgacgcagcgcctcaagctgttgctcttcgtc
atcaattaaccctcactaaagggcg* 
glnE antisense primer Gtggatccaggtgttccagctcattcgcggcggacgcgaaccgtcgctgcaat
cgcgctaatacgactcactatagggctc* 
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 1 ATGAATACCCTTCCAGAACAGTACGCAAACACCGCTCTCCCCACCCTGCC 
51 CGGTCAACCGCAAAATCCATGCGTCTGGCCCCGTGATGAATTAACCGTCG 
101 GTGGGATAAAAGCCCATATCGATACTTTCCAGCGTTGGCTGGGTGATGCC 
151 TTTGACAATGGGATCTCTGCAGAACAGTTGATTGAGGCGCGCACCGAGTT 
201 TATCGACCAGCTCCTGCAACGATTATGGATTGAAGCGGGATTCAGCCAGA 
251 TTGCCGACCTGGCATTGGTCGCCGTCGGTGGCTACGGTCGTGGCGAGCTG 
301 CATCCACTTTCAGACGTCGATTTACTGATTTTAAGCCGTAAAAAGCTCCC 
351 GGACGATCAGGCGCAAAAAGTGGGCGAGCTGTTAACGCTGCTCTGGGATG 
401 TAAAGCTGGAAGTCGGTCATAGCGTGCGCACGCTTGAAGAGTGCATGCTG 
451 GAAGGGTTATCGGATTTAACCGTCGCCACCAATTTAATCGAATCCCGCTT 
501 ATTAATTGGCGATGTTGCGCTGTTCCTCGAACTGCAAAAACATATTTTCA 
551 GCGAAGGATTCTGGCCTTCCGACAAGTTCTACGCGGCGAAAGTTGAAGAA 
glnD sense primer 
  BamHI 
    5’-gaggatcccagaaccagcgccatcagcgttaccatggcaccagctacaaccttgaaccaattaaccctcactaaagggcg-3’ 
601 CAGAACCAGCGCCATCAGCGTTACCATGGCACCAGCTACAACCTTGAACC 
651 AGACATCAAAAGCAGCCCTGGCGGCTTGCGCGATATCCACACTCTGCAAT 
701 GGGTGGCCCGCCGTCATTTTGGCGCAACATCGCTGGATGAAATGGTCGGG 
751 TTTGGCTTCTTAACCTCAGCGGAGCGGGCGGAATTAAACGAATGTCTGCA 
801 TATATTGTGGCGTATTCGCTTTGCCCTGCATCTGGTCGTCAGCCGTTACG 
851 ATAATCGCCTGTTATTCGATCGCCAGCTTAGCGTCGCCCAGCGTCTGAAT 
901 TACAGTGGTGAAGGTAACGAACCGGTCGAGCGGATGATGAAGGATTACTT 
951 CCGCGTTACACGCCGCGTCAGTGAACTCAACCAGATGCTGCTGCAACTGT 
1001 TCGATGAAGCCATCCTCGCCCTTCCCGCCGACGAAAAACCACGTCCAGTG 
1051 GACGATGAGTTTCAGCTACGCGGTACGCTAATCGACCTGCGTGATGAAAC 
1101 ACTATTTATGCGCCAGCCGGAAGCCATCTTGCGTATGTTCTACACCATGG 
1151 TGCACAACAGTGCGATCACCGGCATTTACTCCACCACGCTGCGCCAGTTA 
1201 CGCCATGCCCGTCGCCATCTGCAACAACCGCTGTGTAATATTCCGGAAGC 
1251 ACGAAAACTGTTTTTGAGCATTCTGCGTCACCCCGGAGCGGTGCGGCGCG 
1301 GGCTATTGCCAATGCATCGCCATAGCGTGCTCGGCGCGTARATGCCGCAA 
1351 TGGTCGCATATCGTCGGGCAGATGCAGTTTGATCTGTTCCACGCCTACAC 
1401 GGTGGATGAACATACTATCCGCGTGATGCTGAAACTGGAGAGTTTTGCCA 
1451 GTGAAGAAACGCGCCAGCGCCATCCGTTGTGTGTGGACGTCTGGCCGCGC 
1501 CTGCCGTCAACTGAGCTGATTTTCATCGCCGCGCTGTTTCACGATATCGC 
 3’-ctcgggatatcactcagcataatgacggcagttgactcgactaaaagtagcggcgcgacaaagtgctatagcgcctaggtg-5’ 
                                                          BamHI 
                                                          glnD antisense primer 
1551 CAAAGGACGCGGCGGCGACCACTCCATTCTCGGTGCTCAGGATGTAGTGC 
1601 ATTTTGCCGAACTCCACGGGCTGAACTCACGCGAAACACAGCTGGTCGCC 
1651 TGGCTGGTTCGCCAGCACCTGTTGATGTCGGTGACCGCCCAACGCCGCGA 
1701 TATTCAGGACCCGGAAGTCATCAAGCAGTTTGCCGAAGAAGTGCAAACGG 
1751 AAAATCGTCTGCGCTATCTGGTATGCCTGACTGTGGCTGACATTTGCGCC 
1801 ACCAACGAAACGCTGTGGAATAGCTGGAAGCAAAGTCTGTTGCGTGAGCT 
1851 CTACTTTGCCACCGAAAAGCAGCTACGACGCGGAATGCAAAACACGCCGG 
1901 ATATGCGAACGGGTTCGCCATCACACCAACTCCAGGCACTGGCACTACTG 
1951 CGCATGGATAACATCGACGAAGAGGCGCTGCACCAAATTTGGTCACGCTG 
2001 TCGTGCTAACTATTTTGTCCGCCATAGCCCAAATCAACTGGCCTGGCATG 
2051 CCCGCCATTTATTACAGCATGATTTAAGCAAACCGCTGGTATTGCTTAGC 
2101 CCGCAGCGTACGCGTGGAGGCACCGAGATTTTTATCTGGTATTGCTTAGC 
2151 CCCTTATCTGTTTGCCGCCGTCTGTGCCGAATTAGACCGCCGCAATTTAA 
2201 GTGTTCACGACGCACAAATTTTCACCACTCGCGACGGTATGGCGATGGAT 
2251 ACCTTTATCGTGCTGGAACCCGATGGCAACCCGCTGTCCGCAGATCGTCA 
2301 TGAGGTTATTCGGTTTGGTCTGGAGCAAGTACTGACGCAAAGTAGCTGGC 
2351 AGCCACCGCAGCCCCGTCGCCAACCCGCCAAATTACGCCATTTTACTGTT 
2401 GAAACCGAAGTAACGTTTTTGCCGACCCATACCGACCGCAAATCGTTCCT 
2451 CGAACTGATCGCCCTCGACCAACCTGGACTGCTGGCGCGAGTCGGGAAAA 
2501 TTTTTGCCGATCTGGGAATTTCGCTTCATGGTGCCCGAATTACAACCATT 
2551 GGCGAGCGAGTAGAAGATTTATTCATAATTGCCACCGCTGACCGGCGTGC 
2601 GCTTAATAACGAGTTGCAGCAGGAAGTGCATCAGCGGTTGACAGAGGCCC 
2651 TCAATCCAAACGATAAAGGGTGA 
 
Figure 2.2: DNA sequence of E.coli glnD showing gene orientation and primer positions. The glnD 
sequences were obtained from the Genbank database. The glnD sense primer is indicated in red. The 
BamHI enzyme restriction site is on the 5’ site of the primer and is coloured blue. The primer also 
contains a region specific to the relevant gene adjoining a sequence specific to the kit-supplied FRT 
cassette and this region is bold and underlined on the 3’ side of the primer. The glnD antisense primer 
is indicated in green. The BamHI enzyme restriction site is on the 5’ site of the primer and is coloured 
blue. The primer also contains a region specific to the relevant gene adjoining a sequence specific to 
the kit-supplied FRT cassette and this region is bold and underlined located on the 3’ side. 
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 1 TCATTCTTCCACCAGCCACTTCTGCCAGCTTGCCCGCACCAGTTCACGCT 
 51 CTGCGGTGAAGCAATCCTCCGACACATGGCCCGGCAATTCCTGTAATGCC 
 101 AGATGATGAAGTTCATCGCGAAGCGTAGTGTAAGCACGGGTCAGCGCCAT 
 151 CGCTTCCTGCTCTTCCATAATGTCGTTTTGCGCCAGTAGTTCCAGAATAC 
 201 GCACGTTGTCTGACCAGCGCGTTAACTTCGGTTTTTCATGAGCGTAGCGC 
 251 AACACCAGATATTGGGTAATAAATTCGATATCGGTAATTCCCCCTTCATC 
 301 AGCTTTGATATCAAAGCGATCGCGATGTTTATTGCCGAGATGAGCGCGCA 
 351 TTTTCTCGCGCATTTCCCGCACTTCCGTTTGCAGAGTTTTACCTTCACGC 
 401 GGCAGCGTCATAATCTCGCGACGCACTGCGTCAAAGTGCGCGGTGAGCTG 
 451 CGGATCGCCGTACACTACACGCGCACGCACCAGCGCCTGATGTTCCCACG 
 501 TCCAGGCCTCGTTTTTCTGATAATCGGCAAATGCTTCTGCGGATGTCACC 
 551 AGCATTCCCGCCGCCCCGGACGGACGCAGTCGAGCATCCACTTCATACAA 
 601 AATGCCGGAAGAGGTACGCGTACTGAACAGATGCATAATGCGTTGCGCCA 
 651 GACGCAGATAAAACTGCCGCCCGTCGATTTCCCGCTCACCGTCAGTCATC 
 701 GCATCCATTGGGCAATCATGGAGGAAGATAAGGTCAAGATCGGAACTGTA 
 751 GCCTAACTCCCAGCCGCCCAGCTTGCCGTAGCCGACCACCGCAAAACCAC 
 801 GCCCTTCGCGTTCGTTCAGGTGATTCGGCTTACCGTAGCGGGCAACCATT 
 851 TGAACCCACGCCTGCTGAACGACGGCATCTATCATGGCTTCCGCCAGCCA 
 901 GGTTAAGTGATCGCTCACTTCATCACCGGTAGCGTACCGGCGATATCCGC 
glnE sense primer    BamHI 
    5’-gaggatcctgcgcctgtttgaactgacgcagcgcctcaagctgttgctcttcgtcatcaattaaccctcactaaagggcg-3’ 
951 TGCGCCTGTTTGAACTGACGCAGCGCCTCAAGCTGTTGCTCTTCGTCATC 
1001 TTCCGGCACGCGCAGCAAATACTGGCGCAACTCATCGCGGTAGGCATCGG 
1051 TCGCCGTCGGCTGGTAAAGGGTGTTTGGATCGAGCAATTCATCCAGCAAT 
1101 AATGGATAACGCGCCAGCTGGCTGGCAATCATCGGCGACGCGGCACACAG 
1151 AGAAATCAAATGTTTAAGCGCCGCGGGGAATTCACTGAGCAATTCTAAAT 
1201 AGGTGGTGCGGGTAACAATCCCCACCAGCAAGGCGGTAATGCGCGACAGC 
1251 GTAACGGCAGCGTCTTCACGCGCACAGACATCACTTAGCAGATGCGGCAT 
1301 CAGATGGTCGAGCACCTGACGTCCTCGCGGCCCGATGGTGCGCTTATCCA 
1351 GCTCTTTGCGGAAATCGGCAATCAGCGTTAGCACCTGTTTGCGATCATCC 
1401 TCGCTAAGATGCGCCAGCACTGGCGTAGTGTCATCTTCCTGCAACGCATC 
1451 CTGCCACAGCTCACGCCACTGTTCCGACAGCGACTCTTCCTGAGTTTCAC 
1501 TTTCATCGTCGCCAATCAATTCATTAAACACCCGGCGCACATTGGTCATA 
1551 TGTGCGGTCAGCGCCCCGGTCAGTTGCGGCCAGTCAGCAAAGTCCATCGC 
1601 CCACGCCAGCCGCGCACGATTAAGCTCATCAGAAGGAAGCGTCTGGGTTT 
1651 GTTCGTCGTTAATGCTTTGCAGCAGGTTTTCCAGACGCCGCAGGAACAGA 
1701 TACGCCACTCGCAATTGTTCAGCATCGTTTTCAGAAAGCAGATGCAGCTC 
1751 GGCAATGGCGCTGAGCGTTGGCAGTAAAGATACCCATGCCTAAGGATCAG 
1801 GCGCGATTGCAGCGACGGTTCGCGTCCGCCGCGAATGAGCTGGAACACCT 
 3’-ctcgggatatcactcagcataatcgcgctaacgtcgctgccaagcgcaggcggcgcttactcgaccttgtggacctaggtg-5’ 
                                                          BamHI 
1851 GAACGATAAATTCAATTTCGCGAATGCCGCCTGCGCCGAGTTTGATATTG glnE antisense primer 
1901 CCTTTCATGTTGCGCAGCGACTGAATCACGCTGAAATCGATGTAACGACG 
1951 GAAAACAAACGGGCGCAGCATCGCACGCAACTCGTTAGCATAGACGCCTT 
2001 CGCTATCGCCCATAATCCGCGCCTTGACCATCGCGTAACGCTCCCAGTCG 
2051 CGCCCCTGCTCCTGGTAATAATCTTCCAACGCGGCAAAGCTCAGCACCAG 
2101 CGGGCCACTTTCGCCAAACGGACGCAGCCGCATATCCACGCGATAGACGA 
2151 AGCCATCCTGCGTTGGTTGATCCAGCACTTTAATCAGCCGCTGCCCCATG 
2201 CGGGTAAAAAACTGCGCGTTATCCAGTTCCCGGCGTCCACCCTGCGTACA 
2251 ACCATGTTCCGGCCAGGCAAAAATCAGATCGATATCAGAGGAGAAATTCA 
2301 GCTCCCCACCGCCCAGCTTACCCATGCCTAAAATCAGCAGCGGTTGCGCT 
2351 TCGCCCTGCGCATTGCACGGCGTTCCCCACTCGCGGCAGCAGGCGTCATA 
2401 CAGCCAGTCACGCGCCGCAACAATCAGCGTCTCCGCCAGATAGCTGAGCT 
2451 GCTGCAATATGCTCTCTTCAGTAACCAGTGCCAGCGTTTGCGCCCAGGCG 
2501 ATGCGCACCATAATGCGCCGCCGGAATAGCCGCAGCTCGCGCATTAACCC 
2551 GGCTTCGTCACTCACATTACAGAGCGCCTCCTGCAACCATGCCGCGTAAT 
2601 GCTGCCATTCGTCGGCCTGCGGCGGTTGGCTTTCCAGTTCCGTCAGCCAC 
2651 TCTGGATGCGCAATCACGCTGTCCTGCACAAAATCACTAAAAGTAAGTAC 
2701 TGACTTCGCCTGTGCGCTAAGTGATTCCTCGGCTAAAGGCTCTGGCAGCC 
2751 GCTCAACAACGGTCTGCCAGTACTGCTGTAACGGTGAAGAGAGCGGCTTC 
2801 AT 
Figure 2.3: DNA sequence of E.coli glnE showing gene orientation and primer positions. The glnE 
sense primer is indicated in red. The BamHI enzyme restriction site is on the 5’ site of the primer and 
is coloured blue. The primer also contains a region specific to the relevant gene adjoining a sequence 
specific to the kit-supplied FRT cassette and this region is bold and underlined on the 3’ side of the 
primer. The glnE antisense primer is indicated in green. The BamHI enzyme restriction site is on the 
5’ site of the primer and is coloured blue. The primer also contains a region specific to the relevant 
gene adjoining a sequence specific to the kit-supplied FRT cassette and this region is bold and 
underlined located on the 3’ side. 
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The knockout strains were produced using these primers as described in the kit 
protocol.  The only deviation from the protocol was the incorporation of BamHI 
restriction sites at the ends of the primers (shown in bold in Table 2.1).  This enabled 
the PCR products to be cloned into pGEM T-Easy (Promega Corporation), and the 
cassette was then cut out of the pGEM construct as a BamHI fragment.  Further 
preparation of the knock-out strains was as described in the protocol.   
The kanamycin (Kan) resistance marker was subsequently removed using the 706-
FLP plasmid carrying the site-specific recombinase, as described in the protocol.  
Integrations were confirmed by sequencing.   
 
The strain with the glnD deletion was designated YMC11D, while the strain with the 
glnE deletion was designated YMC11E.  
 
2.2.2 Cloning  
Molecular cloning of target DNA sequences into various vectors was done 
essentially as described by Sambrook et al., (1989). Target DNA sequences were 
cloned into vectors by simple T/A cloning or ligated into vectors after restriction 
enzyme digestion.  
 
2.2.2.1 Ligation and plasmid isolation 
All ligations were done with T4 DNA Ligase (Promega, T4 DNA Ligase) as per the 
manufacturer’s instructions. Ligation reactions were prepared by die addition of 1 µl 
T4 DNA ligase and  1 µl 10 x ligation buffer (Promega, T4 DNA Ligase) to the 
specific insert to vector ratio (20:1 or 3:1) and made up to a final volume of 10 µl with 
nuclease free water. The reaction was incubated overnight at 4ºC. The ligation was 
cleaned up by using the following method: the reaction mixture was dried in vacuo 
using a speedy vac (Sarvant, Speed Vac SC110) for 20 min and the pellet was 
dissolved in 1 ml ice cold (-20°C) 70% ethanol. It was centrifuged at 4°C at 10 000g 
for 30 min and the pellet dried for 10 min under vacuum.  The ligation mixture was 
resuspended in 2 µl dH2O and then transformed into the appropriate E.coli cells see 
sections 2.2.5 and 2.2.6. 
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Plasmids were isolated using the E.Z.N.A. ®Plasmid Miniprep Kit I (Peqlab 
Biotechnology GmbH, Germany). The composition of the E.Z.N.A. ®Plasmid Miniprep 
Kit I is proprietary and the kit was used as per manufacturer’s instructions.  The 
concentration of the plasmid DNA were determined by agarose gel electrophoresis 
making use of MassRuler™ Express DNA Ladder (Fermentas, Germany). 
 
2.2.3 Screening for positive clones 
2.2.3.1 Colony screening PCR 
Colony screening PCR was used to identify clones with the correct insert in pBSK or 
CDFDuet-1 vectors (Section 2.3.1, Figure 2.4).  In order to identify positive clones, 
colonies were randomly picked from fresh transformation plates and resusepended 
in 10 µl dH2O. As template, 1 µl of this bacterial culture was used. The sense 
oligonucleotide TB1: 5’-GATGGATCCACCCGATAACCAG-3’ and the antisense 
oligonucleotide TB2: 5’-GATGGATCCTCGAAAAACCTCG-3’, with both primers 
containing BamHI restriction site (sites underlined in primer sequences) were used to 
identify clones with the correct M.tb GS insert in pBSK. The sense and antisense 
oligonucleotide primer set TBglnE-8: 5’-TAGCATATGGTCGTGACCAAAC-3’ (NdeI 
restriction site underlined) and TBglnE-9: 5’-CAGGATCCTTAACTCCCGAACAC-3’ 
(BamHI restriction site underlined) were used to identify clones with the correct 
TBglnE insert in CDFDuet-1. The cycling conditions were as described in section 
2.2.8. The PCR products were analyzed by running on a 0.8% w/v agarose/TAE gel 
and checked for the correctly sized product as described in section 2.2.4. 
 
2.2.3.2 Restriction enzyme digestion 
Plasmid isolation (section 2.2.2) was carried out on the clones that gave the correctly 
sized band with colony screening PCR, followed by restriction enzyme digestion 
(Sections 2.3.1.1, 2.3.1.2 and 2.3.1.3).  The samples were analysed using a 0.8% 
w/v agarose/TAE gel to verify possible positive clones. 
 
2.2.4 Agarose gel electrophoresis and purification of PCR products 
All PCR reactions and restriction digests were analyzed on 0.8% w/v agarose 
(Promega, USA)/TAE (0.04 M Tris-acetate, 1 mM EDTA, pH 8.0) gels in TAE (0.04 
M Tris-acetate, 1 mM EDTA, pH 8.0) running buffer at 4-10 V/cm.  Each sample was 
loaded in 1x loading dye (0.025% w/v bromophenol blue and 30% v/v glycerol).  
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 2  METHODS 
27 
 
GeneRuler™ 1kb DNA ladder (Fermentas, USA) was used as molecular marker.  
The agarose/TAE gels contained ethidium bromide (EtBr), a DNA base intercalator 
(1.25 ng/ml), for DNA visualization.  The DNA bands were visualized at 312 nm on a 
Bio-Rad Chemidoc Gel Documentation System (Bio-Rad Laboratories, USA), using 
the QuantityOne software.  PCR products were purified (for removal of primer 
dimers, template and non-specific contaminants) using a High Pure PCR Purification 
Kit (Roche diagnostics, Germany). 
 
2.2.5 Preparation of E.coli electrocompetent cells and transformation 
Electrocompetent cells were prepared by the following method (Sambrook et al., 
1989): a single colony of E.coli from the purchased E.coli strain (Novagen, Madison, 
Wisconsin, USA) was inoculated into 5 ml Luria-Bertani (LB) liquid media (1% 
Tryptone, 0.5% yeast extract, 1% NaCl at pH 7) and grown overnight at 37°C with 
shaking (220 rpm on an orbital shaker).  Fresh LB-Broth (50 ml) was inoculated with 
1 ml of the overnight culture and grown at 37°C with shaking (220 rpm on an orbital 
shaker) until the cells reached early to mid-log phase (OD at 600 nm of 0.3-0.6).  To 
harvest the cells, the culture was transferred to two cold 4°C centrifuge tubes and 
pelleted at 4,000g in a Sorvall RC-5C Plus (Sorvall, UK) for 10 minutes (min) at 4°C.  
All the subsequent steps were done at 4°C.  After the supernatant was discarded, 
the cells were washed with 250 ml ice-cold water.  The suspension was centrifuged 
at 4,000g in a Sorvall RC-5C Plus (Sorvall, UK) for 10 min.  This washing step was 
repeated twice.  After the final centrifugation step, the supernatant was immediately 
removed from the loose pellets.  The pellets were resuspended in 10 ml of ice-cold 
10% glycerol in water and incubated on ice for 30 min.  Cells were subsequently 
pelleted (3,000g for 10 min), the supernatant removed and the pellets resuspended 
in 800 μl of 10% ice-cold glycerol.  This was divided into 100 μl aliquots and frozen 
at -70°C. The prepared electrocompetent cells were thawed from -70°C on ice when 
required.  After 10-50 ng plasmid was added to 100 µl cells, the mixture was 
transferred to a pre-chilled 2 mm electroporation cuvette (Hybaid) and a pulse of 
2500 V applied for 5 ms in a Bio-Rad MicroPulser electroporator (Bio-Rad 
Laboratories, Hercules, California) (Dower et al., 1988).  LB liquid media (1 ml) was 
added directly after electroporation and the cells were incubated for 1 hour at 37°C 
with shaking (180 rpm on an orbital shaker).  The transformation mixture was plated 
at different volumes (50 µl, 100 µl and 250 µl) on LB agar (1.5% w/v Bacto-agar in 
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LB medium, autoclaved for 20 min at 121°C) plates containing the appropriate 
antibiotic for the pTBSK construct ampicillin (final concentration of 0.1 mg/ml) was 
added and for the pTBglnE construct both ampicillin (final concentration of 0.1 
mg/ml) and streptomycin (final concentration of 0.05 mg/ml) were added.  The LB 
agar plates were incubated at 37°C for 16 hours in a Sarvall incubator. Colonies on 
these plates were subsequently screened using PCR as described in section 2.2.3.1 
to identify positives colonies.  
 
2.2.6 Preparation of E.coli TSB competent cells and transformation 
A single colony of E.coli was inoculated into 5 ml Luria-Bertani (LB) liquid media (1% 
Tryptone, 0.5% yeast extract, 1% NaCl at pH 7) and grown overnight at 37°C with 
shaking (220 rpm).  Fresh LB-Broth (50 ml) was inoculated with 1 ml of the overnight 
culture and grown at 37°C with shaking (220 rpm) until the cells reached early to 
mid-log phase (OD at 600 nm of 0.3-0.6).  The culture was transferred to a pre-
chilled sterile centrifuge tube and centrifuged at 4,000g for 5 min at 4°C.  After the 
supernatant was discarded, the cells were resuspended in 5 ml ice-cold 
Transformation and Storage Buffer (TSB, 1% Tryptone, 0.5% yeast extract, 1% 
NaCl, 2% PEG 4000, 10mM MgCl2 and 10mM MgSO4)) and incubated on ice for 
approximately 10 min.  This step was followed by transformation. The freshly 
prepared competent cells were used.  100 µl of the cells were mixed with 10-100 ng 
of DNA (as prepared in section 2.2.2 and 2.2.4) in a chilled Eppendorf tube.  The 
transformation mix was placed on ice for 15 min.  After the 15 min incubation, 900 µl 
of ice-cold TSB was added and incubated at 37°C for 60 min to allow expression of 
the antibiotic resistance gene present on the plasmid.  The transformation mixture 
was plated on LB agar plates containing the appropriate antibiotic. 
 
2.2.7 Creating YMC11E(DE3) from YMC11E 
The Novagen λDE3 Lysogenization Kit was used to create YMC11E(DE3). This kit is 
designed for the site specific integration of λDE3 prophage into E.coli chromosome, 
such that the lysogenized host can be used to express target genes cloned in the 
vectors under the control of the T7 promoter. Lysogenization is accomplished in a 
three-way infection with λDE3, a helper phage (B10) and a selection phage (B482). 
The kit also contains a tester phage (4107) for verification of λDE3 lysogeny on most 
host strains, and a positive control lysogen. All phage are provided as clarified 
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lysates, and the positive control lysogen is provided as a glycerol stock. 
Lysogenization of YMC11E was done according to the manufactures manual.  
 
2.2.8 Cloning of M.tb GS and ATase 
The complete coding region of M.tb GS glnA gene was PCR amplified and cloned 
into expression vector pBluescript SKII+ (Agilent Technologies, Germany) plasmid 
map available in Appendix A.  In short, genomic DNA from M.tb H37Rv (ATCC 
25618) from Professor Paul van Helden at the University of Stellenboch was used as 
template during the amplification reaction using Taq DNA polymerase (Strategene, 
USA), together with the sense oligonucleotide TB1: 5’-
GATGGATCCACCCGATAACCAG-3’  and the antisense oligonucleotide TB2: 5’-
GATGGATCCTCGAAAAACCTCG-3’, with both primers containing BamHI restriction 
site (sites underlined in primer sequences). Ex-Taq DNA polymerase (Bioline) was 
routinely used for DNA amplification of up to 2000 base pairs (bp). A typical PCR 
reaction contained 250 nM of each oligonucleotide (forward and reverse primer), 200 
µM of each deoxynucleotide triphosphate (dNTP, Bioline), 1 x reaction buffer 
(supplied), 1 U Ex-Taq polymerase, approximately 80-100 ng DNA template and 
dH2O to a final volume of 25 µl.  The following cycling conditions were used for the 
PCR reaction: 95°C for 5 min which was followed by 30 cycles of 95°C for 1 min, 
50°C for 1 min and 72°C for 1 min, followed by 72°C for 5 min.  Both the PCR 
product and vector were digested with the restriction enzyme BamHI since both the 
oligos were designed with this restriction enzyme site and ligated into pBSK to form 
the final construct, hereafter referred to as pTBSK  with the glnA gene under control 
of the constitutive T3 promotor. The final construct was sent for sequencing at 
Inqaba biotec for verification. 
 
The complete coding region of M.tb adenylyl transferase glnE gene was PCR 
amplified from genomic H37Rv DNA using the sense and antisense oligonucleotide 
primer set TBglnE-8: 5’-TAGCATATGGTCGTGACCAAAC-3’ (NdeI restriction site 
underlined) and TBglnE-9: 5’-CAGGATCCTTAACTCCCGAACAC-3’ (BamHI 
restriction site underlined).  The same PCR reaction mix was used as described in 
section 2.2.8. The following cycling conditions were used for the PCR reaction: 95°C 
for 5 min which was followed by 30 cycles of 95°C for 1 min, 56°C for 1 min and 
72°C for 3 min, followed by 72°C for 5 min. The amplified DNA was then co-digested 
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with NdeI and BamHI and ligated into pGEM-T Easy (Novagen, United Kingdom). A 
ligation mixture was set up at a picomole insert:vector ratio of 20:1 using T4 DNA 
Ligase (Promega Corporation, USA) as per the manufacturer’s instructions. The 
TBglnE insert was ligated into pGem T-easy vector. The ligation was cleaned up by 
using the following method: the reaction mixture was dried in vacuo using a speedy 
vac (Sarvant, Speed Vac SC110) for 20 min and the pellet was dissolved in 1 ml ice 
cold (-20°C) 70% ethanol. It was centrifuged at 4°C at 10 000g for 30 min and the 
pellet dried for 10 min under vacuum.  The ligation mixture was resuspended in 2 µl 
dH2O and then transformed into electrocompetent XL10 Gold as per section 2.2.5. 
The transformation mixture was plated on LB agar plates (1.5% w/v Bacto-agar in LB 
media, autoclaved for 20 min at 121°C) containing 100 g/mL ampicillin, 80 g/mL 5-
bromo-4-chloro-indolyl-β-D-galactopyranoside (X-Gal) and 0.1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG). The plates were incubated at 37°C in a Sarvall 
incubator for 16 hours.  White colonies on these plates were subsequently screened 
using PCR (section 2.2.3.1) to identify positives containing the TBglnE gene. The 
plasmid was isolated described in section 2.2.2, digested with NdeI and BamHI and 
the TBglnE fragment purified from agarose gel see section 2.2.4. The purified DNA 
fragment was ligated (see section 2.2.2) with a NdeI and BglII digested expression 
vector CDFDuet-1 (Novagen, United Kingdom) to construct pTBglnE the plasmid 
maps are available in Appendix A, with glnE downstream of the IPTG-inducible T7lac 
promoter. 
2.2.9 Recombinant protein expression of adenylylated and deadenylylated M.tb 
GS and E.coli GS in E.coli 
For comparison of the production of M.tb GS in E.coli, adenylylated and 
deadenylylated E.coli GS were heterologously expressed and purified.  Recombinant 
deadenylylated E.coli GS was produced in an E.coli strain lacking chromosomal glnA 
(GS) and glnE (ATase) genes.  Adenylylated E.coli GS was produced in a strain 
lacking chromosomal glnA (GS) and glnD (uridylyl transferase) genes (Kenyon et al., 
2011). 
 
2.2.9.1 Production of deadenylylated E.coli GS 
The E.coli YMC11 strain in which the endogenous GS gene is knocked out was used 
as the basic expression host.  To enhance the expression of fully deadenylylated 
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E.coli GS, the endogenous chromosomal E.coli glnE adenylyl transferase gene was 
deleted using the Quick and Easy E.coli Gene Deletion Kit (Gene Bridges, GmbH) to 
create the strain YMC11E as per section 2.2.1.  A pBSK plasmid vector containing 
the glnA gene encoding E.coli GS under the transcriptional control of a constitutive 
T3 promoter was used to transform YMC11E by electroporation as described in 
section 2.2.5.  The resultant recombinant E.coli strain was named pBSK-ECgln 
(YMC11E). This work is published by Kenyon et al., 2011. 
 
pBSK-ECgln (YMC11E) was inoculated into 50 ml LM medium (1% tryptone, 0.5% 
yeast extract, 1% NaCl) supplemented with 50 µl Ampicillin (100 µg/ml).  The 
inoculum was grown at 37ºC for 16 hours with shaking at 220 rpm. Subsequently, 
1ml of the culture was transferred to 50 ml LM medium supplemented with 50 µl 
Amp100.   This second inoculum was again grown at 37ºC for 6 hours with shaking at 
220 rpm.  Subsequently, 8 ml of the culture was transferred to a modified M9 
medium (6 g/l Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl pH 6.3) supplemented with 70 
mM L-glutamate, trace salts (1,000x stock: 4.5 mM CaCl2.2H2O, 6.2 mM FeCl3.6H2O, 
0.63 mM ZnCl2, 0.64 mM CuSO4.5H2O, 0.76 mM CoCl2.6H2O, 2.4 mM MnCl2.4H2O), 
4% glucose, 1 mM MgSO4, 0.1 mM CaCl2 and 1 mM thiamine.  The culture was 
grown at 37ºC for 16 hours with shaking at 220 rpm.  The cells were harvested by 
centrifugation for 10 min at 16,300g and the bacterial pellet used for deadenylylated 
E.coli GS purification. 
 
2.2.9.2 Production of adenylylated E.coli GS 
The E.coli YMC11 strain, lacking the endogenous glnA gene was used.  However, to 
enhance the expression of fully adenylated E.coli GS, the endogenous E.coli uridylyl 
transferase gene (glnD) was deleted using the Quick and Easy E.coli Gene Deletion 
Kit (Gene Bridges, GmbH) to create the strain YMC11D as per section 2.2.1.  The 
same vector as in 2.2.9.1 was introduced into YMC11D by electroporation.  The 
resultant E.coli strain was named pBSK-ECgln (YMC11D).  
 
pBSK-ECgln (YMC11D) was used for the expression of adenylylated GS using a 
similar method to that described above for deadenylylated GS.  The only difference 
is the addition of 5 mM L-glutamine to the M9 medium. The cells were harvested by 
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centrifugation for 10 min at 16,300g and the bacterial pellet used for adenylylated 
E.coli GS purification. 
 
2.2.9.3 Production of deadenylylated M.tb GS 
The E.coli YMC11 strain in which the endogenous GS gene is knocked out was used 
as the basic expression host see section 2.2.9.2.  To enhance the expression of fully 
deadenylylated M.tb GS, the endogenous E.coli adenylyl transferase glnE gene was 
also knocked out by homologous recombination to produce the YMC11E strain as 
per section 2.2.1.  The pTBSK plasmid vector containing the glnA gene encoding 
M.tb GS under the transcriptional control of a constitutive T3 promoter was used to 
transform YMC11E by electroporation. The resultant recombinant E.coli was named 
pTBSK (YMC11E). 
 
pTBSK (YMC11E) was inoculated in 50 ml M9ZB medium (1% w/v N-Z-Amine A; 85 
mM NaCl) containing M9 Salts (22 mM Na2HPO4; 22 mM KH2PO4; 18 mM NH4Cl; 
8.5 mM NaCl) and supplemented with 100 μg/ml ampicillin, 1mM MgSO4 and 4% 
(w/v) glucose.  The inoculum was grown at 28ºC (after temperature studies the 
optimal incubation temperature of 28˚C was selected) for 16 hours with shaking at 
220 rpm on an orbital shaker.  Subsequently, 5 ml of the culture was transferred to 
250 ml of the same medium and the culture grown at 28ºC for 16 hours.  The 
cultures were harvested by centrifugation for 10 min at 16,300g (4ºC) and the 
bacterial pellet used for deadenylylated M.tb GS purification.  
 
2.2.9.4 Production of adenylylated M.tb GS 
Adenylylated M.tb GS was produced using YMC11E(DE3) containing both pTBSK 
and pTBglnE see section 2.2.8.  This strain was inoculated into 50 ml of the same 
medium as in section 2.2.9.3, including 50 µg/ml streptomycin.  The cultures were 
incubated at 33ºC (after temperature studies the optimal incubation temperature of 
33˚C was selected) for 16 hours with shaking at 220 rpm.  Thereafter, 5 ml was 
transferred to 250 ml of the same medium and grown at 33ºC for a further 8 hours.  
M.tb adenylyl transferase expression was then induced by the addition 1 mM IPTG.  
After a further incubation at 33ºC for 16 hours with shaking at 220 rpm on an orbital 
shaker, the cultures were harvested by centrifugation for 10 min at 16,300g (4ºC) 
and the bacterial pellet used for adenylylated M.tb GS purification. 
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2.2.10 Quality control of isolated M.tb GS and E.coli GS 
2.2.10.1 Protein concentration 
Protein concentrations were determined by using the Quant-ITTM Protein Assay Kit 
(Invitrogen, USA) that is used in conjunction with the QUBITTM fluorometer. The 
protein-containing sample is made up to 10 μl, to which 190 μl of the Quant-ITTM 
working solution (1 μl Quant-ITTM reagent and 199 μl Quant-ITTM buffer) is added. 
After 15 minutes incubation at room temperature, the fluorescence is quantified by 
using the QUBITTM fluorometer. The following protein standards 0 ng/µl, 200 ng/µl 
and 400 ng/µl were included in the Quant-ITTM Protein Assay Kit and used in 
conjunction with the QUBITTM fluorometer as per supplier’s manual.    
 
2.2.10.2 SDS-PAGE analysis 
Sodium dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to analyse the molecular mass and purity of the isolated enzymes.  Gels consisted of 
a 4% stacking gel (4% Bio-Rad Acrylamide-Bisacrylamide mix, 0.1% SDS, 0.05% 
ammonium persulphate, 0.1% TEMED, 0.05 M Tris- HCl, pH 6.8) and a 12% 
separating gel (12% Bio-Rad Acrylamide-Bisacrylamide mix, 0.1% SDS, 0.05% 
ammonium persulphate, 0.1% TEMED, 0.375 M Tris-HCl, pH 8.8).  An aliquot of 
protein sample (±60 µg) was transferred to a clean microcentrifuge tube. 
Subsequently, an equal volume of denaturing buffer (1.2% SDS, 30% glycerol, 15% 
ß-mercaptoethanol, 0.18 mg/ml bromophenol blue, 0.15 M Tris, pH 6.8) was added. 
The protein samples were denatured at 90°C for 5 minutes.  Ten μl of each sample 
was loaded onto the gel. Electrophoresis was performed in a 0.025 M Tris, 0.2 M 
Glycine, 0.1% SDS buffer (pH 8.3) at 200 V in a Bio-Rad Mini Protean 3 
Electrophoresis system. Protein bands were visualized with Coomassie Blue G250 
staining solution (0.1 g Coomassie Blue G250 in 40% methanol, 10% acetic acid), 
followed by destaining (40% methanol, 10% acetic acid). 
 
2.2.10.3 -glutamyl transferase assay for enzyme activity 
This functional assay was carried out to: i) confirm the functionality of the purified GS 
enzyme; and ii) assess the degree of adenylylation of the purified enzymes.  Both 
the adenylylated and deadenylylated forms of the enzymes were found to be active 
in this assay in the presence of Mn2+. When the same assay is further supplemented 
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with Mg2+, only the deadenylylated enzyme is active. The activities of the two forms 
of the enzyme are therefore differentiated on the basis of the difference in activity in 
the presence of Mn2+ or Mg2+.  The assay protocol was adapted from Shapiro and 
Stadtman (1970).  The composition of the Mn2+ reaction mix was 15 mM L-glutamine, 
0.4 mM Na.ADP, 30 mM sodium arsenate, 0.3 mM MnCl2, 60 mM hydroxylamine in 
50 mM imidazole buffer (pH 7.0).  The composition of the Mn2+ + Mg2+ reaction mix 
was the same, except that an additional 60 mM MgCl2 was added.  A blank reaction 
mix was prepared in the same manner as the Mn2+ reaction, but the ADP and 
arsenate components were absent.  Both assays were carried out in a total volume 
of 600 μl.  The assay mix was equilibrated for 5 min at 37°C, and then initiated by the 
addition of 50 μl of purified enzyme preparation.  The reaction was allowed to 
proceed for 30 min and then terminated by the addition of 900 μl Stop Mix (1 M 
FeCl3, 0.2 M trichloroacetic acid, 7.1% v/v HCl).  The samples were centrifuged at 
10,361g for 2 min to remove any precipitate, and the absorbance measured at 540 
nm in a Perkin Elmer precisely lambda 35 UV/VIS spectrometer.  The degree of 
adenylylation was calculated from the ratio of the deadenylylated γ-glutamyl 
transferase activity (Mn2+ + Mg2+ reaction) to the total γ-glutamyl transferase activity 
(Mn2+ reaction), taking the number of subunits into account (Shapiro and Stadtman, 
1970). 
 
2.2.11 Purification of adenylylated and deadenylylated M.tb GS and E.coli GS 
2.2.11.1 Purification of adenylylated and deadenylylated M.tb GS  
Step 1 (streptomycin sulphate precipitation): The bacterial pellet (prepared in section 
2.2.9.3 and 2.2.9.4) was resuspended in 10 ml of RBA (10 mM imidazole pH 7, 10 
mM MnCl2) buffer and sonicated for 20 min on a 50% on/off cycle with a Vibracell 
sonicator (Sonics and materials Inc, USA) with a 40% dutycycle and a 5 output 
controle, followed by centrifugation for 10 min at 12,100g (4ºC) to collect the soluble 
E.coli lysate.  A precipitation step was carried out to eliminate nucleic acids by 
adding streptomycin sulphate to a final concentration of 1% w/v and stirring at 4ºC 
for 10 min.  After centrifugation for 10 min at 12,100g (4ºC), the supernatant was 
retained and the pH was adjusted to pH 4.4 with 8% HCl.  The supernatant was 
slowly stirred at 4ºC overnight, followed by centrifugation at 12,100g (4ºC) for 10 min 
and aspiration of the supernatant. 
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Step 2 (anion-exchange chromatography): A column containing 5 ml bed volume 
DEAE Sepharose CL-6B (Pharmacia Biotech) was prepared and equilibrated with 5 
column volumes of Buffer H (50 mM HEPES pH 7.6, 10 mM MnCl2) containing 
100 mM NaCl.  The final supernatant from Step 1 was applied and the column 
washed with 10 column volumes of Buffer H containing 100 mM NaCl.  Bound M.tb 
GS was eluted by applying a step gradient of Buffer H containing 0.4 M, 0.5 M, 0.6 M 
and 0.7 M NaCl.  Fractions were collected and assayed for the presence of M.tb GS 
using the -glutamyl transferase assay see section 2.2.10.3.  The fractions with GS 
activity were pooled and dialysed in SnakeSkinTM dialysis tubing (Thermo Scientific, 
USA) with a 10,000 molecular weight cut off overnight against Buffer H containing 
100 mM NaCl as per supplier’s manual. 
 
Step 3 (AMP affinity chromatography): A column containing 5 ml bed volume AMP 
Sepharose (Sigma A1271 adenosine-5’-monophosphate-agarose, cross-linked 4% 
beaded agarose) was prepared and equilibrated with 5 column volumes of Buffer A 
(10 mM imidazole pH 7.0, 10 mM MnCl2, 150 mM NaCl).  The pooled M.tb GS 
fractions from Step 2 were applied and allowed to bind for 1 ½ hours with gentle 
shaking at 4ºC. The column was washed with 10 column volumes Buffer A.  M.tb GS 
was eluted with 10 ml of Buffer B (10 mM imidazole pH 7.0, 10 mM MnCl2, 450 mM 
NaCl, and 2.5 mM ADP).  Fractions were collected and the fractions with -glutamyl 
transferase (see section 2.2.10.3) activity were pooled and dialysed in SnakeSkinTM 
dialysis tubing (Thermo Scientific, USA) with a 10,000 molecular weight cut off 
overnight against Buffer H containing 100 mM NaCl as per supplier’s manual. 
 
Sodium dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) described 
in section 2.2.10.1 was used to analyse the molecular mass and purity of the isolated 
enzymes.  Protein concentrations were determined by using the Quant-ITTM Protein 
Assay Kit (Invitrogen, USA) which includes the following protein standards 0 ng/µl, 
200 ng/µl and 400 ng/µl in conjunction with the QUBITTM fluorometer as per 
supplier’s manual.    
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2.2.11.2 Purification of adenylylated and deadenylylated E.coli GS 
Step 1 (streptomycin sulphate precipitation): The bacterial pellet (prepared in section 
2.2.9.1 and 2.2.9.2) was resuspended in 10 ml of RBA (10 mM imidazole pH 7, 10 
mM MnCl2) and sonicated for 20 min on a 50% on/off cycle (as described in section 
2.2.11.1), followed by centrifugation for 10 min at 12,100g (4ºC) to collect the soluble 
E.coli lysate.  A precipitation step to eliminate nucleic acids was carried out by 
adding streptomycin sulphate to a final concentration of 1% and stirring at 4ºC for 10 
min.  After centrifugation for 10 min at 12,100g (4ºC) the supernatant was retained 
and the pH was adjusted to pH 5.15 with dilute HCl (8%).  The supernatant was 
stirred at 4ºC for 15 min, followed by centrifugation at 12,100g for 10min (4ºC).  The 
supernatant was retained, and 30% by volume of ice cold (4ºC) saturated (NH4)2SO4 
solution was added.  The pH was adjusted to pH 4.6, and the solution stirred at 4ºC 
for 15 min, followed by centrifugation at 12,100g for 10 min (4ºC).  The precipitate 
was resuspended in 5 ml RBA and stirred at 4ºC for 3 hours, before the pH was 
adjusted to pH 5.7.  Stirring continued at 4ºC overnight, followed by centrifugation at 
12,100g for 10 min (4ºC).  
 
Step 2 (AMP affinity chromatography): A 5 ml Bed volume AMP Sepharose column 
(Sigma A1271 adenosine-5’-monophosphate-agarose, cross-linked 4% beaded 
agarose) was prepared and equilibrated with 5 column volumes of Buffer A (10 mM 
imidazole pH7, 10 mM MnCl2, 150 mM NaCl).  The E.coli GS supernatant from Step 
1 was applied and allowed to bind for 1 hour with gentle shaking at 4ºC.  The column 
was washed with 10 column volumes of Buffer A.  The E.coli GS was eluted with 
12 ml of Buffer B (10 mM imidazole pH7, 10 mM MnCl2, 450 mM NaCl, 2.5 mM 
ADP).  Fractions were collected and assayed using the -glutamyl transferase assay 
(see section2.2.10.3).  The fractions with E.coli GS activity were pooled and dialysed 
in SnakeSkinTM dialysis tubing (Thermo Scientific, USA) with a 10,000 molecular 
weight cut off overnight against RBA as per supplier’s manual. 
 
2.2.12 Mass Spectrometry 
An ABI QSTRA-ELITE (QTOF) Mass Spectrometer was used. A 40 µl aliquot of 
purified GS in 10 mM imidazole pH 7.0 was loaded on an OPTI-LYNX C4 trap 
cartridge at 100 µl/min using 2% acetonitrile and 0.1% formic acid.  Samples were 
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eluted using linear acetonitrile gradient (2-90% acetonitrile and 5% formic acid) in 
5min and TOF-MS spectra, in the range 700-1700 mz, collected using an ABI 
QSTRA-Elite mass spectrometer with TurboIon source installed.  The multiply 
charged series of TBGS was deconvoluted by the Bayesina Protein Recostruct tool 
of Bioanalyst QS 2.0 using a mass range of 40-70 kD and signal to noise threshold 
of three.  
 
2.2.13 Hydrolysis of GS for determination of phosphate content 
The relative phosphate content of the purified GS proteins was determined by 
hydrolysis to release the phosphate (Ludden and Burris, 1978).  Purified GS (4 to 8 
nmol in 1 ml) was digested by the addition of 4 M HCl (1 ml), the mixture was mixed 
carefully by inverting the tubes and then evaporated to dryness in air.  The residue 
was resuspended in 2 M HCl (1 ml) plus 20 µl of H2O2 (30% v/v), and the mixture 
was again evaporated to dryness.  Five sequential additions of H2O2 (200 µl) with 
evaporation to dryness were used to complete the hydrolysis.  The residue was 
resuspended in Milli-Q water (1 ml), and phosphate content was determined by using 
the BioVision Phosphate colorimetric assay kit as per supplier’s manual.   
 
2.2.14 HPLC analysis 
Samples were analysed on a Agilent series 1100 HPLC fitted with a Phenomenex 5µ 
LUNA C18 column.  Each sample was automatically injected (2 µl) and separated 
with a mobile phase containing 51 mM KH2PO4, PIC A Low UV Reagent (Waters 
Coorperation), 25% (v/v) acetonitrile.  The flow rate of the mobile phase was 1 
ml/min with UV detection. An AMP, ADP and ATP standard was used to calibrate the 
HPLC and the concentration of ADP in each sample was determined by the area 
under the curve, using Agilent ChemStation (Revision B.02.01) software.  The ADP 
values in the blank wells were subtracted from enzyme-containing wells, and 
percentage enzyme activity in each well calculated relative to the average net ADP 
values of the control wells. 
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2.3 Results 
2.3.1 Construction of pTBSK and M.tb glnE-CDFDuet for the expression of 
adenylylated and deadenylylated M.tb GS 
The M.tb glnE gene, encoding adenylyl transferase (ATase), was inserted into the 
second multiple cloning site (MCS) of the Novegen vector CDFDuet-1.  The MCS is 
preceded by a T7lac promoter and ribosome binding site.  The vector carries the 
CloDF13-derived CDF replicon, the lacI gene and the streptomycin resistance gene, 
and was designated pTBglnE.  This CloDF13 replicon is compatible with a number of 
replicons, including the ColE1 replicon found in pBluescript vectors.  pBluescript 
vectors carry the ampicillin resistance gene.  The M.tb glutamine synthetase glnA 
gene is contained in pBluescript SKII+, in a construct named pTBSK.  The 
compatible replicons and different antibiotic resistance markers enable the plasmids 
to be used in combination for co-expression in a single host strain.  The expression 
of glnA is constitutive, under control of the T3 promoter, while the expression of glnE 
is under the regulation of the T7lac promoter and is induced by the addition of IPTG.  
Both plasmids are indicated in Figure 2.4.  
 
These two vectors were introduced into the E.coli GS auxotrophic strain containing a 
deletion in the E.coli glnE gene (YMC11E).  To allow IPTG-inducible expression of 
the M.tb adenylyl transferase from the T7lac promoter in pTBglnE, the strain was a 
lysogen of bacteriophage DE3. 
 
 
 
 
 
 
 
 
 
Figure 2.4: (A) Vector map of pTBglnE for IPTG-inducible expression of M.tb glnE. (B) Vector map of 
pTBSK for constitutive expression of M.tb glnA. 
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2.3.1.1 Construction of pTBSK expression vector 
Both the PCR product and expression vector were digested with the restriction 
enzyme BamHI and ligated to form the final construct, hereafter referred to as 
pTBSK, with the glnA gene under control of the constitutive T3 promotor. After 
plasmid isolation pTBSK was digested with BamHI and the resulting fragments at 
2,961 bp (vector backbone) and 1,703 bp (glnA insert) are indicated in Figure 2.5 
lane 2. 
 
                                       
Figure 2.5: Restriction enzyme digest of pTBSK to verify the correct insert and vector size. Lane 1: 
NEB 1kb marker, with the sizes indicated in kb on the left. Lane 2: BamHI digest of pTBSK with the 
vector at 2,961 bp and the glnA insert at 1,703 bp. 
2.3.1.2 Construction of M.tb glnE-CDFDuet expression vector 
The complete coding region of M.tb glnE was amplified and cloned into the pGEM-T 
Easy vector (Novagen). Genomic DNA from M.tb H37Rv cultures was used as 
template during the amplification reaction and the fragments cloned as described in 
section 2.2.8. The plasmid was isolated and a digest was set up with NdeI, BamHI 
and XmnI. As can seen from Figure 2.6, NdeI/BamHI/XmnI digestion of M.tb 
glnE:pGEM-T should give fragments of ~3 kb, ~2 kb and ~1 kb.  XmnI was included 
to fragment the ~ 3 kb backbone into ~2 kb and ~1 kb, in order to separate it from 
the ~3 kb desired  M.tb glnE fragment. The digest was analyzed on a 0.8% 
agarose/TAE gel and the NdeI/BamHI fragment was cut out and purified. 
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Figure 2.6: Restriction enzyme digest of M.tb glnE:pGEM-T to verify the correct insert and vector 
size. Lane 1: NEB 1kb marker, with the sizes indicated in kb on the left. Lane 2: NdeI, BamHI and 
XmnI enzyme digest of M.tb glnE:pGEM-T with the vector at ~1 kb and ~2 kb and the M.tb glnE insert 
at ~3 kb.    
Agarose gel elecrophoresis of the purified M.tb glnE fragment determined the 
concentration at ~17 ng by the Mass ruler as indicated in Figure 2.7 A. The purified 
M.tb glnE fragment was used as insert and ligated into the NdeI/BglII enzyme sites 
of the CDF-Duet-1 vector. From a positive colony the pTBglnE plasmid was isolated 
and restriction enzyme digested to confirm the fragments as indicated in Figure 2.7 
B. Restriction enzyme digests of pTBglnE with KpnI will give the following fragment 
sizes: 59 bp, 1,243 bp and 5,459 bp in size. When the expected fragment sizes were 
compared with the fragment sizes in Figure 2.7 B lane 3 it was concluded that the 
insert was ligated correctly into the vector. Just to verify the following digest was also 
set up: Lane 4: NcoI digest, with fragments of 2,640 bp and 4,121 bp in size. Lane 5: 
PstI digest, with fragment of 153 bp, 547 bp, 591 bp, 735 bp, 801 bp and 3,934 bp in 
size. Lane 6: PvuI digest, did not cut. Lane 7: SalI digest, with fragments of 26 bp, 
235 bp, 292 bp, 2,097 bp and 4,111 bp in size. Lane 8: XhoI digest, with fragments 
of 144 bp, 420 bp, 618 bp, 1,018 bp and 4,561 bp in size. All of these correspond 
with the expected fragments sizes as indicated in Figure 2.7 B.    
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Figure 2.7: (A) Concentration determination of M.tbglnE: Lane 1: Mass Ruler Express High range 
(Fermentas). Lane 2: M.tb glnE with an estimate concentration of ~17 ng. (B) Restriction enzyme 
digests of pTBglnE: Lane 1: NEB 1kb marker. Lane 2: ClaI digest, did not cut. Lane 3: KpnI digest, 
with fragments of 59 bp, 1,243 bp and 5,459 bp in size. Lane 4: NcoI digest, with fragments of 2,640 
bp and 4,121 bp in size. Lane 5: PstI digest, with fragment of 153 bp, 547 bp, 591 bp, 735 bp, 801 bp 
and 3,934 bp in size. Lane 6: PvuI digest, did not cut. Lane 7: SalI digest, with fragments of 26 bp, 
235 bp, 292 bp, 2,097 bp and 4,111 bp in size. Lane 8: XhoI digest, with fragments of 144 bp, 420 bp, 
618 bp, 1,018 bp and 4,561 bp in size.     
  
2.3.1.3 Co-transformation of pTBSK and TBglnE:CDFDuet-1  
Plasmids pTBSK and pTBglnE were transformed into TSB competent 
YMC11E(DE3), with selection requiring both ampicillin and streptomycin due to the 
antibiotic resistance gene on pTBSK and pTBSglnE plasmids respectively.  Plasmid 
purification and restriction enzyme digests were done to verify the presence of both 
plasmids, with the correct fragments indicated in Figure 2.8. On the left hand side of 
Figure 2.8 the numbers represents the fragment sizes of the 1kb marker. When 
pTBSK and pTBglnE plasmids were digested with SalI the following fragment sizes 
were expected 2,097 bp, 3,173 bp and 4,111 bp. This was confirmed with the 
fragment sizes obtained in Lane 2 of Figure 2.8 for pTBSK and pTBglnE enzyme 
digest of the plasmids, therefore both the plasmids and the fragment were present 
and correct. The SalI enzyme digest of pTBglnE should provide two fragments 
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(2,097 bp and 4,111 bp in size). These sizes were obtained and are indicated in 
Lane 4 of Figure 2.8. 
 
 
                                    Size(kb) 
                                            
Figure 2.8: Enzyme digests of pTBSK + pTBglnE and pTBglnE alone. Lane 1: NEB 1kb marker. Lane 
2: SalI digest of pTBSK + pTBglnE with fragment sizes of 2,097 bp, 3,173 bp and 4,111 bp. Lane 3: 
Empty lane. Lane 4: SalI digest of pTBglnE with fragment sizes of 2,097 bp and 4,111bp.    
 
2.3.2 Production and purification of adenylylated and deadenylylated M.tb GS 
and E.coli GS  
Deadenylylated M.tb GS was expressed from pTBSK in E.coli YMC11E.  
Adenylylated M.tb GS was produced in YMC11E(DE3) via co-expression of M.tb GS 
in pTBSK and M.tb ATase in pTBglnE.  M.tb GS was expressed constitutively, while 
ATase production was induced by the addition of IPTG.  The two plasmids used 
contain compatible origins of replication and can thus be maintained stably in the 
same strain.  Figure 2.9 illustrates a SDS-PAGE of the cell-free E.coli soluble 
extracts, as well as the purified adenylylated and deadenylylated forms of M.tb GS.  
The average protein concentrations from three purifications of adenylylated and 
deadenylylated M.tb GS are 120  28 and 145  49 µg/ml, respectively.  The 
estimated size is in agreement with the theoretical ~53.4 kDa per subunit of the M.tb 
GS dodecamer. 
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Figure 2.9:  12% SDS-PAGE gel of cell-free E.coli extracts, as well as purified adenylylated and 
deadenylylated M.tb GS.  Lane 1: molecular weight marker with size in kDa indicated on left 
(PageRuler Protein ladder, Fermentas).  Lane 2: Adenylylated M.tb GS cell-free extract.  Lane 3: 
Adenylylated M.tb GS purified protein.  Lane 4: Deadenylylated M.tb GS cell-free extract.  Lane 5: 
Deadenylylated M.tb GS purified protein. 
Deadenylylated E.coli GS was expressed from pBSK in E.coli YMC11E.  
Adenylylated E.coli GS was produced in YMC11D. Adenylylated and deadenylylated 
E.coli GS was expressed constitutively.  After expression and purification, the 
purified adenylylated and deadenylylated E.coli GS were analysed on 8.5% SDS-
PAGE.  Figure 2.10 illustrates a SDS-PAGE of the purified adenylylated and 
deadenylylated forms of E.coli GS.  The average protein concentrations from three 
purifications of adenylylated and deadenylylated E.coli GS are 118  28 and 120  
15 µg/ml, respectively.  The estimated size is in agreement with the theoretical ~51.7 
kDa per subunit of the E.coli GS dodecamer. 
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                  Size(kd)             1            2          3 
                                          
Figure 2.10:  12% SDS-PAGE gel of purified adenylylated and deadenylylated E.coli GS.  Lane 1: 
molecular weight marker with size in kDa indicated on left (PageRuler Protein ladder, Fermentas).  
Lane 2: Purified deadenylylated E.coli GS protein.  Lane 3: Purified adenylylated E.coli GS protein.  
 
2.3.3 Determination of the adenylylation state of M.tb GS and E.coli GS 
2.3.3.1 -glutamyl transferase enzyme assay 
The -glutamyl transferase enzyme assay was carried out with purified GS to: i) 
confirm the functionality of the purified enzymes, and ii) assess the degree of 
adenylylation of the purified enzyme.  At a specific pH, the total enzyme activity of 
GS (both adenylylated and deadenylylated) occurs in the presence of Mn2+.  At the 
same pH in the presence of Mn2+ and an excess Mg2+, only the deadenylylated 
component of the enzyme activity is measured.  The resultant ratio is then used to 
calculate the degree of adenylylation of the enzyme.  After three purifications, the 
typical degree of adenylylation for deadenylylated M.tb GS is 3%  2%, while the 
adenylylated form is 70%  4% adenylylated indicated in Table 2.2.  For comparison 
purposes, adenylylated and deadenylylated E.coli GS yielded results of 0% and 95% 
 3% adenylylation respectively, indicated in Table 2.2. 
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Table 2.2: Average protein concentrations and % adenylylation as determined by -
glutamyl transferase assays of M.tb GS and E.coli GS 
Enzyme Protein  concentration % Adenylylation 
Adenylylated M.tb GS 96.4µg/ml 70%  4% 
Deadenylylated M.tb GS 91.8µg/ml 3%  2% 
Adenylylated E.coli GS 90.5µg/ml 95%  3% 
Deadenylylated E.coli GS 131µg/ml 0% 
 
2.3.3.2 Mass Spectrometry  
MS analysis of deadenylylated M.tb GS yielded a single peak with a calculated mass 
of 53,438.00 Da (Figure 2.13), in agreement with the theoretical mass of 53.4 kDa.  
Deadenylylated E.coli GS (Figure 2.11) had a calculated mass of 51,774.00 Da 
(theoretical mass = 51.7 kDa).  Adenylylated E.coli GS (Figure 2.12) was calculated 
to be 52,100.00 Da (theoretical mass = 52.1 kDa), with a single peak indicating 
100% adenylylation. The 330 Da adenyl moiety accounts for the mass difference 
between the adenylylated and deadenylylated forms of each enzyme.  Adenylylated 
M.tb GS would not ionise properly, therefore the spectra obtained (Figure 2.14) that 
shows 85% adenylylation, could therefore be potentially higher than 85%.   
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Figure 2.11: MS analysis of deadenylylated E.coli GS had a calculated mass of 51,774.00 Da 
(theoretical mass = 51.7 kDa) 
 
 
 
Figure 2.12: MS analysis of adenylylated E.coli GS had a calculated mass of 52,100.00 Da 
(theoretical mass = 52.1 kDa). 
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Figure 2.13: MS analysis of deadenylylated M.tb GS had a calculated mass of 53,437.00 Da 
(theoretical mass = 53.4 kDa) 
 
 
 
Figure 2.14: MS analysis of adenylylated M.tb GS had a calculated mass of 53,795.00 Da 
(theoretical mass = 53.7 kDa) 
 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 2  RESULTS 
48 
 
2.3.3.3 Enzyme Hydrolysis  
The hydrolysis of GS for determination of phosphate content was carried out on the 
purified enzymes to confirm the degree of adenylylation (Figure 2.15). Each adenyl 
moiety contains 1 phosphate, and 1 µM of GS (containing 12 subunits) should 
contain 12 µM of phosphate, if each subunit is adenylylated.  The result obtained for 
the adenylylated M.tb GS enzyme was the formation of 0.93 µM phosphate produced 
per µM GS active site, i.e. 94% adenylylated.  In the case of the deadenylylated 
enzyme there was no formation of phosphate.   The results obtained for E. coli GS 
were 0.95 µM and 0 µM for adenylylated and deadenylylated GS, respectively. 
 
 
Figure 2.15: Hydrolysis of M.tb and E.coli GS purified protein (adenylylated and deadenylylated) for 
phosphate concentration determination.  A blue colour indicates the presence of free phosphate. 
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Table 2.3 is a summary of the adenylylation states of both M.tb GS and E.coli GS 
determined by different methods including mass spectrometry, hydrolysis and 
phosphate concentration, and -glutamyl transferase assay. 
Table 2.3:  Summary of adenylylation states of M.tb GS and E.coli GS determined 
by different methods: (1) mass spectrometry, (2) hydrolysis and phosphate 
concentration, and (3) -glutamyl transferase assay. 
Quality 
control 
assays  
M.tb GS E.coli 
Deadenylylated Adenylylated Deadenylylated Adenylylated 
MS  0% 85 1% 7% 100 0% 
Phosphate 
concentration 
0 µM 0.93  2µM 0 µM 0.95  1µM 
-Glutamyl 
transferase 
3  2% 68  4% 0% 87  3% 
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2.4 Discussion 
M.tb GS is a potentially valuable therapeutic target for tackling the problem of 
tuberculosis disease.  Its regulation via adenylylation of a tyrosine residue on each 
subunit makes it distinct from the human form of the enzyme.  Previous reports of 
heterologous expression of M.tb GS in E.coli have shown that the endogenous 
ATase activity of E.coli does not adenylylate M.tb GS sufficiently, with only 25% of 
the M.tb GS subunits produced displaying adenylylation (Laemlli, 1970). The use of 
this expression system was therefore not considered optimal for the expression of 
adenylylated M.tb GS for further study.   
Here we have described an E.coli production system lacking endogenous GS and 
ATase activity, which utilises the co-expression of the M.tb ATase with M.tb GS.  
Each gene was provided on a separate plasmid, the glnA gene on a pBluescript 
SKII+ plasmid with the ColE1 origin of replication, and the glnE gene on a CDFDuet-
1 plasmid containing a CloDF13 replicon.  These replicons are compatible, and the 
two plasmids can be stably co-maintained, provided the relevant antiobiotic selective 
pressure is exerted: ampicillin for pBluescript SKII+ and streptomycin for pDFDuet-1 
(Held et al., 2003).  Mehta and co-workers expressed M.tb GS in E.coli host strains 
that were deficient in chromosomal GS (glnA).  They found that the E.coli ATase was 
inefficient in adenylylating the heterologous M.tb GS, with only ~25% of subunits 
being modified (Mehta et al., 2004). By co-expressing M.tb ATase and M.tb GS we 
improved the percentage of subunits modified (or adenylylated) with ± 60-70% to ± 
85-94%. In this way, we have produced recombinant M.tb GS that has a better 
adenylylation state than any previously reported.   
The E.coli enzymes were produced recombinantly from pBluescript SKII+ in E.coli 
strains lacking endogenous GS (for deadenylylated enzyme) or both GS and uridylyl 
transferase (adenylylated enzyme). The E.coli GS enzymes were only cloned, 
expressed and purified to be used as a model and for comparison with M.tb GS.     
Three methods were used to assess the degree of adenylylation of adenylylated and 
deadenylylated M.tb GS, and E.coli GS.  The first assay used, termed the -glutamyl 
transferase enzyme assay, is a variation of the reverse of the reaction that GS 
catalyses: 
 Glutamate + NH4
+ + ATP →    glutamine + ADP + Pi + H
+  
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In this reverse reaction; hydroxylamine and glutamine react to form -
glutamylhydroxamate and free ammonia in the presence of ADP, arsenate and 
manganese or magnesium (EP2008210 A1, 2008; Shapiro and Stadtman, 1970).  
This forms the basis of an assay for GS activity.  At the correct pH, this is derived 
from determining the isoelectric point of the enzyme, the transferase activities of both 
the adenylylated and deadenylylated forms of GS are the same.  The two forms can, 
however, be distinguished because at the isoelectric point, fully adenylylated GS is 
completely inhibited by 60mM Mg2+, whereas the deadenylylated enzyme is 
unaffected (Bender et al., 1977). Based on the data from the -glutamyl transferase 
assay, the adenylylation state of adenylylated M.tb GS expressed in this novel 
system is at least 68% compared to the 25% obtained from Mehta and co-workers.  
The second assay used is the determination of the inorganic phosphate 
concentration after the hydrolysis of both adenylylated and deadenylylated Mtb GS. 
After the hydrolysis of the enzymes in the case of the deadenylylated enzyme there 
was no formation of phosphate. For the adenylylated Mtb GS each adenyl moiety 
contains 1 phosphate, and 1 µM of GS (containing 12 subunits) should contain 12 
µM of phosphate, if each subunit is adenylylated.  The result obtained for the 
adenylylated M.tb GS enzyme was the formation of 0.93 µM phosphate produced 
per µM GS active site, i.e. 94% adenylylated compared to the 25% obtained from 
Mehta and co-workers. 
The third method used to assess the adenylylation is mass spectrometry.  MS 
spectra showed distinct peaks for adenylylated and deadenylylated enzymes, with 
calculated masses agreeing with the theoretical values.  Based on this data, it can 
be concluded that the adenylylation state of adenylylated M.tb GS expressed in this 
novel system is at least 85% from the MS spectra obtained.   
In addition, the rate of conversion of ATP, glutamate and ammonia to glutamine and 
ADP was assessed using HPLC.  This is termed the ‘forward’ or ‘biosynthetic” 
reaction and is assayed in two different assays; one which measures the ability of 
glutamine synthetase to convert glutamate to glutamine in the presence of ATP, and 
the second determines the conversion of ATP to ADP and AMP in the same assay 
mixture. These assays will be discussed in Chapter 3. 
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Chapter 3  
 
Differential inhibition of adenylylated and deadenylylated forms of 
M.tb glutamine synthetase in E.coli by ATP scaffold-based 
inhibitors 
 
3.1 Introduction 
GS was explored as a candidate new target for the development of innovative anti-
TB drugs. In particular, whether post-translation mechanisms (i.e. adenylylation) of 
GS regulation could provide a possible clue to the development of anti-microbial 
compounds that would be safe and effective against TB, and possibly presenting 
cydal activity for latent or resistant form of the M.tb. The rationale of the project can 
be summarised as follows: 
 
GS is an essential enzyme in bacterial metabolism, and previous studies have 
shown that inhibition/deletion of this enzyme can result in a static effect for 
pathogenic M.tb. GS belongs to the glutamine synthetase 1-β group of enzymes that 
are regulated via adenylylation of a single tyrosine residue (Kenyon et.al., 2011). The 
adenylylation mechanism of GS is specific to bacterial forms of the enzyme and 
induces significant modifications in the active site and ion requirements for the 
catalytic activity of GS. The novel reaction mechanism and catalytic site elucidated 
by CSIR researchers and protected in two PCT patents could be used for the design 
and selection of candidate inhibitor molecules that could afford a specific activity 
against bacterial GS and could be considered as promising hits for the development 
of novel TB agents. As the adenylylated GS and the deadenylylated GS utilise 
different divalent metal ions in the reaction, it is believed that the overall structure 
and conformation of the ATP in the active site as well as the coordinating amino acid 
residues are significantly different, allowing for the selection of distinct classes of 
compounds specifically inhibitory to either adenylylated or deadenylylated forms of 
the enzyme (Kenyon et. al., 2011).     
 
A collection of 213 compounds will be tested against the adenylylated and 
deadenylylated forms of both M.tb GS and E.coli GS at a concentration of 10 μM. 
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The rational design and selection of these inhibitors were based on the typical ATP 
binding site since GS utilize ATP. The test compounds were designed and 
synthesized at CSIR Biosciences.  Three sets of inhibitors were synthesized for 
testing: namely the 5 000, 10 000 and 12 000 series. The 5 000 series is the 
substituted pyrimidine series, the 10 000 series is the aminated imidazopyridenes 
series and the 12 000 series is related to the aminated imidazopyridenes. 
 
3.1.2 Study Objectives 
 Objective 1: To examine the inhibitory effect of a library of ATP scaffold-based 
inhibitors and the identification of possible adenylylated and deadenylylated 
M.tb GS inhibitors. 
 
 Objective 2: To demonstrate differential inhibition of adenylylated and 
deadenylylated M.tb GS and using adenylylated E.coli GS, deadenylylated 
E.coli GS and mammalian GS enzymes as controls.   
 
 Objective 3: Validation of assays: The HPLC based assay, Molybdate 
colorimetric phosphate assay and the colorimetric Kit based phosphate assay. 
The determination of the following parameters: intra-plate reproducibility, 
inter-plate reproducibility and the Z’ factor determination. 
 
 Objective 4: Determination of IC50 of hit compounds and the HeLa cell 
cytotoxicity assay of these hit compounds.   
 
 Objective 5: Testing of compounds against M.tb strains in a Bactec 460 TB™ 
assay. 
 
 Objective 6: Testing of compounds in a macrophage assays. 
 
 Objective 7: LogD and Caco-2 permeability determination of the hit 
compounds. 
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3.2 Methods 
 
3.2.1 Test compounds 
The test compounds were designed and synthesized at CSIR Biosciences.  
Essentially three different sets of inhibitors were synthesized for testing: namely the 
5 000, 10 000 and 12 000 series. The 5 000 series is the substituted pyrimidine 
series (Figure 3.2A). In the 5 000 series, the hydrogen bonding pattern is retained 
with varying steric components in the imidazole/sugar region of ATP. The 10 000 
series is the aminated imidazopyridenes series (Figure 3.2B), where a hydrogen 
bonding network is retained with the placing of substituents in different areas of 3D 
space. The 12 000 series is related to the aminated imidazopyridenes (Figure 3.2B), 
where a hydrogen bonding network is retained and the compounds are spatially 
related to guanosines. 
A B 
 
 
 
 
 
Figure 3.2: Classes of inhibitors: A, the pyrimidine series. B, the imidazo-pyridine series. 
 
3.2.2 HPLC-based analysis 
3.2.2.1 Standard assay 
Concentrations of substrates used in the final assay were based on their Km values 
determined by Kenyon et al., (2011) and set at approximately 3-times the Km value. 
For the 10 μM fixed concentration screens, 20 μL of 0.1 mM compound stocks in 
dimethyl sulfoxide (DMSO) were added to duplicate microtitre plate wells. Each well 
then received 180 μL of an enzyme/substrate/buffer master stock to achieve a final 
concentration of 50 mM HEPES (pH 7.15), 4 mM sodium glutamate, 4 mM NH4Cl, 
1.8 mM MgCl2, 0.8 mM ATP and 5 μg/mL deadenylylated M.tb GS in 10% DMSO. 
For adenylylated M.tb GS the same conditions were used, except that 50 mM 
HEPES (pH 6.95) and 1.8 mM MnCl2 was used. Enzyme and ATP was added to the 
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master stock immediately before distribution onto the plates. The reactions were 
incubated at 37ºC for 2 hours (hrs), before being terminated by the addition of 1 μL 
50% trichloroacetic acid (TCA) to each well. Blank wells (no enzyme) were also 
prepared for each individual compound. In addition, each plate contained control 
wells (10% DMSO without inhibitor) and blank control wells (10% DMSO, no 
inhibitor, no enzyme). After termination of the reactions, ADP levels in each well 
were determined by HPLC. The samples were analysed on an Agilent series 1100 
HPLC fitted with a Phenomenex Luna 5μ C18 column. Each sample was 
automatically injected (2 μL) and separated with a mobile phase containing 51 mM 
KH2PO4, PIC A Low UV Reagent (Waters Cooperation), 25% (v/v) acetonitrile. The 
flow rate of the mobile phase was 1 ml/min with UV detection (295nm). An AMP, 
ADP and ATP standard was used to calibrate the HPLC and the concentration of 
ADP in each sample was determined by the area under the curve using Agilent 
ChemStation (Revision B.02.01) software. The ADP values in the blank wells were 
subtracted from enzyme-containing wells, and percentage enzyme activity in each 
well calculated relative to the average net ADP values of the control wells without 
inhibitor. 
 
3.2.2.2 Pre-incubation assays 
After adding 20 µL 0.1 mM compound stock to each well, the wells received 164 µL 
adenylylated or deadenylylated M.tb GS in 50 mM HEPES (pH 6.95 or pH 7.15 
respectively), 4 mM NH4Cl, 1.8 mM MnCl2 or MgCl2. The plates were incubated at 
37ºC for 2 hrs, after which the reactions were initiated by adding sodium glutamate 
and ATP to final concentrations of 4 mM and 0.8 mM respectively and a final 
reaction volume of 200 μL. After further 2 hr incubation, the reactions were 
terminated and ADP levels measured as described above. 
 
3.2.3 Dose-response assays 
These were carried out using the pre-incubation protocol described in section 
3.2.2.2. Serial 4-fold dilutions of compounds were prepared in DMSO. For test 
compounds, the highest starting concentration for the dilution series was 1 mM for 
the first assay and 2 mM for the second. Eight dilutions were performed in DMSO to 
produce a concentration range of 1 mM to 61 nM or 2 mM to 122 nM. Twenty µL of 
each dilution was distributed into duplicate wells of the reaction plate, before adding 
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enzyme in HEPES/ammonium chloride/MnCl2 or MgCl2 and proceeding with the pre-
incubation procedure as described in section 3.2.2.2.  
 
3.2.4 E.coli and mammalian GS assays 
The E.coli GS screen was carried out as described in section 3.2.2.1 for the M.tb GS 
standard assay, except that the adenylylated and deadenylylated M.tb GS enzymes 
were replaced by their E.coli counterparts. The mammalian GS assay was carried 
out using the pre-incubation protocol described in section 3.2.2.2 for M.tb GS, using 
the purified bovine enzyme (MSc. Thesis of Lutendo Mathomu, 2011, UNISA) and 
buffer composition as described for the deadenylylated form of the M.tb enzyme. 
 
3.2.5 Determination of inorganic phosphate 
3.2.5.1 Molybdate colorimetric phosphate assay 
The assay was carried out according to the standard M.tb GS protocol (described in 
section 3.2.2.1), except that reactions were terminated by the addition of 180 µL 
molybdate colorimetric reagent (prepared fresh daily) containing 1.2 N sulphuric 
acid, 0.5% ammonium molybdate, 2% ascorbic acid. After 15 min at 37oC, 
absorbance was measured at 620 nm with a multiwell plate reader. 
 
3.2.5.2 Colorimetric kit phosphate assay 
The assay was carried out using the BioVision™ phosphate assay kit (BioVision™ 
Research Products, CA). Enzyme/inhibitor reactions were prepared in a 96-well plate 
exactly as described in the standard M.tb GS protocol (see section 3.2.2.1). At the 
end of the incubation, reaction mixes were diluted 5x in water by transferring 40 µL 
from each well to a second plate containing 160 µL water per well. Subsequently, 30 
µL of the phosphate reagent supplied with the kit (proprietary composition) was 
added to each well and the absorbance was read at 620 nm using a multiwell 
spectrophotometer after a 5 minute incubation. 
 
3.2.6 HeLa cell cytotoxicity assay 
HeLa cells (Human Negroid cervix epitheloid adenocarcinoma, ECACC) were 
routinely maintained as monolayer cell cultures in Eagle's minimal essential medium 
(EMEM) containing 5% fetal bovine serum, 2 mM L-glutamine and 50 µg/ml 
gentamicin at 37ºC in a 5% CO2 incubator. To perform the cytotoxicity assay, the 
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cells (3 - 19 passages) were used to inoculate 96-well microtiter plates at plating 
densities of 7000 cells/well. After incubating for 24 hrs, the culture medium was 
replaced with medium containing serial dilutions of the experimental compounds. 
Each dilution series consisted of 8 x 3-fold serial dilutions, spanning the final 
concentration range 100 - 0.05 µM. Triplicate wells were used for each concentration 
point (n = 3). The dilutions were prepared from compound stocks of 10 mM in 
DMSO, thus the final DMSO content in the highest compound concentration wells 
was 1%. Control wells consisted of cells incubated in medium with 1% DMSO, while 
blank wells contained medium without cells. Emetine was used as a positive control 
drug standard.  The plates were incubated for 48 hrs after addition of the 
compounds. The cellular protein present after the incubation period was fixed to the 
bottom of each well with cold 50% TCA, washed in tap water and stained with 0.4% 
sulforhodamine B (SRB) in 1% acetic acid. Unbound dye was removed by washing 
with 1% acetic acid, after which protein-bound dye was solubilised with 10 mM Tris 
base and transferred to a duplicate 96-well plate. Optical density was measured at 
540 nm using a Tecan Infinite F500 multiwell spectrophotometer. OD540 values of the 
blank wells were subtracted from the readings obtained for all the other wells, and 
percentage cell viability at each test compound concentration calculated relative to 
the untreated (DMSO alone) control wells. Percentage viability was plotted against 
Log (compound concentration) and the IC50 for each compound calculated from fitted 
non-linear regression dose-response curves using GraphPad Prism software. 
 
3.2.7 Testing of compound against M.tb strains in a BACTEC 460TB™ assay. 
3.2.7.1 Bacterial strains 
All M.tb strains used were from a strain bank kept in the Division Molecular Biology 
and Human Genetics of the University of Stellenbosch. M.tb H37Rv reference strain 
(ATCC 25618) and a clinical isolate of M.tb were used to evaluate compounds for 
anti-tuberculosis activity. Both strains were sensitive to the breakpoint concentrations 
(aproximately 10x higher than their minimal inhibitory concentrations (MIC)) of 
isoniazid (0.25ug/ml), ethambutol (9.4ug/ml), and rifampicin (2.0ug/ml) (Collin et al., 
1997). These sensitivity values were determined before and logged into a TB strain 
database. 
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3.2.7.2 Test Compounds 
The compounds identified using the methodology stipulated in section 3.2.1 to 3.2.5 
were used in the BACTEC 460TB™ assay (Siddiqi et al., 1993). The identified 
compounds were dissolved and diluted with 100% DMSO. 
 
3.2.7.3 Bacterial selection 
All mycobacterial colonies were cultured and selected from Lowenstein-Jensen slant 
(Kenneth et al., 2005) cultures followed by culture in Middlebrook 7H9 mycobacterial 
growth medium supplemented with OADC (0.005% v/v oleic acid (Merck), 0.5% w/v 
BSA Fraction V, 0.2% v/v glucose, 0.02% v/v catalase (Merck), w/v 0.085% NaCl). 
Cultures were stained by acid-fast staining (Ziehl-Neelsen staining) to control for 
contamination. This is a selective staining method for the mycolic acids found in the 
mycobacterial cell wall. An aliquot of the mycobacterial culture was immobilized onto 
a glass slide by heating for 20 min at 65 °C. The slide was covered completely with 
0.3% carbol-fuchsin (Becton Dickenson, USA) and heated until steaming. The 
carbol-fuchsin was rinsed off with water after incubation of 5 min at room 
temperature. The slide was destained by flooding the slide with 5% alcohol at room 
temperature for 2 min. The slide was rinsed with water and stained with 0.3% 
methelyne blue counter stain (Becton Dickenson, USA) and left at room temperature 
for 2 min. The slide was analysed with a light microscope after the slide was rinsed 
with water and left to air dry. The mycobacterial cells were stained pink 
(mycobacterial cells are acid-fast) while non-mycobacterial cells were stained blue 
(non-acid fast bacteria) and thus be an indication of contamination. 
 
3.2.7.4 BACTEC 460TB™ system determination of mycobacterial growth 
All work was carried out in the BSL3 laboratory of the Division of Molecular Biology 
and Human Genetics of the University of Stellenbosch. The BACTEC 460TB™ 
system has been devised to monitor mycobacterial growth of the slow growing 
species. The bacteria are grown on a radioactive substrate and the radioactive 
carbon dioxide produced is directly proportional to the mycobacterial growth rate. 
Read-out values are expressed as growth index (GI). M.tb reference strain H37Rv 
was cultured in 7H9 mycobacterial medium (Difco) enriched with ADC (0.5% w/v 
BSA Fraction V, 0.2% v/v glucose, 0.015% v/v catalase (Merck)) with continuous 
stirring at 37 °C. When cultures reached a density of approximately 0.16 at OD600 
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(one McFarland), 0.1 ml was inoculated into a BACTEC 12B medium vial. These 
primary cultures were incubated at 37 °C until a growth index of 500 (± 50) was 
reached. These primary cultures were used for drug testing of known and unknown 
compounds. The above protocol was also followed to generate a primary culture 
from the clinical isolate of M.tb. Unknown compounds, supplied in DMSO, were 
sterilized through a 13 mm organic solvent resistant syringe filter with 0.22 micron 
pore size (Millex-LG). Undiluted and sequentially diluted samples were tested for 
growth inhibitory activity. One hundred microliters of primary culture and 0.1 ml drug 
compound were added to a BACTEC 460TB™ vial, the vials incubated at 37ºC, and 
the growth monitored every 24 hrs. Controls included cultures with and without 
compound solvent. GI readings were continued until the controls reached the 
maximum GI value of or below 999. Control GI values between 50 and 800 are 
normally used to evaluate the efficacy of compounds with possible anti-tuberculosis 
activity. 
 
3.2.8 Testing of screening hits against M.tb in a macrophage assay 
3.2.8.1 M.tb cultures 
M.tb H37Rv reference strain and clinical MDR strain (Beijing220) were cultured in 
7H9 broth supplemented with 10% oleic acid-albumin-dextrose catalase (OADC, 
Difco, BD Biosciences, Mountain View, CA, USA) and 2% glycerol and 0.05% Tween 
80 (Glickman et. al., 2000). Liquid cultures were grown for up to 3 weeks and stored 
at -80°C in 1ml aliquots with 15% glycerol. Clumps were eliminated by 30 passages 
through a needle (26-gauge 3/8; 0.45 x 10 for intradermal injection; BD Biosciences, 
USA). Before infection, viability of mycobacteria was evaluated by the propidium 
iodide exclusion method to ensure >90% viability. Contamination was checked by 
the Ziehl-Neelsen stain (ZN) see section 3.2.7.3. The required amount of 
mycobacteria was spun down at 16 300 g for 5 min. The supernatant was removed 
and the bacteria resuspended in PBS (phosphate buffered saline) and passaged 
again 20 times and then used for macrophage infection. 
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3.2.8.2 Manipulation of mouse bone marrow-derived macrophages (MBMM) 
All animal studies were carried out under the Stellenbosch University Animal Ethics 
application number (11GH_PIE01). Bone marrow cells were obtained from femurs of 
6-8 week-old C57BL/6 female mice and seeded into 24-well tissue culture plates. 
The culture medium was RPMI-1640 (Sigma, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco), 10% L-929 cell conditioned medium (a 
source of colony stimulating factor-1) with no antibiotics. Incubation was performed 
at 37°C, 5% CO2. At 5 days after seeding, adherent cells were washed twice with 
RPMI and re-fed with complete medium. Medium was then renewed every second 
day. 
 
3.2.8.3 Macrophage infection and harvesting of TB 
Frozen aliquots of M.tb (H37Rv/Beijing220) were removed from the -80°C freezer 
where they were kept for long-term storage and thawed and processed as indicated 
above see section 3.2.8.1. Infection of the 7-Day old MBMM in 24-well plates was 
performed in triplicate with 100 μl of bacterial suspension relative to a multiplicity of 
infection of 2 (2 MOI), and incubated for 4 hrs at 37°C , 5% CO2. After the 4 hrs 
incubation period, non-ingested M.tb (H37Rv/Beijing220) was removed by washing 4 
times with ice-cold PBS. Fresh RPMI medium (1 ml) was added and again on day 2. 
At day 4 post infection the test compounds were added at the desired concentrations 
between 10 μM and 100 μM. Included were uninfected, infected (no drug) and 
isoniazid drug controls. On days 1, 2 or 3 post drug intervention the macrophages 
were washed 3 times with cold PBS (4°C) and then the bacteria harvested by adding 
1 ml 0.025% SDS for 5 min to lyse the adherent macrophages. The contents of each 
well were placed into separate Eppendorf tubes and the bacteria were pelleted at 
13000 rpm for 5 min. The bacteria was resuspended in 100 μl 7H9 Middlebrook 
medium and then inoculated into BACTEC 460TB™ vials. Growth was monitored 
over time until the BACTEC 460TB™ readings of the infected (no drug) control 
reached about 500. The percentage growth inhibition for each drug compound was 
determined by relating the linear growth unit readings to the infected (no drug) 
control. 
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3.3 Results 
3.3.1 Assay Characteristics - Linearity/Incubation time 
To evaluate the comparative enzyme inhibitory activity of compounds in an end-point 
assay, it is preferable that the assay is terminated when product formation over time 
is linear. In addition, incubation time may significantly affect signal vs. background 
values and thus the optimal assay window. Consequently, an experiment was 
carried out where time-dependent ADP product formation by adenylylated M.tb GS 
was measured. The standard assay method (see section 3.2.1.1) was carried out, 
except that the reaction was terminated at 30 min intervals from 0 - 270 min by the 
addition of 1 µL 100% TCA to the reaction wells. The amount of ADP formed at the 
different time-points was determined by HPLC. Blank wells contained no enzyme. 
 
The ADP HPLC (area under the curve) levels obtained for the blanks (no enzyme) at 
each time-point were subtracted from ADP values obtained for the corresponding 
time-point reactions containing adenylylated M.tb GS. The resulting net ADP levels, 
as well as the blank ADP levels, were plotted against time (Figure 3.3). 
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Figure 3.3: Standard M.tb GS assay – linearity/incubation time. Where not shown, error bars fall 
within symbols. 
 
The net ADP levels increased linearly with incubation time from approx. 90 - 150 
min. However, the net ADP levels decreased precipitously after 180 min. This was 
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due to an increase in blank ADP levels. The results indicate that ATP is labile under 
the reaction conditions, resulting in the non-enzymatic production of ADP at longer 
incubation times. The results suggest that enzyme incubations should be restricted 
to 2 - 2.5 hrs to ensure optimal enzyme activity and signal vs. background windows. 
 
3.3.2 E.coli GS screen 
For comparison purposes, adenylylated and deadenylylated E.coli GS was also 
heterologously expressed, purified and used in the inhibitor studies.  
 
To determine if the panel of 213 compounds including the two standard inhibitors 
methionine sulfoximine (MSO) and phosphinothricin (PhosT) GS inhibitors inhibits 
adenylylated and deadenylylated E.coli GS, the compounds were incubated at a final 
concentration of 10 μM with purified adenylylated and deadenylylated E.coli GS. 
After incubation, ADP levels were determined by HPLC to derive the residual 
percentage enzyme activity for each inhibitor relative to untreated controls. The 
screen results obtained for the adenylylated and deadenylylated forms of the E.coli 
GS enzyme are shown in Figure 3.4 A and B. 
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Figure 3.4: E.coli GS enzyme screen. The residual percentage adenylylated (A) and deadenylylated 
(B) GS enzyme activities after incubation with 10 µM of the individual compounds is shown, along 
with horizontal lines depicting the average % enzyme activity obtained with all compounds, as well as 
an indication of the confidence interval of the results, expressed as the average activity ± 3 x standard 
deviation (SD). Percentage activity obtained with MSO and PhosT is shown in blue, and candidate 
inhibitors in red.  
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With the exception of one compound (10067) and the MSO and PhosT standards, 
none of the compounds inhibited the deadenylylated form of E.coli GS (Figure 3.4 
B). In the case of the adenylylated form of the enzyme, activities in the presence of 
the compounds were scattered more widely around the mean, as demonstrated by 
the wider ± 3 x SD window (Figure 3.4 A). Nonetheless, 5 compounds (indicated in 
red in Figure 3.4 A) caused a discernible inhibition of the enzyme. Inhibitory activities 
of the compounds obtained in the screens are summarized in Table 3.1.  
 
Table 3.1: Candidate inhibitors of adenylylated and deanylylated E.coli GS. 
 
 
 
 
3.3.3 M.tb GS screen 
Following the promising results obtained in the E.coli GS screen which suggested 
that compounds may be able to discriminately inhibit the adenylylated and 
deadenylylated forms of the enzyme, the 213 compounds were re-screened at 10 
µM against the recombinantly expressed and purified adenylylated and 
deadenylylated M.tb GS enzymes. The first screen was carried out with the 
deadenylylated form of the M.tb enzyme. As a read-out for enzyme activity, a more 
rapid kit-based phosphate assay was used instead of ADP quantitation by HPLC. As 
shown in Figure 3.5 A, the results produced a significant scatter around the average 
percentage enzyme activity, which precluded a confident identification of inhibitors. 
No compounds inhibited deadenylylated GS activity by >40%, compared to the 75% 
and 85% inhibition obtained for the standards MSO and PhosT respectively 
(indicated in blue in Figure 3.5 A). The screen was repeated with adenylylated 
Compound % E.coli GS Inhibition 
Adenylylated Deadenylylated 
1 (PhosT) 100 97 
2 (MSO) 100 99 
5032 26 0 
5041 53 0 
10029 27 6 
10047 79 5 
10054 22 7 
10063 25 1 
10067 0 81 
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enzyme, using ADP HPLC quantitation as a measure of GS activity (Figure 3.5 B). 
On this occasion, 4 compounds (indicated in red in Figure 3.5 B) demonstrated clear 
inhibition of 35% - 46% of the enzyme compared to the rest of the compounds with 
an average inhibition of 2%, in addition to the 60% inhibition obtained with the MSO 
and PhosT standards. The inhibitory activities of the candidate inhibitors identified in 
the adenylylated GS screen are summarized in Table 3.2, along with the results 
obtained for the MSO and PhosT standards.  
 
Of note is the fact that compound 10057 was the most inhibitory test compound in 
both the adenylylated and deadenylylated screens (the red data point to the far right 
in Figure 3.5 A and B).  
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Figure 3.5: M.tb GS enzyme screen. The residual percentage adenylylated (A) and deadenylylated 
(B) GS enzyme activities after incubation with 10 µM of the individual compounds are shown, along 
with horizontal lines depicting the average percentage enzyme activity obtained with all compounds, 
as well as an indication of the confidence interval of the results, expressed as the average activity ±3 
x SD. Percentage activity obtained with MSO and PhosT is shown in blue. Candidate inhibitors 
identified in the adenylylated GS screen are shown in red in B. For comparative purposes, the latter 
inhibitors are also indicated in red in the deadenylylated enzyme screening results (A). 
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Table 3.2: Candidate inhibitors of adenylylated and deanylylated M.tb GS 
 
 
 
 
 
 
 
 
 
3.3.4 Pre-incubation M.tb GS assay 
Subsequent to the M.tb GS screens reported above (Figure 3.5), M.tb GS assays 
using the standard inhibitors MSO and PhosT at a fixed 10 µM concentration often 
yielded GS inhibitory activities that varied from one experiment to the next, as well as 
intra-experimentally (plate-to-plate variability). In addition, attempts to determine the 
IC50 of these standard compounds produced highly erratic results. In an attempt to 
improve the reproducibility of inhibitor activity data, we explored pre-incubating the 
GS enzymes with the test compounds for two hours, prior to initiating the enzyme 
reaction by adding substrate for an additional 2 hrs. This was in contrast to the 
hitherto approach of adding test compounds and substrate simultaneously. 
 
To assess the pre-incubation approach, two experiments were carried out with 
deadenylylated M.tb GS and the 4 candidate inhibitors (5009, 5024, 10057 and 
12004), as well as MSO and PhosT (Exp 1 in Figures 3.6 A and B). In the second 
experiment (Exp 2 in Figures 3.6 A and B), three additional compounds from the 
panel of 213 (5056, 10037 and 12005) that were found not to be active against the 
GS enzymes in the earlier screens were also included as controls. In the 
experiments, compounds 5009, 5024, 10057 and 12004 that yield only low inhibitory 
activity against deadenylylated M.tb GS using the normal approach (compounds, 
enzyme and substrate added concurrently; Figure 3.6 A, Table 3.3), were very 
inhibitory when they were pre-incubated with the enzyme prior to substrate addition 
(Figure 3.6 B, Table 3.3). The control compounds (5056, 10037 and 12005) 
remained poor inhibitors under pre-incubation conditions. 
 
Compound % M.tb GS Inhibition 
Adenylylated Deadenylylated 
1 (PhosT) 60 ±3% 85 ±1% 
2 (MSO) 61 ±4% 75 ±2% 
12004 35 ±2% 22 ±3% 
5009 36 ±2% 0 ±0% 
5024 36 ±3% 0 ±0% 
10057 46 ±2% 37 ±2% 
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Table 3.3: Inhibitory activities of test compounds against deadenylylated M.tb GS 
using conditions in which the enzyme is pre-incubated with the compounds for 2 
hours before adding substrate to initiate the GS reaction (Pre-incubation) vs. no pre-
incubation (No – compounds, enzyme and substrate added concurrently). 
 
Compound 
% M.tb GS inhibition 
No 
Pre-incubation 
Pre-
incubation 
No 
Pre-incubation 
Pre-
incubation 
PhosT 100 ±0% 81 ±3% 95 ±1% 82 ±1% 
MSO 100 ±0% 94 ±2% 96 ±1% 92 ±2% 
5009 36 ±1% 97 ±1% 35 ±2% 95 ±2% 
5024 14 ±2% 99 ±1% 23± 1% 97 ±2% 
10057 23 ±1% 99 ±2% 20 ±2% 97 ±1% 
12004 20 ±1% 98 ±2% 21 ±1% 95 ±3% 
5056   0 ±0% 22 ±1% 
10037   0 ±0% 8 ±2% 
12005   0 ±0% 11± 3% 
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Figure 3.6: Inhibitory activities of test compounds against deadenylylated M.tb GS using conditions in 
which the enzyme is pre-incubated with the compounds for 2 hours before adding substrate to initiate 
the GS reaction (B) vs. no pre-incubation, i.e. compounds, substrate and enzyme added concurrently 
(A). Where not shown, error bars fall within symbols. Exp 1: Consist of the 4 candidate inhibitors 
(5009, 5024, 10057 and 12004), as well as MSO and PhosT. Exp 2: Consist of the same as Exp 1 
including three additional compounds from the panel of 213 (5056, 10037 and 12005).  
A 
B 
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3.3.5 Pre-incubation M.tb GS screens 
Based on the markedly improved deadenylylated M.tb GS inhibitory activity of test 
compounds when they are pre-incubated with the enzyme prior to initializing the GS 
reaction, screens of the 213 compound panel against adenylylated and 
deadenylylated enzyme were repeated using the pre-incubation protocol, in the 
prospect of identifying candidate inhibitors additional to the 4 that were previously 
found. The results of the screens are shown in Figure 3.7.  
 
With the deadenylylated enzyme, the 4 existing candidate inhibitors (5009, 5024, 
10057 and 12004) again demonstrated significant GS inhibition using the pre-
incubation protocol (Figure 3.7 A, red data points). Two additional compounds with 
promising inhibitory activity were also selected for further evaluation (5045, 10059 - 
green data points in Figure 3.7 A). 
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Figure 3.7: M.tb GS enzyme screen using the pre-incubation protocol. The residual percentage 
adenylylated (B) and deadenylylated (A) GS enzyme activities after incubation with 10 µM of the 
individual compounds are shown, along with horizontal lines depicting the average % enzyme activity 
obtained with all compounds, as well as an indication of the confidence interval of the results, 
expressed as the average activity ± 3 x SD. Percentage activity obtained with MSO and PhosT is 
shown in blue. Candidate inhibitors previously identified in the adenylylated GS screen are shown as 
red data points. Additional compounds selected for further evaluation are shown as green data points. 
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With the adenylylated enzyme, the percentage enzyme activities in the presence of 
the individual compounds varied widely, producing a pronounced scatter of values 
around the mean and consequently a very wide confidence interval (Figure 3.7 B). 
This complicated the selection of candidate inhibitors. Nonetheless, the 4 existing 
inhibitors (red data points, Figure 3.7 B) were amongst the 14 most active 
compounds, with 10057 yielding an inhibition of 100%. Six additional compounds 
were selected as candidate inhibitors for further evaluation (5, 5002, 5012, 5016, 
5029 and 10059 - green data points, Figure 3.7 B). Note that compound 10059 (the 
green data point furthest to the right in Figure 3.7 A and B) had also been identified 
in the deadenylylated enzyme screen. The percentage inhibition obtained for the 
existing and new inhibitors are displayed in Table 3.8 (the “Exp1” columns). 
 
3.3.6 Assay Characteristics – Phosphate vs. HPLC assay 
GS catalyses the reversible conversion of L-glutamic acid, ATP and ammonia to L-
glutamine, ADP and inorganic phosphate via a γ-glutamyl phosphate intermediate. A 
standard assay therefore applied to measure GS activity is the HPLC quantification 
of ADP formed from ATP. However, this assay is reasonably labour- and resource-
intensive and not ideally suited for medium-throughput inhibitor screens in a 96-well 
microtitre plate format. We therefore investigated a colorimetric assay based on the 
formation of the inorganic phosphate and the use of molybdate to create a 
chromophore measurable at 820 nm. As an alternative to the molybdate-based 
phosphate assay, the BioVision™ phosphate assay kit for colorimetric inorganic 
phosphate quantitation was also explored.  
 
3.3.6.1 Data processing 
For the molybdate phosphate assay, percentage GS enzyme activity was calculated 
as: 
 
%GS activity = [mean OD820 (inhibitor) – mean OD820 (background control)] / [mean 
OD820 (+DMSO control) – mean OD820 (background control)] x 100.  
 
For the colorimetric kit assay, percentage GS activity was calculated as above; using 
OD620 instead, while activity in the HPLC assay was calculated using ADP area 
under the curve as opposed to OD. 
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3.3.6.2 Correlation between colorimetric phosphate and HPLC ADP assays 
To investigate the agreement between enzyme inhibition results obtained with the 
three assays, deadenylylated M.tb GS was incubated with a limited panel of 29 
experimental GS inhibitors as well as reference standard inhibitors (PhosT - 
compound 1; MSO - compound 2) at a fixed single inhibitor concentration of 10 μM. 
The percentage residual enzyme activity obtained for each inhibitor was determined 
with the three assays in parallel and the results compared.  
 
The bar graph in Figure 3.8 graphically depicts the percentage GS activity obtained 
with each inhibitor (inhibitor identity numbers are displayed on the X-axis) using the 
three parallel assays.  
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Figure 3.8: Correlation of deadenylylated M.tb GS inhibitory activities of 10 µM test compounds, as 
measured by the molybdate-based and kit-based inorganic phosphate assays, respectively, as well 
as the HPLC-based ADP assay. Where not shown, error bars fall within symbols. 
 
The reference inhibitors 1 and 2 significantly inhibited GS activity by 76%-99% 
according to all three assays. However, some inconsistencies between the assays 
were found with the remaining experimental inhibitors, particularly with the 
molybdate-based phosphate assay (e.g. compounds 10031 and 10032). To better 
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illustrate the assay result correlations, percentage enzyme activity obtained with the 
HPLC ADP assay was compared with the respective colorimetric phosphate assays 
using X-Y plots, as shown in Figure 3.9 A and B. 
 
               
 
 
                 
Figure 3.9: Correlation of deadenylylated M.tb GS enzyme activity in the presence of 10 µM test 
compounds, as measured by the HPLC-based ADP assay and the molybdate-based inorganic 
phosphate assays (A) and kit-based inorganic phosphate assay (B).  
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As seen from the correlation graphs, the kit phosphate assay provides a better 
correlation of enzyme inhibitory activity with the HPLC assay than the molybdate 
phosphate assay. The latter appears to yield several false positives (denoted by the 
circled data points in Figure 3.9 A).  
 
3.3.6.3 Further comparison of colorimetric phosphate and HPLC ADP assays 
for GS activity 
Based on its better correlation with the HPLC assay compared to the molybdate 
assay, as discussed above, the BioVision™ phosphate assay kit was provisionally 
selected for multi-well plate screens of potential GS inhibitors. To further assess its 
utility as a GS activity screening method, additional parameters were explored. A 
screen of the entire panel of 213 compounds was carried out using deadenylylated 
and adenylylated M.tb GS. In parallel, GS activity in the presence of 10 µM 
compounds was measured by quantifying ADP levels by HPLC, or inorganic 
phosphate levels using the BioVision™ phosphate assay kit. Three parameters were 
investigated: 
i) Intra-plate reproducibility - an indication of the precision with which 
replicate measurements are made. The coefficient of variation (CV %) was 
calculated for 27 well replicates on the first plate of the individual assays 
as CV% = standard deviation/replicate mean x 100. The average of the 27 
CV% values is presented in Table 3.3. 
ii) Inter-plate reproducibility - the mean ADP or phosphate levels obtained for 
the positive control wells (enzyme without inhibitor) on 5 different plates 
were averaged and the coefficient of variation determined as a 
percentage. 
iii) The Z’-factor value was calculated for 5 plates from the respective assays, 
and the average value is presented in Table 1. The Z’ is derived from the 
mean and standard deviations of the positive control wells (enzyme, no 
inhibitor) and blank wells (no enzyme, no inhibitor) on each plate: Z’ = 1-
[3*(SDpos + SDblank)/(Meanpos-Meanblank)]. Z’~1.0 indicates an ideal assay, 
while Z’ ≥0.5 is indicative of a very good assay in terms of dynamic range 
(assay window between positive signals and background) and precision. Z’ 
<0 is suspect. 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 3  RESULTS 
76 
 
Table 3.4: Reproducibility and precision of GS enzyme activity determinations in 
the presence of 10 µM test compounds, as measured by the HPLC-based ADP 
assay and the BioVision™ phosphate assay kit for the determination of inorganic 
phosphate.  
 
 
 
 
 
 
 
 
 
 
The results presented in Table 3.4 suggest that both the HPLC and phosphate kit 
assays yield very precise and reproducible GS activity results, as judged from the 
low CV. In fact, the phosphate kit produces more reproducible well replicate and 
inter-plate readings. However, the kit assay produced very poor Z’-factor values, 
compared to the corresponding values for the HPLC assay. This is brought about by 
very high background absorbance readings obtained with the phosphate kit, which 
seriously reduces the assay window between positive and background signals. In 
fact, in follow-up assays, the window was often reduced even further, thus rendering 
the assay useless for expressing fractional inhibitory activities of test compounds. 
For this reason, the quantification of ADP by HPLC was adopted as the assay 
method for all subsequent compound screens. 
 
3.3.7 Assay Characteristics - Pre-incubation assay 
In the standard GS assay, compounds and substrates are mixed with the enzyme 
simultaneously immediately prior to incubation. However, it was later found that pre-
incubation of the enzyme with compounds prior to substrate addition enhanced the 
inhibitory effect of compounds. The pre-incubation protocol was therefore used in 
several fixed concentration screens and dose-response assays. To further evaluate 
the reproducibility and precision of the assay, the data obtained from 3 assays was 
used to calculate intra-plate reproducibility (precision of ADP readings from replicate 
Parameter Deadenylylated 
M.tb GS 
Adenylylated M.tb 
GS 
Pi kit HPLC 
ADP 
Pi kit HPLC 
ADP 
Intra-plate CV% 
(n=27) 
2.0 14.0 3.0 14.7 
Inter-plate CV% 
(n=5) 
3.4 12.7 6.9 17.5 
Average Z’ 
(n=5) 
-0.07 0.78 0.28 0.76 
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wells), inter-plate reproducibility (reproducibility of ADP readings obtained for positive 
control wells in separate plates) and average Z’ values (overall assay window and 
precision obtained per plate). The data from 5 separate assays was further used to 
calculate inter-assay reproducibility (the reproducibility of ADP readings for positive 
controls on the first plate of 5 assays carried out on separate occasions).  The 
reproducibility parameters were expressed as CV, calculated as the standard 
deviation/mean x 100. Results are shown in Table 3.5. 
 
Table 3.5: Reproducibility and precision of GS enzyme activity determinations, as 
measured by the HPLC-based ADP assay using the pre-incubation protocol.  
 
 
 
 
 
 
 
 
 
 
 * Assay 1; ** Assay 2 and 3. 
All parameters were calculated using the ADP area under the curve values obtained by HPLC. CV 
was calculated as standard deviation/mean x 100. Assay 1, 2 and 3 refer to the fixed concentration 
compound screen and two subsequent compound dose-response assays, respectively. To calculate 
inter-assay reproducibility, data from two additional dose-response assays carried out with MSO and 
PhosT was used. For inter-plate and inter-assay CV calculations, ADP values obtained in positive 
control wells of individual plates was used. For intra-plate CV calculations, ADP values obtained from 
replicate wells containing compounds was used. 
 
In general, results obtained with the deadenylylated M.tb GS enzyme were more 
precise and reproducible than those obtained with adenylylated enzyme, as 
evidenced by the lower CV values. An exception is the inter-assay reproducibility, 
which produced a lower CV in the case of the adenylylated enzyme. Importantly, the 
inter-assay CV values suggest that the enzyme activities in separate assays were 
Parameter Deadenylylated M.tb 
GS 
Adenylylated M.tb GS 
Assay 
1 
Assay 
2 
Assay 
3 
Assay 
1 
Assay 
2 
Assay 
3 
 
 
CV 
% 
Intra-plate 
(n=27*, 39**) 
4.7 9.5 4.2 10.5 8.3 21.7 
Inter-plate 
(n=5*, 3**) 
4.1 8.2 3.0 51.9 13.9 20.4 
Inter-assay 
(n=5) 
53.7 22.8 
 Average Z’ 
(n=5*, 3**) 
0.97 0.75 0.83 0.75 0.56 0.49 
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reasonably comparable, despite the fact that different batches of enzyme were used 
in each case. 
 
3.3.8 HeLa cytotoxicity assay 
In the preceding screens with the M.tb GS enzyme (see sections 3.3.3 to 3.3.5), four 
inhibitors (5009, 5024, 10057 and 12004) showed promising inhibition of 
adenylylated GS. To assess the overt cytotoxicity and potential selectivity of the 
inhibitors, they were incubated with the human HeLa cell line and their effect on cell 
numbers determined. The standard GS inhibitors MSO and PhosT were also 
included, as well as a cytotoxic control compound, emetine. The amount of cells 
present after incubation was determined using the colorimetric protein-binding dye 
sulforhodamine B (see Methods, section 3.2.5) and expressed as percentage cell 
viability relative to untreated controls. To quantify cytotoxicity, dose-response plots of 
percentage cell viability vs. log compound concentration were prepared, in order to 
derive the 50% inhibitory concentrations (IC50) of the individual compounds (Figure 
3.10; Table 3.6) 
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Figure 3.10: HeLa cell cytotoxicity determination. The percentage cell viability after incubation with 
serial dilutions of the individual test compounds vs. log compound concentration is shown. Lines were 
fitted by non-linear regression analysis using GraphPad Prism. Each data point is the mean of three 
replicate wells. Where not shown, error bars fall within symbols. 
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Table 3.6: HeLa cell cytotoxicity IC50 values. IC50s were calculated by non-linear 
regression analysis using GraphPad Prism.  
 
 
 
 
 
   
 
 
 
 
 
 
 *The IC50s are estimates based on the trends of the dose-response curves in Figure 3.6 accurate 
IC50s could not be derived due to the incomplete sigmoidal dose-response plots. 
 
The reference standard compound (emetine) yielded an IC50 of 0.040 µM, which is in 
close agreement with the average IC50 of 0.043 µM obtained for emetine in previous 
sulforhodamine B cytotoxicity assay experiments (Larsson et al., 2012). By contrast, 
none of the experimental compounds significantly reduced cell numbers at the 
highest test concentration of 100 µM, and only one compound had an estimated IC50 
below this concentration (10057 - 87.5 µM). The assay Z’-factor for the compounds 
ranged from 0.93 - 0.96, demonstrating excellent assay windows and accuracy. The 
results suggest that the compounds do not possess significant overt cytotoxicity. 
 
3.3.9 Evaluation of LogD and Caco-2 permeability of hit compounds 
LogD and Caco-2 permeability of the four candidate inhibitors of adenylylated M.tb 
GS identified in the earlier screen was assessed by an international service provider 
(Cerep). Results obtained are presented in Table 3.7.  
 
LogD is a pH-dependent partitioning coefficient that is experimentally determined by 
quantitating the distribution of a compound between a water phase (buffered at pH 
7.4) and an organic phase (n-octanol). As such, it is a measure of the lipophilicity of 
a compound at physiological pH, which in turn affects the solubility, permeability, 
protein binding, distribution, metabolism and general in vivo pharmacokinetic 
behaviour of the compound. Lipophilic compounds (LogD >5) tend to be subject to 
No. Compound IC50 (µM) Estimated 
IC50 * 
1 Emetine 0.04  
2 Phosphinotricin >100 218.0 
3 L-Methionine Sulfoximine >100 235.5 
4 5009 >100 321.2 
5 5024 >100 323.4 
6 12004 >100 239.9 
7 10057 50 - 100 87.5 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 3  RESULTS 
80 
 
more rapid metabolism and higher protein binding, coupled with poor solubility, 
which can lead to low bioavailability. Conversely, hydrophilic compounds (LogD <0) 
are highly soluble but their membrane permeability and oral absorption is 
compromised. To achieve a good balance between solubility and lipophilicity, a 
compound should thus have a LogD of 0-5. The results obtained from an 
international service provider (Cerep) (Table 3.7 A) indicate that compounds 5024, 
12004 and 10057 have LogD values in the desired range (0.85, 0.89 and 4.21 
respectively), while compound 5009 is more hydrophilic (-0.82).  
 
Table 3.7: LogD (A) and Caco-2 permeability (B) results obtained from Cerep for the 
candidate M.tb GS inhibitors 5009, 5024, 10057 and 12004. 
 
A 
Assay 
(LogD, n-octanol 
PBS, pH7.4) 
Inhibitor 
I.D. 
Test 
Concentration(M) 
Weighted Average of 
Three Replicates 
Partition Coefficient  5009 0.0001 -0.82 
Partition Coefficient  5024 0.0001 0.85 
Partition Coefficient  10057 0.0001 4.21 
Partition Coefficient  12004 0.0001 0.89 
 
B 
Compound 
Assay 
(TC7, pH6.5/7.4) 
Permeability (10-6cm/s) Percent Recovery (%) 
1st 2de Mean 
Permeability 
1st 2de Mean 
Recover
y 
5009 A-B Permeability 0.01 0.01 <0.01 102 96 99 
5024 A-B Permeability 58.30 54.93 56.6 111 109 110 
10057 A-B Permeability 39.62 41.91 40.8 63 63 63 
12004 A-B Permeability 0.10 0.10 <0.1 93 105 99 
 
Caco-2 permeability is a measure of the ability of a compound to cross an intact 
intestinal epithelium cell monolayer and thus predicts the oral absorption of a 
compound. Compounds with a permeability of >20 x10-6 cm/s are regarded as highly 
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permeable, while values <2 x10-6 represent low permeability. The Cerep results 
(Table 3.7 B) show that compounds 10057 and 5024 yield high permeability values 
(40.8 x10-6 and 56.6 x10-6 cm/s respectively) and are thus predicted to be well 
absorbed from the intestinal tract. By contrast, compound 12004 has low 
permeability. As expected from the hydrophilicity of compound 5009 (LogD <0), it 
demonstrates very poor permeability in the Caco-2 system (<0.01 x10-6 cm/s). 
 
3.3.10 Pre-incubation M.tb GS assay - further evaluation of candidate inhibitors 
In total, 7 compounds were earmarked as new candidate M.tb GS inhibitors after the 
pre-incubation protocol screens, in addition to the 4 identified in the first screening 
round. The 11 inhibitors were subsequently subjected to three additional rounds of 
screening against adenylylated and deadenylylated M.tb GS using pre-incubation at 
10 µM, in order to confirm their inhibitory activities, as well as to explore their 
selectivity’s for one form of the enzyme vs. the other. The average percentage 
inhibition and corresponding standard deviation obtained for each compound over 
the 4 separate assays are shown in Table 3.8 and Figure 3.11. Based on the relative 
average inhibition of the adenylylated and deadenylylated enzymes, the compounds 
were provisionally categorized as selective for either of the two forms, or non-
selective (Table 3.8). One compound (5045) displayed significant selectivity for the 
deadenylylated enzyme; while 4 compounds suggested specificity for adenylylated 
GS and 6 appeared relatively non-selective. The latter category included the two 
most active test compounds; 10057 and 10059.  
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Table 3.8: Fixed concentration evaluation of 11 candidate inhibitors in M.tb GS 
enzyme assays using the pre-incubation protocol. The percentage enzyme inhibition 
obtained with the compounds (10 µM final concentration) in 4 separate screens is 
shown, along with the average inhibition for each compound over the 4 screens and 
the corresponding SD.  The colour coding of the highlighted table cells is clarified in 
the bottom legend.  
 
 
Adenylylated M.tb GS (% inhibition) Deadenylylated M.tb GS (% inhibition) 
Comp. 
(10µM) Exp 1 Exp 2 Exp 3 Exp 4 AVG SD Exp1 Exp 2 Exp 3 Exp 4 AVG SD 
PhosT 100 95 97 100 98 2 100 98 100 100 100 1 
MSO 100 100 96 100 99 2 100 100 99 100 100 1 
5 48 33 40 29 38 8 0 0 6 0 2 3 
5002 68 40 38 35 45 15 0 10 8 14 8 6 
5009 37 50 50 22 40 13 57 41 44 44 47 7 
5012 55 31 32 42 40 11 14 16 4 24 15 8 
5016 51 43 46 30 43 9 7 19 3 13 11 7 
5024 46 48 43 36 43 5 49 44 52 44 47 4 
5029 79 46 56 60 60 14 5 8 7 9 7 2 
5045 0 0 0 0 0 0 44 45 54 48 48 5 
10057 100 99 98 100 99 1 67 62 47 58 59 9 
10059 82 99 82 100 91 10 49 48 36 43 44 6 
12004 39 32 33 30 34 4 50 43 38 38 42 6 
             
 
 Non-selective 
         
 
  Adenylylated 
         
 
  Deadenylylated 
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Figure 3.11: Fixed concentration evaluation of 11 candidate inhibitors in M.tb GS enzyme assays 
using the pre-incubation protocol. The average percentage GS inhibition obtained for each compound 
over the 4 independent screens against the deadenylylated and adenylylated forms of the enzyme is 
plotted. Error bars represent standard deviation. Where not shown, error bars fall within symbols.  
 
3.3.11 Mammalian GS assay 
To assess the species selectivity of the compounds and their potential for toxicity or 
side-effects, the 11 candidate inhibitors selected and evaluated using the pre-
incubation M.tb GS assay protocol were further screened using the same approach 
against mammalian GS (mGS) isolated from bovine liver. Percentage inhibition of 
mGS by the compounds at a final concentration of 10 µM ranged from 0 - 40% 
(Figure 3.12, Table 3.9). The two standard GS inhibitors PhosT and MSO both 
inhibited the bovine enzyme by 100%. A concern is the fact that the two most potent 
M.tb GS inhibitors (10057 and 10059) also appeared to have the most effect on 
mGS activity, which could be a source of side-effects in further development. Based 
on the average inhibitory values obtained for the compounds against adenylylated 
M.tb GS (Table 3.8), 10057 displayed a 2.9-fold selectivity for the M.tb enzyme, 
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compared to 2-fold in case of 10059 (Table 3.9). The activity of 10057 against the 
bovine GS enzyme might be related to the fact that it displayed signs of some 
cytotoxicity in the HeLa cell assay (estimated IC50 = 87.5 µM; Table 3.5). 
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Figure 3.12: Fixed concentration evaluation of 11 candidate inhibitors in an mGS enzyme assay 
using the pre-incubation protocol. Where not shown, error bars fall within symbols.  
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Table 3.9: Fixed concentration evaluation of 11 candidate inhibitors in a mammalian 
GS (mGS) enzyme assay using the pre-incubation protocol. Results obtained 
against adenylylated M.tb GS are extracted from Table 3.7. 
 
 
Compound 
% mGS 
inhibition SD 
Average 
adenylylated 
M.tb GS 
inhibition  % 
-fold 
selectivity 
PhosT 100 0.0 88 0.9 
MSO 100 0.0 99 1.0 
5 17 0.4 37 2.2 
5002 15 0.0 60 4.0 
5009 24 0.0 52 2.2 
5012 27 0.4 37 1.4 
5016 11 0.2 35 3.2 
5024 3 0.0 56 18.7 
5029 0 0.0 51 ? 
5045 4 0.0 0 0.0 
10057 30 0.2 87 2.9 
10059 40 1.3 81 2.0 
12004 12 0.4 33 2.8 
 
 
3.3.12 M.tb GS dose-response assays 
To obtain a more accurate reflection of the activity and adenylylated vs. 
deadenylylated selectivity of the 11 candidate inhibitors, dose-response assays were 
performed on the 2 forms of the enzyme to derive compound IC50 (50% inhibitory 
concentration) values. Dose-response assays were initially performed using a pre-
incubation protocol with the standard inhibitors PhosT and MSO. Based on the 
results, IC50 values derived from the dose-response curves suggested, firstly, that 
adenylylated M.tb GS is more sensitive to inhibition by the standards than the 
deadenylylated form of the enzyme and, secondly, that PhosT is a more potent 
inhibitor of the M.tb enzymes than MSO (Figure 3.13). 
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Figure 3.13: Dose-response assays for MSO and PhosT standard inhibitors. Percentage GS activity 
was plotted against log (compound concentration) and sigmoidal dose-response curves fitted to the 
data points using non-linear regression analysis. The curves were used to derive the IC50 values for 
the inhibitors (displayed in the top right legend).  Where not shown, error bars fall within symbols. 
 
Subsequently, the panel of 11 candidate inhibitors was subjected to two separate 
dose-response assays. In the first (Table 3.10, Assay 3), the highest final starting 
concentration for the serial compound dilutions was 100 µM, which was increased to 
200 µM for the second assay (Table 3.10, Assay 4). Attempts to use higher starting 
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concentrations were thwarted by the appearance of visible precipitates in most of the 
compound wells. Table 3.10 summarizes the IC50 evaluations for the test 
compounds, as well as values obtained for PhosT and MSO in concurrent assays. 
 
Table 3.10 Dose-response assays for MSO, PhosT and 11 candidate M.tb GS 
inhibitors. The latter were assayed on two separate occasions (Assay 3 and 4) using 
adenylylated and deadenylylated M.tb GS. Where relevant, IC50 values were derived 
from non-linear regression analysis of dose-response curves (Figure 3.10).  
 
Compound 
Adenylylated GS IC50 (µM) Deadenylylated GS IC50 (µM) 
Assay 
4 
Assay 
3 
Assay 
2 
Assay 
1 
Assay 
4 
Assay 
3 
Assay 
2 
Assay 
1 
1 (PhosT) ~0.001 0.37 0.016 0.016 0.11 0.33  0.83 
2 (MSO) 0.07 3.42 0.16 0.14 0.44 2.76  1.6 
5 >200 >100   >200 >100   
5002 >200 >100   >200 >100   
5009 >200 >100   >200 >100   
5012 >200 >100   >200 >100   
5016 >200 >100   >200 >100   
5024 >200 >100   >200 >100   
5029 >200 >100   >200 >100   
5045 >200 >100   >200 >100   
10057 3.51 15.6   13.2 17.3   
10059 3.56 31.2   17.1 19.2   
12004 >200 >100   >200 >100   
 
For reasons that are unclear, besides compounds 10057 and 10059, the candidate 
inhibitors failed to inhibit either form of the enzyme sufficiently to produce dose-
response curves, resulting in predicted IC50s above the highest starting 
concentrations of the compounds. This is in contrast to the fact that they repeatedly 
demonstrated inhibitory activity against either or both forms of M.tb GS at a fixed 
concentration of 10 µM. A possibility may be that the compounds form small 
aggregates invisible to the naked eye at high starting concentrations, resulting in 
serial dilutions that contain considerably less than the nominal concentration of 
active, monomeric compound. Nonetheless, compounds 10057 and 10059 produced 
dose-response graphs that were used to derive IC50 values for both (Figure 3.10). 
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The second assay (Assay 4) further suggests that the two compounds may be 
slightly more inhibitory (3.8 - 4.8 fold) towards the adenylylated form of M.tb GS. 
 
A 
 
 
 
 
 
 
 
  
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Dose-response assays for compounds 10057 and 10059, performed with adenylylated 
and deadenylylated M.tb GS in a pre-incubation protocol on two separate occasions (Assay 3 and 4). 
Percentage GS activity was plotted against log (compound concentration) and sigmoidal dose-
response curves fitted to the data points using non-linear regression analysis. Where not shown, error 
bars fall within symbols.  
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A further concern is the variation in IC50 values obtained for the standard inhibitors 
MSO and PhosT using both forms of M.tb GS, but especially the adenylylated 
enzyme. The source of the variability is still unclear.  
 
3.3.13 M.tb BACTEC 460TB™ assays 
Compounds identified following the primary screening for enzymatic activity against 
adenylylated and deadenylylated M.tb GS were tested for antibacterial activity using 
a BACTEC 460TB™ assay with H37Rv reference strain. Compound 10057 showed 
approximately 50% growth inhibition at 100 µM on day 6 of incubation relative to the 
controls. However, the growth rate also increased over the period of incubation 
indicating that bacterial doubling is taking place although at a slower rate. All the 
other compounds and other concentrations showed no effect on mycobacterial 
growth rate (ΔGI) over the incubation period. Compounds 1 and 2 were MSO and 
PhosT and were included as controls in the study. 
 
3.3.14 Intracellular drug testing in Mouse Bone Marrow-Derived Macrophages 
Intracellular survival of M.tb (H37Hv/Beijing220) in mouse bone-marrow derived 
macrophages was monitored in response to compounds. A first batch of 6 
compounds (10057, 5024, 12004 and 5009) were tested in the pilot test and 
compound 10057 showed activity at a concentration of 100 μM. The percentage 
killing exhibited by compound 10057 was about 93% as indicated in Figure 3.11. 
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Figure 3.11: Intracellular survival of M.tb (H37Rv) in mouse bone-marrow derived macrophages after 
5-day post-infection period followed by intervention on D5 PI with different compounds, MOI 2:1, 5 
day incubation at 37
o
C, 5% CO2. Cells were sacrificed on Day 2 Post Drug Intervention. Only Drug 
10057 shows activity.  But Drug 2 shows no activity in this initial screen, which may be due to the fact 
that Drug 2, was resuspended in DMSO instead of Water for this pilot test. Where not shown, error 
bars fall within symbols. 
 
In the time course experiment (using the H37Rv lab strain) compound 2 was 
resuspended in water and showed activity on Day 2 post drug intervention. The 
percentage killing on Day 2 for compound 10057 was 73% at 100 μM and 27% at 50 
μM. 
 
The second batch of 7 compounds was provided for testing, namely (compounds 5, 
5002, 5012, 5016, 5029, 5045 and 5059). In the pilot macrophage assay (using this 
time the clinical isolate Beijing220 MDR strain) only compounds 5029, 5045 and 
5059 showed activity at a concentration of 100 μM (see Figure 3.12). The 
percentage killing exhibited by compounds 5029, 5045 and 5059 were 67%, 64% 
and 54% respectively at 100 μM. As a comparative control a new aliquot of 
compound 10057 was tested in the same assay. The percentage killing exhibited by 
compound 10057 at 100 μM in this assay was about 65%, which corresponds well 
with the result obtained in the time-course experiment (73%). 
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Figure 3.12: Intracellular survival of M.tb (H37Rv) in mouse bone-marrow derived macrophages after 
5-day post-infection period followed by intervention on D5 PI with different compounds, MOI 2:1, 5 
day incubation at 37
o
C, 5% CO2. Cells were sacrificed on Day 2 Post Drug Intervention. Only Drugs 
5029, 5045 and 10057 shows activity. Where not shown, error bars fall within symbols. 
 
Compounds 5029, 5045 and 10057 were tested further at concentrations 10 μM, 50 
μM and 100 μM for 3 days (see Figure 3.13). In this experiment drug 5045 showed 
the best activity (73% killing) at 100 μM which concurs with the results of the 
extracellular assay. However visually the mouse macrophages did appear more 
granular in the presence of drugs 5029 and 5045 at 100 μM, possibly indicates a 
toxic effect at this concentration. 
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Figure 3.13: Intracellular survival of M.tb (H37Rv) in mouse bone-marrow derived macrophages after 
5-day post-infection period followed by intervention on D5 PI with different compounds, MOI 2:1, 5 
day incubation at 37
o
C, 5% CO2. Cells were sacrificed on Day 2 Post Drug Intervention. Drug 5045 
showed the best activity (73% killing) at 100 μM. Where not shown, error bars fall within symbols. 
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3.4 Discussion 
Several gaps exist in the TB drug development pipeline worldwide as very few new 
drugs or drug candidates are in the pipeline. Big pharmaceutical companies have not 
invested in TB drug development, as historically the disease did not pose a 
significant threat to the developed world. However, the threat of MDR-TB and the 
increased world demand for treatment of Latent TB Infection has prompted a number 
of global initiatives such as the Global Alliance for TB Drug Development and the 
Stop TB Partnership (WHO 2006); all aimed at ensuring a pipeline of new TB drug 
leads to ensure new more effective TB drugs enter clinical development.   
 
The primary invention of this project relates to a biochemical pathway that yielded a 
new drug target that can be exploited to develop new therapies against M.tb. GS 
catalyses the conversion of glutamate to glutamine via a glutamyl phosphate 
intermediate, utilising ATP. ATP is utilized as either Mg-ATP or Mn-ATP, depending 
on the adenylylation state of the enzyme. The enzyme is regulated via adenylylation 
in bacteria containing the GS-1 form of the enzyme. 
 
About 213 compounds were tested against the adenylylated and deadenylylated 
forms of both M.tb GS and E.coli GS at a concentration of 10 μM. The rational 
design and selection of these inhibitors were based on the typical ATP binding site.  
         
         Figure 3.1: The basic structural characteristics of the ATP site (Traxler, 1996). 
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Approximately 213 compounds were tested for their ability to inhibit GS that had 
been synthesized and purified in both the adenylylated and deadenylylated forms. It 
has been shown that GS in the adenylylated form uses a novel histidine kinase-like 
reaction mechanism in the phosphorylation of the carboxyl of glutamate. The primary 
outcome of the project was the demonstration of the selective inhibition of 
adenylylated GS and the identification of specific compounds capable of inhibiting 
adenylylated GS.  
 
Compounds showing activity towards the adenylylated and/or deadenylylated forms 
of E.coli and M.tb GS enzymes at a single micromolar (µM) concentration were 
confirmed with repeated testing before being evaluated with full dose-responses to 
assess IC50 values and rank the order of potencies towards the adenylylated and 
deadenylylated forms of E.coli and M.tb GS. Compounds showing activity for the 
adenylylated or deadenylylated forms of the M.tb GS enzyme were further assessed 
for selectivity vis-à-vis the mammalian enzyme and for antibacterial action in a 
cellular model of M.tb infection. Any compound showing a selective activity for the 
adenylylated versus the deadenylylated and mammalian forms of the enzyme could 
be considered for further hit-to-lead and lead optimisation campaigns for the 
development of novel candidates for the treatment of TB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 3  DISCUSSION 
95 
 
The following inhibitors were identified as possible inhibitors of M.tb GS. The 
chemical structures and their selectivity are shown in Figure 5. 
             
 
Figure 5: Chemical structures of the 11 synthesized ATP scaffold-based inhibitors which shown 
promising inhibition of M.tb GS enzymes. They are divided into three distinct groups non-selective, 
deadenylylated selective and the adenylylated selective.     
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Based on the dose-response assays, compounds 10057 and 10059 have emerged 
as the most promising anti-M.tb GS inhibitors with IC50 (μM) values of 9.6 μM and 
17.4 μM respectively. They have regularly produced the most potent inhibitory 
activity against M.tb adenylylated GS enzyme in fixed concentration screens with 
87% and 81% respectively. Compounds 10057 and 10059 are structurally very 
similar as indicated in Figure 6 below. In the case of 10057, preliminary ADME 
properties (LogD, permeability) are favourable with a value of 4.21. In further 
development, attention may be paid to improving the selectivity of the compounds 
vis-à-vis mammalian forms of GS, to reduce the possibility of side-effects as 
inhibitory activity of 30% and 40% respectively were observed.  These compounds 
also showed selective inhibition of the adenylylated M.tb GS.  
 
                                                   
 
Figure 6: Chemical structures of compounds 10057 and 10059 which have emerged as the most 
promising anti-M.tb GS inhibitors.     
These two compounds that have been found to be inhibitory to M.tb GS may now be 
used as templates to synthesize additional target specific compounds as part of a 
lead optimisation programme and further optimised to yield a suitable drug candidate 
for clinical evaluation. 
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Chapter 4  
 
The effect of deuterated ATP on E.coli and M.tb Glutamine 
synthetases regulation 
 
4.1 Introduction 
4.1.1 Enzyme Kinetics 
Enzymes catalyse numerous reactions in nature, often causing spectacular 
accelerations in the catalysis rate. One aspect of understanding how enzymes 
achieve these feats is to explore how they use the limited set of residue side chains 
that form their ‘catalytic toolkit’. Combinations of different residues form ‘catalytic 
units’ that are found repeatedly in different unrelated enzymes. Most catalytic units 
facilitate rapid catalysis in the enzyme active site either by providing charged groups 
to polarize substrates and to stabilize transition states, or by modifying the pKa 
values of other residues to provide more effective acids and bases. Given recent 
efforts to design novel enzymes, the rise of structural genomics and subsequent 
efforts to predict the function of enzymes from their structure, these units provide a 
simple framework to describe how nature uses the tools at her disposal, and might 
help to improve techniques for designing and predicting enzyme function. 
 
4.1.2 Mechanisms of enzyme catalysis 
Enzymes, and the principles by which they perform catalysis, have been the subject 
of intense study for over a hundred years, in which time the mechanisms of many 
different enzymes have been investigated in great detail. Serine proteases, for 
example, have been the focus of countless structural (Perona and Craik, 1997), 
kinetic (Hedstron, 2002) and theoretical (Topf et al., 2002; Ishida and Kato, 2004) 
studies. Even now, however, when the general principles that govern enzyme 
catalysis seem to be well understood (Blow, 2000), new theories continue to be 
proposed to explain puzzling aspects of enzyme catalysis (Williams et al., 2004), and 
novel resources are being developed (Porter et al., 2004) to answer ongoing 
questions about the evolution and mechanism of enzymes. For instance, how do 
enzymes catalyse the diverse range of reactions found in a cell with only a small set 
of different chemical groups? Of the 20 naturally occurring amino acids, only the 11 
polar and charged residues are generally observed to engage directly in catalysis 
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(Bartlett, 2002). These residues fall into seven different chemical groups: imidazole 
(histidine), guanidinium (arginine), amine (lysine), carboxylate (glutamate, aspartate), 
amide (glutamine, asparagine), hydroxyl (serine, threonine, and tyrosine) and thiol 
(cysteine). Of course, enzymes also use metal ions (Williams, 2003), cofactors 
(Mure, 2004; Murataliev 2004) and water molecules (Hernick and Fierke, 2005) to 
aid catalysis. However, a source of catalytic power that does not require additional 
groups stems from the ability of catalytic residues to interact with each other and 
thus to affect each other’s chemical properties (Harris and Turner, 2002). But not all 
combinations of residues are useful: some might have no effect on or even reduce 
the power of their component residues. By reviewing the available structural and 
biochemical data, one can show which combinations of residues are used by 
enzymes and how their interactions affect enzyme properties. We also need to 
consider some important aspects of enzyme chemistry, such as the role of 
hydrophobic residues, metal ions, cofactors or water, quantum effects or the 
importance of factors such as entropy and binding energy. 
 
This investigation was undertaken to ascertain the extent to which the adenyl group 
within ATP plays a direct role in the regulation of ATP binding and/or phosphoryl 
transfer within glutamine synthase and thus enzyme catalysis. To this end the role of 
the C8-H of ATP on the binding and/or phosphoryl transfer on the enzyme activity 
was elucidated in comparative enzyme activity assays using ATP and ATP 
deuterated (See section 4.1.3) at the C8 position.  
 
4.1.3 The identification and functionality of deuterium 
Deuterium was first identified by Harold Clayton Urey in the study of physics in 1933 
then introduced to chemistry and biological chemistry. Molecular deuteration is the 
substitution of normal hydrogen (protium) by deuterium (heavy hydrogen) atom in a 
compound (Tung, 2010).  
 
The deuterium atom is an isotope of hydrogen, differing from normal hydrogen by 
containing one neutron and one proton in its nucleus, this results in a change in 
atomic mass from 1(AMU) to 2(AMU) which doubles the atomic mass of a normal 
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hydrogen (protium). The nucleus of deuterium is called deuteron while the nucleus of 
protium consists of one proton and has an atomic mass of 1(AMU) (Tung 2010; 
Bateau et al., 2009 and Limbach et al., 1990). Deuterium was firstly discovered by 
Urey, Brickwedde and Murphy in 1933 in the study of water electrolysis (Limbach et 
al., 1990 and Wade et al., 1999). 
Deuteration of a molecule is as a result of a change in covalent bond between a 
carbon to hydrogen (C-H) and the carbon to deuterium (C-D) bond (Wade et al., 
1999). The compound being deuterated only shows insignificant physical property 
changes. These property changes include hydrophobicity, chemical molecular mass 
and pKa (Tung, 2010). The C-D bond formed when a molecule is fully deuterated is 
much stronger than the C-H bond of a normal compound causing a reduced reaction 
rate when comparing these molecules. The rate of reaction ratio of a deuterated 
molecule when compared with the reaction rate of an undeuterated molecule is 
called the Kinetic Isotope Effect (KIE=VH/VD). In this study we focus on imidazole 
and purine compounds which are aromatic compounds. 
 
4.1.4 Functionality of ATP 
The study carried out by Fiske and Subbarow in 1929 was the first to define the ATP 
molecule, and was then followed by Lipmann in 1941 who elaborated on the function 
and structure of ATP in the cell (Novak et al., 2011). The ATP molecule consists of 
two regions: the polar and nonpolar moiety (Figure 4.1). The polar region consists of 
a ribose sugar and three phosphates while the nonpolar region comprises the 
adenine moiety. ATP is the energy source for all living organisms. It is essential 
because it plays many roles from transporting many ions across the concentration 
gradient of the cellular membrane, to control function and signalling of numerous 
systems in all living organisms (Salisu et al., 2011).  
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4.1.5 Deuteration of ATP 
The ATP adenine base is a heterocyclic aromatic compound with nitrogen atoms in 
its ring structure (Figure 4.1 A). It consists of a six membered ring attached to a five 
membered ring where both rings fulfil their aromatic properties by contributing 
electrons which are located on the p-orbital, with a lone pair of electrons in the sp2-
orbital which is perpendicular the p-orbital. These electron characteristics cause 
these molecules to be less reactive than other aromatic compounds. In ATP the 
protons (Figure 4.1 B) at position 2 and 8 are the first to be substituted during 
deuteration. The deuteration of the proton at position 2 is depended on pH thus the 
deuteration of the proton at position 8 will be deuterated first. 
 
 
 
 
 
Figure 4.1: Schematic illustration of the structure of ATP: A ATP structure showing the nonpolar 
adenine moiety and the polar moiety consisting of the ribose sugar and phosphate moieties. B Atom 
numbering of the adenine moiety to show locations of the protons in the ATP structure to be 
substituted during deuteration. 
 
Comparative assays were run to determine the effect of ATP and C8D-ATP on the 
specific activity of the enzymes investigated in Chapter 2 and 3, namely adenylylated 
and deadenylylated E.coli GS and adenylylated and deadenylylated M.tb GS.   
 
 
A B 
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4.1.6 Study Objectives 
 Objective 1: To determine the specific activity of adenylylated and deadenylylated 
E.coli GS in the presence of ATP and C8D-ATP (deuterated ATP). 
 
 Objective 2: To determine the specific activity of adenylylated and deadenylylated 
M.tb GS in the presence of ATP and C8D-ATP (deuterated ATP). 
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4.2 Methods 
4.2.1 Construction, expression and purification of E.coli and M.tb GS 
The construction, expression and purification of E.coli and M.tb GS is described and 
discussed in Chapter 2. 
 
4.2.2 C8-D ATP synthesis 
The synthesis of ATP deuterated at the C8 position (C8-D ATP) was carried out 
based on the method of Heller et al. (1968). A 20 mM solution of Na2ATP in D2O 
(Sigma) containing 60 mM triethylamine (TEA) was incubated at 60ºC for 144 hrs. 
The TEA was removed by twice passing the solution over a Dowex 20W ion 
exchange resin (Sigma) in the acid form. The pH of the solution was adjusted to pH 
12 with NaOH prior to the second pass over the resin. The pH of the solution was 
adjusted to pH 6.3 prior to freeze drying. The extent of the deuteration at the C8 
position was determined by 1H NMR and mass spectroscopy. The 1H NMR was 
carried out on a Varian VNMRS 600 MHz NMR in D2O. 
 
4.2.3 Steady-State kinetic analysis  
4.2.3.1 Steady-State kinetic analysis of adenylylated and deadenylylate E.coli 
GS 
The effect of the concentration of ATP and C8D-ATP on the specific activities of 
E.coli adenylylated and deadenylylated GS was determined at concentrations 
ranging from 150 to 3000 mM ATP and C8D-ATP in assays containing 4 mM 
sodium-glutamate, 4 mM NH4Cl, 5.4 mM NaHCO3 in 20 mM imidazole buffer. The 
deadenylylated E.coli GS assay was carried out at pH 7.4 (± pH 0.05), and at MgCl2 
concentrations equivalent to 3 times the ATP concentration. The adenylylated E.coli 
GS assay was carried out at pH 6.6 (± pH 0.05), and at MnCl2 concentrations 
equivalent to 3 times the ATP concentration. The reaction was stopped by the 
addition of 100% trichloroacetic acis to give a pH of 2-3. The assay solutions were 
centrifuged prior to HPLC analysis. After termination of the reactions and 
centrifugation, ADP levels were determined by HPLC. The samples were analysed 
on an Agilent series 1100 HPLC fitted with a Phenomenex Luna 5μ C18 column. 
Each sample was automatically injected (0.2 μL) and separated with a mobile phase 
containing 51 mM KH2PO4, PIC A Low UV Reagent (Waters Cooperation), 25% (v/v) 
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acetonitrile. The flow rate of the mobile phase was 1 ml/min with UV detection. An 
AMP, ADP and ATP standard was used to calibrate the HPLC and the concentration 
of ADP in each sample was determined by the area under the curve using Agilent 
ChemStation (Revision B.02.01) software. All specific enzyme activities were 
expressed as moles ADP formed per minute per milligram protein and illustrated as 
graphs using GraphPad Prism 5 software. 
 
4.2.3.2 Steady-State kinetic analysis of adenylylated and deadenylylate M.tb 
GS 
The effect of the concentration of ATP and C8D-ATP on the specific activities of M.tb 
adenylylated and deadenylylated GS was determined at concentrations ranging from 
150 to 3000 M ATP and C8D-ATP in assays containing 4 mM sodium-glutamate, 4 
mM NH4Cl in 50 mM HEPES buffer. The deadenylylated M.tb GS assay was carried 
out at pH 7.15 (± pH 0.05), and at MgCl2 concentrations equivalent to 3 times the 
ATP concentration. The adenylylated M.tb GS assay was carried out at pH 6.6 (± pH 
0.05), and at MnCl2 concentrations equivalent to 3 times the ATP concentration. The 
reaction was stopped by the addition of 100% trichloroacetic acis to give a pH of 2-3. 
The assay solutions were centrifuged prior to HPLC analysis. After termination of the 
reactions and centrifugation, ADP levels were determined by HPLC. The samples 
were analysed on an Agilent series 1100 HPLC fitted with a Phenomenex Luna 5μ 
C18 column. Each sample was automatically injected (0.2 μL) and separated with a 
mobile phase containing 51 mM KH2PO4, PIC A Low UV Reagent (Waters 
Cooperation), 25% (v/v) acetonitrile. The flow rate of the mobile phase was 1 ml/min 
with UV detection. An AMP, ADP and ATP standard was used to calibrate the HPLC 
and the concentration of ADP in each sample was determined by the area under the 
curve using Agilent ChemStation (Revision B.02.01) software. All specific enzyme 
activities were expressed as moles ADP formed per minute per milligram protein and 
illustrated as graphs using GraphPad Prism 5 software. 
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4.3 Results 
ATP was deuterated specifically at position C8 as outlined in the Experimental 
Procedures and the deuteration was assessed by 1H NMR.  
 
4.3.1 The effect of ATP and C8D-ATP on adenylylated and deadenylylate E.coli 
and M.tb GS 
The effect of the ATP and C8D-ATP concentration on the specific activities of 
adenylylated and deadenylylated E.coli and M.tb GS were determined as indicated 
by Figures 4.2 to 4.5. The effect of the ATP and C8D-ATP on the specific activity of 
the enzyme was expressed over a concentration profile that included the ATP or 
C8D-ATP concentrations that would allow vmax to be calculated as well as an ATP or 
C8D-ATP concentration profile at low concentrations that would allow for the 
accurate determination of the KIE. The best-fit to the data was obtained for the 
specified kinetic model using the non-linear regression algorithms of the GraphPad 
Prism 5 software. As part of the software output a data-table is created containing 
150 data-points defining the best kinetic fit for each enzyme’s response to the 
presence of either ATP or C8D-ATP. These response curves were then used to 
define the KIE by the conventional estimation of KIE: 
   
KIE =  
𝑣H
𝑣D
 
 
The KIED was also determined using the following function: 
           
KIED =  
𝑣D
𝑣H
 
      
  Where vD = specific activity in the presence of C8D-ATP 
   vH = specific activity in the presence of ATP. 
 
The calculation of KIED was used as the data obtained is instructive in a putative role 
that the C8-H of ATP plays in the regulation of phosphoryl transfer.  
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The following parameters were defined from Figure 4.2 and Figure 4.3; the KIE was 
obtained in response to the presence of C8D-ATP as indicated on Figure 4.2 B and 
Figure 4.3 B. In both cases the KIE obtained was a primary KIE as extent of the KIE 
was two-fold or in excess of two-fold. Adenylylated E.coli GS and M.tb GS (Figure 
4.2 A and Figure 4.3 A) use a similar mechanism with the KIED asymptoting to a 
level of 0.5 at Vmax (KIE = 2). Adenylylated E.coli GS and M.tb GS are both 
dodecamers consisting of two stacked hexameric structures consisting of 12 
identical subunits. The subunits probably interact allosterically on the binding of ATP. 
Figure 4.2: E.coli adenylylated glutamine synthetase activity and KIE: A Effect of the concentration of 
ATP (represented on the graph by the black circles) and C8D-ATP (represented on the graph by the 
black squares) on the specific activity of adenylylated E.coli GS. B Effect of the concentration of ATP 
(indicated by the black line on the graph) and C8D-ATP (indicated by the blue line on the graph) on 
the KIE of adenylylated E.coli GS. 
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Figure 4.3: M.tb adenylylated glutamine synthetase activity and KIE: A Effect of the concentration of 
ATP (represented on the graph by the black circles) and C8D-ATP (represented on the graph by the 
black squares) on the specific activity of adenylylated M.tb GS. B Effect of the concentration of ATP 
(indicated by the black line on the graph) and C8D-ATP (indicated by the blue line on the graph) on 
the KIE of adenylylated M.tb GS. 
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The following parameters were defined from Figure 4.4 and Figure 4.5; the KIE was 
obtained in response to the presence of C8D-ATP as indicated on Figure 4.4 B and 
Figure 4.5 B. In both cases the KIE obtained was a primary KIE as extent of the KIE 
was two-fold or in excess of two-fold. Deadenylylated E.coli GS and M.tb GS (Figure 
4.4 A and Figure 4.5 A) use the same mechanism for regulation. The KIED of the 
deadenylylated E.coli GS and M.tb GS negatively asymptote to 1 at Vmax (Figure 4.4 
B and Figure 4.5 B). Deadenylylated E.coli GS and M.tb GS are multimeric and 
allosteric regulation may occur via the interaction of subunits. 
 
 
Figure 4.4: E.coli deadenylylated glutamine synthetase activity and KIE: A Effect of the concentration 
of ATP (represented on the graph by the black circles) and C8D-ATP (represented on the graph by 
the black squares) on the specific activity of deadenylylated E.coli GS. B Effect of the concentration of 
ATP (indicated by the black line on the graph) and C8D-ATP (indicated by the blue line on the graph) 
on the KIE of deadenylylated E.coli GS. 
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Figure 4.5: M.tb deadenylylated glutamine synthetase activity and KIE: A Effect of the concentration 
of ATP (represented on the graph by the black circles) and C8D-ATP (represented on the graph by 
the black squares) on the specific activity of deadenylylated M.tb GS. B Effect of the concentration of 
ATP (indicated by the black line on the graph) and C8D-ATP (indicated by the blue line on the graph) 
on the KIE of deadenylylated M.tb GS. 
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4.4 Discussion 
The role of the KIE defining the kinetic models of the enzymes investigated has led 
to models for the regulation of the binding of ATP being proposed.  
In classical steady-state kinetics as represented by the Briggs-Haldane modification 
of the Michaelis-Menton formulation (Equation 1), 
            koff    kcat 
 E  +  S  ES  E  +  P    (Eq. 1) 
             kon  
 
with kon = k1, koff = k-1 and kcat =  k2, k2 >> k-1, and the Michaelis constant, KM 
obtained from  
 M
1
21
[ES]
[E][S]
K
k
kk


      (Eq. 2) 
 
It is proposed in enzymes such as Deadenylylated E.coli and M.tb GS that the 
enzyme kinetics follows classical Michaelis-Menton kinetics, where an equilibrium is 
set up between the enzyme concentration [E] and the substrate concentration [S] 
and binding of the second ATP is dependent on the conversion of the second active 
site into an ATP binding form by the release of ATP from the first active site, as 
defined by the coordinated half-sites mechanism. In enzymes using this mechanism 
of regulation, KM is dependent on k-1 and k2. The KIE obtained in these enzymes 
asymptotes to a value of 1. At low ATP concentrations the effect of the deuteration of 
C8 is to allow binding to occur for long enough to allow the reaction to occur and 
negate the effect of k-1, thereby shifting the equilibrium to k2. At high ATP 
concentrations the impact of the ATP concentration relative to the impact of ATP 
binding on the rate of reaction is significantly higher and as a result there is a 
concomitant decrease in the KIE. The impact of binding and the reaction rate, 
however, equilibrate to a KIE of 1. The maximum rate of binding can only ever be 
equivalent to the maximum rate at which the second ATP binding site is converted to 
the ATP binding form by the release of ATP from the first site. The classical impact 
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of deuteration on the KIE when the KIE is a primary effect, as determined by vH/vD, 
should yield a KIE of 2 or more (0.5 as determined by vD/vH as outlined above). As 
the regulation of the enzyme activity and ligand binding in these enzymes function in 
a coordinated half-the-sites mechanism binding in the second site only occurs on 
release of the ADP from the first site, it is therefore proposed that deuteration of the 
ATP improves the binding characteristics but does not impact on the catalysis of 
phosphoryl transfer. As the equilibrium shifts towards the binding of ATP with 
increasing ATP concentration the deuterated ATP binds effectively twice as 
efficiently as the non-deuterated ATP thereby negating the impact of the deuteration 
on the apparent enzyme activity at high ATP concentrations, yielding a KIE of 1.   
 In enzymes where the second active site is made available to ATP binding by the 
conversion of ATP to ADP, in other words binding may occur to the second site prior 
to the release of the ATP from the first site; the KM is dependent on k1 and k2. This 
occurs in the case of adenylylated E.coli and M.tb GS where the KIE becomes 2 at 
vmax. The impact of this binding is that at any point in time up to two reactions might 
be occurring simultaneously in two active sites. At high ATP concentrations, the 
deuterated ATP binds twice as efficiently as the non-deuterated ATP, allowing the 
KIE to asymptote to 2. At low concentrations, the deuteration has the same effect as 
occurs in the previous model, whereby binding occurs for a long enough period to 
negate the effect of k-1. At high concentrations, the effect of deuteration is 
superseded by the concentration effect and as two or more active sites is able to 
function simultaneously; this allows the KIE to asymptote to 2 or more. It is 
conceivable that on adenylylation of GS the interaction between two subunits 
effectively creates a dimer of dimer interaction.  
My making use of deuterated ATP we were able to show that the adenylylated and 
deadenylylated GS fundamentally differ in functionality. Proven that and also making 
use of the expression system to produce 95% adenylylated GS we clearly shown 
that adenylylated GS is active where it is shown in literature that the enzyme is 
basically inactive (Metha et al., 2004) and therefore making the adenylylated form of 
GS a potential new drag target. You can also go one step further and conclude that 
the deuteration of compounds may increase the “activity” of compounds leading to a 
lower IC50 values which will contribute significantly to the drug development process. 
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Chapter 5 
 
Concluding Discussion 
 
5.1 Concluding Discussion 
Mycobacterium tuberculosis (M.tb) glutamine synthetase (GS) is a potentially 
valuable therapeutic target for tackling the problem of tuberculosis disease.  Its 
regulation via the adenylylation of a tyrosine residue on each subunit makes it 
distinct from the human form of the enzyme.  Previous reports of heterologous 
expression of M.tb GS in Escherichia coli  (E. coli) have shown that the endogenous  
adenylyl transferase (ATase) activity of E. coli does not adenylylate M.tb GS 
sufficiently, with only 25% of the M.tb GS subunits produced displaying adenylylation 
(Mehta et al., 2004). The use of this expression system was therefore not considered 
optimal for the expression of adenylylated M.tb GS for further study.   
Here we have described an E. coli production system lacking endogenous GS and 
ATase activity, which utilises the co-expression of the M.tb ATase with M.tb GS.  
Each gene was provided on a separate plasmid, the glnA GS gene on a pBluescript 
SKII+ plasmid with the ColE1 origin of replication, and the glnE ATase gene on a 
CDFDuet-1 plasmid containing a CloDF13 replicon.  These replicons are compatible, 
and the two plasmids can be stably co-maintained, provided the relevant antiobiotic 
selective pressure is exerted: ampicillin for pBluescript SKII+ and streptomycin for 
pDFDuet-1 (Held et al., 2003).  Mehta and co-workers (2004) expressed M.tb GS in 
E. coli host strains that were deficient in only chromosomal GS (glnA).  They found 
that the E. coli ATase was inefficient in adenylylating the heterologous M.tb GS, with 
only ~25% of subunits being modified (Mehta et al., 2004). By co-expressing M.tb 
ATase and M.tb GS we improved the percentage of subunits modified (or 
adenylylated) with ± 60-70% to ± 85-94%. In this way, we have produced 
recombinant M.tb GS that has a better adenylylation state than any previously 
reported.   
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The adenylylated and deadenylylated E. coli GS enzymes were also produced 
recombinantly, from pBluescript SKII+ in E. coli strains lacking endogenous GS (for 
deadenylylated enzyme) or both GS and uridylyl transferase (adenylylated enzyme). 
These E. coli GS enzymes were only cloned, expressed and purified to be used as a 
model and for comparison with M.tb GS.     
Three methods were used to assess the degree of adenylylation of adenylylated and 
deadenylylated M.tb GS, and E. coli GS.  The first assay used, termed the -glutamyl 
transferase enzyme assay, is a variation of the reverse of the reaction that GS 
catalyses: 
              Glutamate + NH4
+ + ATP →    glutamine + ADP + Pi + H
+  
In this reverse reaction; hydroxylamine and glutamine react to form -
glutamylhydroxamate and free ammonia in the presence of ADP, arsenate and 
manganese or magnesium (EP2008210 A1, 2008; Shapiro and Stadtman, 1970).  
This forms the basis of an assay for GS activity.  At the correct pH (derived from 
determining the isoelectric point of the enzyme), the transferase activities of both the 
adenylylated and deadenylylated forms of GS are the same.  The two forms can, 
however, be distinguished because at the isoelectric point, fully adenylylated GS is 
completely inhibited by 60 mM Mg2+, whereas the deadenylylated enzyme is 
unaffected (Bender et al., 1977). Based on the data from the -glutamyl transferase 
assay, the adenylylation state of adenylylated M.tb GS expressed in this novel 
system is at least 68% compared to the 25% obtained from Mehta and co-workers.  
The second assay used is the determination of the inorganic phosphate 
concentration after the hydrolysis of both adenylylated and deadenylylated Mtb GS. 
In the case of the deadenylylated enzyme, there is no formation of phosphate after 
the hydrolysis. For the adenylylated Mtb GS, each adenyl moiety contains 1 
phosphate, and 1 µM of GS (containing 12 subunits) should contain 12 µM of 
phosphate, if each subunit is adenylylated.  The result obtained for the adenylylated 
M.tb GS enzyme was the formation of 0.93 µM phosphate produced per µM GS 
active site, i.e. 94% adenylylated compared to the 25% obtained from Mehta and co-
workers. 
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The third method used to assess the adenylylation is mass spectrometry.  MS 
spectra showed distinct peaks for adenylylated and deadenylylated enzymes, with 
calculated masses agreeing with the theoretical values.  Based on this data, it can 
be concluded that the adenylylation state of adenylylated M.tb GS expressed in this 
novel system is at least 85% from the MS spectra obtained.   
In addition, the rate of conversion of ATP, glutamate and ammonia to glutamine and 
ADP was assessed using HPLC.  This is termed the ‘forward’ or ‘biosynthetic” 
reaction and is assayed by HPLC to determine the conversion of ATP to ADP. 
Several gaps exist in the TB drug development pipeline worldwide as very few new 
drugs or drug candidates are in the pipeline. Big pharmaceutical companies have not 
invested in TB drug development, as historically the disease did not pose a 
significant threat to the developed world. However, the threat of multi-drug resistant 
(MDR)-TB and the increased world demand for treatment of Latent TB Infection has 
prompted a number of global initiatives such as the Global Alliance for TB Drug 
Development and the Stop TB Partnership (WHO 2006); all aimed at ensuring a 
pipeline of new TB drug leads to ensure new more effective TB drugs enter clinical 
development.   
The primary invention of this project relates to a biochemical pathway that yielded a 
new drug target that can be exploited to develop new therapies against M.tb. GS 
catalyses the conversion of glutamate to glutamine via a glutamyl phosphate 
intermediate, utilising ATP. ATP is utilized as either Mg-ATP or Mn-ATP, depending 
on the adenylylation state of the enzyme. The enzyme is regulated via adenylylation 
in bacteria containing the GS-I form of the enzyme, a mechanism not found in the 
GS-II in humans. 
213 compounds were tested against the adenylylated and deadenylylated forms of 
both M.tb GS and E. coli GS at a concentration of 10 μM. The rational design and 
selection of these inhibitors were based on the typical ATP binding site. It has been 
shown that GS in the adenylylated form uses a novel histidine kinase-like reaction 
mechanism in the phosphorylation of the carboxyl of glutamate. The primary 
outcome of the project was the demonstration of the selective inhibition of 
adenylylated GS and the identification of specific compounds capable of inhibiting 
adenylylated GS.  
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Compounds showing activity towards the adenylylated and/or deadenylylated forms 
of E. coli and M.tb GS enzymes at a single micromolar (µM) concentration were 
confirmed with repeated testing before being evaluated with full dose-responses to 
assess IC50 values and rank the order of potencies towards the adenylylated and 
deadenylylated forms of E. coli and M.tb GS. Compounds showing activity for the 
adenylylated or deadenylylated forms of the M.tb GS enzyme were further assessed 
for selectivity vis-à-vis the mammalian enzyme and for antibacterial action in a 
cellular model of M.tb infection. Any compound showing a selective activity for the 
adenylylated versus the deadenylylated and mammalian forms of the enzyme could 
be considered for further hit-to-lead and lead optimisation campaigns for the 
development of novel candidates for the treatment of TB. Based on the dose-
response assays, two compounds have emerged as the most promising anti-M.tb 
GS inhibitors with IC50 (μM) values of 9.6 μM and 17.4 μM respectively. They have 
regularly produced the most potent inhibitory activity against M.tb adenylylated GS 
enzyme in fixed concentration screens with 87% and 81% inhibition, respectively. 
These compounds, 10057 and 10059, are structurally very similar. These two 
compounds that have been found to be inhibitory to M.tb GS may now be used as 
templates to synthesize additional target specific compounds as part of a lead 
optimisation programme and further optimised to yield a suitable drug candidate for 
clinical evaluation. 
In the study we also looked at the utilization of ATP by looking at the enzyme kinetics 
of both M.tb GS and E. coli GS as well as the kinetic isotope effect of these 
enzymes. It is proposed that for enzymes such as M.tb GS and E. coli GS, the 
enzyme kinetics follow the classical Michaelis-Menton kinetics where an equilibrium 
is set up between the enzyme concentration [E] and the substrate concentration [S] 
and binding of the second ATP is dependent on the conversion of the second active 
site into an ATP binding form by the release of ATP from the first active site, as 
defined by the coordinated half-sites mechanism. In enzymes using this mechanism 
of regulation, KM is dependent on k-1 and k2. The kinetic isotope effect (KIE) was 
determined using ATP and ATP deuterated at the C8-H of the adenyl moiety. The 
KIE is defined as vH/vD, where vD = specific activity in the presence of C8D-ATP, and 
vH = specific activity in the presence of ATP.  The KIE obtained in these enzymes 
asymptotes to a value of 1. At low ATP concentrations the effect of the deuteration of 
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C8 is to allow binding to occur for long enough to allow the reaction to occur and 
negate the effect of k-1, thereby shifting the equilibrium to k2. At high ATP 
concentrations the impact of the ATP concentration relative to the impact of ATP 
binding on the on-rate of reaction is significantly higher and as a result there is a 
concomitant decrease in the KIE. The impact of binding and the reaction rate 
however equilibrate to a KIE of 1. The maximum rate of binding can only ever be 
equivalent to the maximum rate at which the second ATP binding site is converted to 
the ATP binding form by the release of ADP from the first site.  
As the regulation of the enzyme activity and ligand binding in these enzymes 
function in a coordinated half-the-sites manner, and binding in the second site only 
occurs on release of the ADP from the first site, it is therefore proposed that 
deuteration of the ATP improves the binding characteristics but does not impact on 
the catalysis of phosphoryl transfer. As the equilibrium shifts towards the binding of 
ATP with increasing ATP concentration, the deuterated ATP effectively binds twice 
as efficiently as the non-deuterated ATP, thereby negating the impact of the 
deuteration on the apparent enzyme activity at high ATP concentrations, yielding a 
KIE of 1.   
This work contributes to the field of mycobacterial drug discovery on a number of 
different levels firstly: a novel expression system has been developed for the 
expression and production of adenylylated GS. This system may be useful for the 
expression and production of other essential mycobacterial enzyme which also 
undergoes post-translation modifications like the adenylylation of GS is this case. 
Secondly as many drugs targeting the ATP binding site contain purine and imidazole 
moieties, the deuteration of ligands at the site equivalent to the C8 of the imidazole 
moiety of ATP, could lead to enhanced efficacy and ligand binding in a drug design 
programme. This project therefore has formed part of an ongoing programme of the 
chemical biology of the diversity of the ATP binding sites in biology and their 
potential use in drug design. It has been clearly demonstrated the adenylylation of 
bacterial GS creates sufficient diversity in the active site thereby allowing the design 
of selective inhibitors targeting either the adenylylated or the deadenylylated forms of 
the enzyme. In conclusion GS is an essential enzyme in bacterial metabolism, and 
previous studies by Kenyon and co-workers have shown that inhibition/deletion of 
this enzyme can result in a static effect for pathogenic M.tb. Since the adenylylation 
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mechanism is specific to the bacterial form of the enzyme and induces significant 
modifications in the active site and also the ion requirements for the catalytic activity 
of GS is novel this makes GS potential new drug target. 
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Figure A1: Flowchart of the experimental outline for the targeted disruption of genes on the 
E. coli chromosome.         
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